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Abstract 
Membrane remodeling occurring in Gram-negative bacteria is a fundamental process involved 
in many aspects of bacterial physiology. Bacteria have evolved a variety of membrane 
modifications, e.g., outer membrane vesicles (OMVs), nanotubular membrane structures, 
lipopolysaccharide alteration, allowing them to better cope with a constantly changing, often 
hostile, environment. The overall goal of this dissertation was to investigate the influence of 
the macromolecular modification of the cell wall of Gram-negative bacteria on the development 
of antibiotic resistance and formation of outer membrane vesicles. One section of this work 
examines the phenomenon of the bacterial OMVs with respect to the mechanism underlying 
their formation and their contribution to antibiotic resistance. This research showed that all of 
the investigated opportunistic pathogens including Acinetobacter baumannii, Citrobacter 
freundii, Enterobacter sp., Escherichia coli and Serratia marcescens were able to continuously 
release vesicles into the surrounding milieu during in vitro growth. I validated that OMVs 
constitute an ubiquitous secretion system that may play a pivotal role in the transmission of 
enzymatically active compounds (e.g., active β-lactamases), antibiotic resistance genes (e.g., 
KPC-2), and overall bacterial survival. However, the general mechanism underlying OMV 
formation still needs to be understood. Here, I demonstrated that the hemolysin F gene (hlyF), 
a putative virulence factor associated with highly virulent strains of avian pathogenic E. coli 
and neonatal meningitis E. coli, is involved in OMV formation. Overexpression of hlyF 
increased OMV production in E. coli and the presence of the truncated version of this gene led 
to a hypovesiculation phenotype. Therefore, hlyF appears to be part of a natural biological 
switch, regulating the vesiculation process in Gram-negative bacteria. Furthermore, I 
demonstrated that some clinical isolates of C. freundii may release OMVs acting as vehicles 
for transferring antibiotic resistance genes over longer distances. Field emission scanning 
electron microscopy (FE-SEM) and transmission electron microscopy (TEM) visualized the 
shedding of DNA-containing OMVs. Exposure to OMVs derived from the carbapenemase gene 
KPC-2-containing donor cells resulted in gene transfer to E. coli. The second section of this 
work, focused on the modification of lipopolysaccharide (LPS), mediated by the plasmid-borne 
mcr-1 gene, leading to colistin resistance in Enterobacteriaceae. I established a methodology 
for purification of a full-length MCR-1 and showed an in vitro activity of this enzyme for 
catalyzing phosphoethanolamine (pEtN) hydrolysis from a lipid substrate. Lastly, I discovered 
that an optimized level of Ca2+ is required for the functionality of the mcr-1-mediated 
resistance. With this, I was able to develop a novel calcium-enhanced medium for the improved 
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determination of Colistin resistance and the detection of mcr-1-producing Enterobacteriaceae. 
The medium devised here has been patented and a related patent application examining 
conditions associated with MCR-1 activity is ongoing.
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Zusammenfassung 
Modifikationen der Struktur der Membranen Gram-negativer Bakterien sind ein fundamentaler 
Prozess, der in vielen Aspekten der Bakterienphysiologie relevant ist. Bakterien haben eine 
Vielzahl von Membranmodifikationen entwickelt, wie z. B. äußere Membranvesikel (OMV), 
nanotubuläre Membranstrukturen und Lipopolysaccharid-Veränderung, die ihnen erlauben, mit 
einer ständig wechselnden und oft feindlichen Umwelt zurecht zu kommen. Das Ziel dieser 
Dissertation war es, den Einfluss der makromolekularen Zellwandmodifikation auf die 
Entwicklung der Antibiotikaresistenzen und die Bildung von äußeren Membranvesikeln von 
Gram-negativen Bakterien zu untersuchen. Ein Teil dieser Arbeit untersucht das Phänomen der 
bakteriellen OMV im Hinblick auf den Mechanismus, der ihrer Entstehung zugrunde liegt, und 
ihren Beitrag zur Antibiotikaresistenz. Diese Untersuchungen zeigten, dass alle getesteten 
opportunistischen Krankheitserreger, einschließlich Acinetobacter baumannii, Citrobacter 
freundii, Enterobacter sp., Escherichia coli und Serratia marcescens während des Wachstums 
in vitro kontinuierlich Vesikel in das umgebende Milieu freisetzen konnten. Ich konnte zeigen, 
dass OMV ein allgegenwärtiges Sekretionssystem darstellen, welches eine Schlüsselrolle bei 
der Übertragung von enzymatisch aktiven Verbindungen (z. B. aktiven β-Lactamasen), 
Antibiotikaresistenzgenen (z. B. KPC-2) und dem gesamten bakteriellen Überleben spielen 
kann. Der allgemeine Mechanismus der OMV-Bildung muss jedoch noch verstanden werden. 
Hier konnte ich zeigen, dass das Hämolysin F Gen (hlyF), ein mutmaßlicher Virulenzfaktor, 
der mit hochvirulenten Stämmen von aviären E. coli und neonatalen Meningitis E. coli 
assoziiert ist, an der OMV-Bildung beteiligt ist. Die Überexpression von hlyF erhöhte die 
OMV-Produktion in E. coli und die Anwesenheit der verkürzten Version dieses Gens führte zu 
einem Hypovesikulations-Phänotyp. Daher scheint hlyF Teil eines natürlichen biologischen 
Regulators zu sein, der den Vesikulationsprozess bei Gram-negativen Bakterien steuert. 
Darüber hinaus habe ich gezeigt, dass einige klinische Isolate von C. freundii OMV als Vehikel 
für die Übertragung von Antibiotikaresistenzgenen über längere Distanzen fungieren können. 
Die Feldemissions-Rasterelektronenmikroskopie (FE-REM) und die Transmissions-
elektronenmikroskopie (TEM) visualisierten die Freisetzung von DNA-haltigen OMV. Die 
Exposition gegenüber OMV, die aus den Carbapenemase Gen KPC-2-enthaltenden 
Spenderzellen stammen, führte zu einem Gentransfer in E. coli. Der zweite Teil dieser Arbeit 
konzentrierte sich auf die Modifikation des Lipopolysaccharids (LPS), verursacht durch das 
Plasmid-getragene mcr-1-Gen, was zu einer Colistinresistenz in Enterobacteriaceae führte. Ich 
etablierte eine Methode zur Aufreinigung eines vollständigen MCR-1 Proteins und zeigte eine 
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in vitro Aktivität dieses Enzyms als Katalysator der Phosphoethanolamin (pEtN)-Hydrolyse 
eines Lipidsubstrats. Schließlich entdeckte ich, dass für die Funktionalität des mcr-1-
vermittelten Widerstands ein optimiertes Niveau von Ca2+ erforderlich ist. Damit konnte ich 
ein neuartiges Calcium-supplementiertes Medium zur verbesserten Bestimmung der Colistin-
Resistenz und der Identifizierung von mcr-1-produzierenden Enterobacteriaceae entwickeln. 
Das hier entwickelte Medium wurde patentiert, eine ähnliche Patentanmeldung ist geplant, die 
die hiermit verbundenen Zusammenhänge der MCR-1-Aktivität untersucht. 
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Patents & Publications 
Parts of this work have been published in the following patents literature and manuscripts: 
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Patent Office  
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intrinsic/adaptive colistin resistance. Germany. Submitted to the German Patent Office  
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Abbreviations 
List of abbreviations 
Amp  Ampicillin 
BMD  Broth microdilution 
bp Base pair 
BSA Bovine serum albumin 
CaCl2 Calcium chloride 
Cam Chloramphenicol 
cAMPs Cationic antimicrobial peptides 
CE-MHB Cation-enhanced mueller hinton broth 
CLSI Clinical and Laboratory Standards Institute  
Da Dalton 
ddH2O Distilled deionized water 
DNA Deoxyribonucleic acid 
DNAse Deoxyribonuclease 
DTT Dithiothreitol 
EDTA Ethylenediaminetetraacetic acid 
EPS Extracellular polymeric substances 
ER Endoplasmic reticulum 
EUCAST European Committee on Antimicrobial Susceptibility Testing 
FA Formaldehyde 
FBS Fetal bovine serum 
FE-SEM Field-emission scanning electron microscopy 
GA Glutaraldehyde 
GES Guanidinium thiocyanate solution 
GFP Green fluorecent protein 
HeLa cells  Human cervical cancer cells 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HGT Horizontal gene transfer 
hlyF Hemolysin F 
HPLC High pressure liquid chromatography 
IM Inner membrane 
IPTG Isopropyl -D-1-thiogalactopyranoside 
Km Kanamycin 
KPC-2 Klebsiella pneumoniae carbapenemase 2 
LB Luria broth 
LPS Lipopolysaccharide 
MALDI-TOF-MS Matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry 
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mcr-1 mobilized colistin resistance gene 1 
MEM Minimum essential media 
MIC Minimum inhibitory concentration 
MHB Mueller hinton broth 
mRNA Messenger ribonucleic acid 
MS Mass spectrometry 
MSC Multiple cloning site 
MVs Membrane vesicles 
MW Molecular weight 
NMR Nuclear magnetic resonance 
NP Nucleoprotein 
NSAF Normalized spectral abundance factor 
OD Optical density 
OM Outer membrane 
OMP Outer membrane protein 
OMV Outer membrane vesicle 
PBP Penicillin-binding protein 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PDB Protein data bank  
pEtN Phosphoethanolamine   
PG Peptidoglycan 
PL Phospholipid 
Pm Polymyxin 
PQS Pseudomonas quinolone signal 
PVDF membrane Polyvinylidene fluoride membrane 
RNA Ribonucleic acid 
RT Room temperature 
S1-PFGE S1 nuclease digestion followed by Pulsed-field Gel Electrophoresis 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM Scanning electron microscope 
TBE buffer Tris-borate-EDTA buffer 
TC Transconjugant 
TCS Two-component system 
TEM Transmission electron microscope 
TM Transmembrane 
Tris Tris(hydroxymethyl)aminomethane 
WCL Whole cell lysate 
WT Wild type 
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1 Introduction 
1.1 Gram-negative pathogens studied in the thesis 
Gram-negative bacteria are characterized by their cell envelopes, which are composed of inner 
and outer membranes that are separated by the periplasm containing peptidoglycan (Needham 
& Trent 2013). They are prevalent globally, in almost all environments that support life. The 
Proteobacteria are a major group of Gram-negative bacteria, comprising a wide variety of 
pathogens, such as Acinetobacter, Escherichia, Salmonella, Neisseria, Vibrio, Helicobacter, 
Yersinia and many other noteworthy genera. Bacteria that are not pathogenic, but are present 
within the host e.g. as colonizers, are known as commensal bacteria. In healthy individuals, 
commensal Gram-negative bacteria are involved in maintaining fitness and wellness, as they 
regulate colonization and eradication of pathogens as well as acquisition of nutrients (Kamada 
et al. 2013). In this PhD thesis, various clinical isolates of pathogens have been studied. Each 
of the investigated bacterial species, is shortly described below in this chapter. All bacteria used 
in the thesis are listed in Table 3.7.  
Acinetobacter baumannii (A. baumannii) is an emerging and often multidrug-resistant, 
opportunistic, nosocomial pathogen that causes infections in immunocompromised and 
chronically ill individuals. A. baumannii is considered as causing a variety of severe nosocomial 
infections, including bacteremia, meningitis, wound infections, urinary tract infections, skin 
and soft tissue infections and ventilator-associated pneumonia, which represents the most 
important disease caused by this bacterium (Dijkshoorn et al. 2007). In recent years, increasing 
numbers of A. baumannii outbreaks have been reported by hospitals and long-term care 
facilities all over the Europe (Jones et al. 2015). Even though the increasing global importance 
of A. baumannii as a nosocomial pathogen, still little is known about the virulence factors 
responsible for its pathogenesis. A. baumannii exhibits several pathogenic traits, including 
biofilm formation, serum resistance, iron acquisition, adherence to and invasion of host cells 
and formation of outer membrane vesicles (OMVs) (Nho et al. 2015). However, specific 
virulence factors of this bacterium have not been fully determined. 
Citrobacter freundii (C. freundii) is a clinically relevant opportunistic pathogen, member of 
family Enterobacteriaceae that has been associated with several nosocomial infections in 
immunocompromised patients. C. freundii related illnesses include respiratory tract infections, 
urinary tract infections, bloodstream infections and neonatal meningitis (Pepperell et al. 2002). 
Introduction 
 
14 
 
In recent years, C. freundii have demonstrated reduced susceptibility not only to traditional 
antibiotics such as ampicillin, carbenicillin, and cephalothin, but also to third-generation 
cephalosporins and carbapenems (Gaibani et al. 2013). In this thesis, the Klebsiella pneumoniae 
carbapenemase-2 (KPC-2) producing, multidrug-resistant C. freundii isolates have been 
investigated in the context of gene transfer mediated by outer membrane vesicles (OMVs). 
Enterobacter sp. is a rod-shaped bacterium that belongs to the family of Enterobacteriaceae. 
Bacteria of this genus are ubiquitous in nature. They are found in the intestinal tracts of animals 
and plants resulting in their wide distribution in soil, water, and sewage. A number of strains of 
Enterobacter are pathogenic and cause opportunistic infections in immunocompromised 
individuals. Enterobacter can cause a variety of conditions, ranging from bacteremia and eye 
and skin infections to urinary tract infections, pneumonia and meningitis (Davin-Regli & Pagès 
2015). 
Escherichia coli (E. coli) is a facultatively anaerobic, rod-shaped bacterium that is generally 
found in the lower intestine of warm-blooded organisms. E. coli is the most widely studied 
prokaryotic model organism for investigating molecular and cellular processes, including 
membranes remodeling. Nevertheless, E. coli is not only laboratory workhorse, but it can also 
be a highly versatile and frequently lethal pathogen. A number of different E. coli strains cause 
various intestinal and extraintestinal illnesses by means of different virulence factors affecting 
a wide range of the host cell activities (Kaper et al. 2004). The various pathotypes of E. coli 
include intestinal pathogens: enteropathogenic E. coli (EPEC), enterohaemorrhagic E. coli 
(EHEC), enterotoxigenic E. coli (ETEC), enteroaggregative E. coli (EAEC), enteroinvasive E. 
coli (EIEC), diffusely adherent E. coli (DAEC) and extraintestinal pathogen, comprising 
uropathogenic E. coli (UPEC) and meningitis and sepsis-associated E. coli (MNEC). 
Serratia marcescens (S. marcescens) is an opportunistic Gram-negative pathogen that causes 
infections in patients with compromised host defense mechanisms. S. marcescens cause a broad 
range of hospital-acquired infections, including respiratory tract infections, urinary tract 
infections, meningitis, pneumonia, conjunctivitis wound and eye infections and septicaemia 
that can progress into sepsis. The major factors for sepsis caused by S. marcescens are 
hospitalization, placement of intravenous catheters, intraperitoneal and urinary catheters as well 
as previous instrumentation of the respiratory tract. An important characteristic of S. 
marcescens is its ability to produce beta-lactamase enzymes (AmpC- Betalactamases), which 
confers resistance to the broad spectrum beta lactam antibiotics (Panigraphy 2015). 
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In general, this research represents a comprehensive examination of the selected Gram-
negative bacterial species with respect to their ability to cell wall remodeling that leads to 
antibiotic resistance and vesicle formation. All of the isolates investigated here are widespread 
pathogens that constitute a common and well-known health issue worldwide. 
1.2 Cell envelope of Gram-negative bacteria 
In order to discuss the modification of bacterial cell wall, it is necessary to be familiar with the 
architecture of the Gram-negative envelope where all changes originate (Figure 1.1). The cell 
wall is composed of the outer and inner membranes separated by a periplasm, which contains 
a thin layer of peptidoglycan (PG) (Needham & Trent 2013). The outer membrane consists of 
phospholipids in the inner leaflet and the glycolipid lipopolysaccharide (LPS) anchored to the 
outer leaflet. Integral components of the outer bilayer are the β-barrel outer membrane proteins 
(OMPs), called porins that form nonspecific channels to allow translocation of small 
hydrophilic molecules across the membrane. LPS is composed of three main domains: the lipid 
A, the core oligosaccharide and the O antigen. Lipid A consists of a phosphorylated 
glucosamine disaccharide unit with fatty acyl chains that bind the LPS to the outer membrane 
and act as a scaffold for the assembly of the negatively charged core domain and the O-antigen 
subunit (Raetz et al. 2007). Divalent cations cross-bridge adjacent lipopolysaccharide 
molecules are preventing the electrostatic repulsion between the negatively charged entities. 
These lateral interactions stabilize the integrity of the outer membrane and provide the barrier 
against the environment by limiting the permeability of different agents through the membrane 
(Wu et al. 2013). In addition, LPS serves as an important defense system due to the fact that 
gram-negative bacteria can alter LPS structure to resist killing by cationic antimicrobial 
peptides (cAMPs) and to evade the host innate immune system (Chen & Groisman 2013). The 
murein (peptidoglycan) sacculus is the shape-determining component of the cell envelope 
located between outer and inner membranes. It protects the cell from rupture due to osmotic 
and mechanical stresses (Vollmer & Bertsche 2008). Lipoproteins Pal and Lpp are covalently 
bound to murein layer and together with inner membrane proteins TolA, TolQ, TolR and a 
periplasmic protein TolB maintain the envelope integrity by cross-linking all cell wall layers 
(Cascales et al. 2002). 
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Figure 1.1 The cell wall of Gram-negative bacteria. (A) A field-emission scanning electron microscope 
image of an Escherichia coli cell (scale bar of 200 nm). (B) A schematic cross-section of the Gram-
negative cell wall, showing the typical inner and outer membranes (IM, OM) that are separated by the 
periplasm layer, which contains peptidoglycan molecules (PG). The outer leaflet of the outer membrane 
consists of lipopolysaccharide (LPS), which is bound to the membrane by the lipid A domain. The inner 
leaflet of the outer membrane and the complete inner membrane contain only phospholipids. In both 
bilayers can be embedded a range of different types of membrane protein. (C) The LPS macromolecule 
is composed of three major domains: lipid A, the inner and outer core oligosaccharides, and a polymeric 
O-antigen subunit. 
1.3 Cell membrane remodelling 
Membrane remodeling is an essential part of many biological processes found in all domains 
of life and is achieved by the interplay between proteins and lipids (McMahon & Gallop 2005). 
Modification of cell membranes occurs largely through two processes, first is a membrane 
fission where one membrane divides into two and second is a membrane fusion where two 
membranes assemble together to form one (Tan & Ramamurthi 2013). The discovery of the 
soluble NSF attachment protein receptor (SNARE) as well as the dynamin protein family and 
endosomal sorting complex for transport (ESCRT) have led to a better understanding of the 
mechanisms that regulate membrane fusion and fission in eukaryotes (Figure 1.2). In contrast 
to eukaryotes, in prokaryotes the specific protein complexes responsible for cell wall 
remodeling remain still elusive, mainly because the factors that may possibly mediate these 
modification events are likely essential for bacterial viability. The primary role of SNARE 
proteins is to mediate the fusion of vesicles with their target membrane bound compartments, 
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whereas ESCRT protein complexes facilitate a unique mode of membrane changes resulting in 
membranes bending and budding (Schuh & Audhya 2014; Ungar & Hughson 2003). 
Additionally, other well-studied eukaryotic molecules involved in membrane modification are 
Bin-amphiphysin-Rvs (BAR) domain proteins. They play key roles in many cellular processes 
including clathrin -dependent and -independent endocytosis, cytokinesis as well as T-tubule 
morphogenesis. It is believed that the BAR proteins can be curved to various degrees, and 
therefore generate either positive or negative curvature of membranes (Davtyan et al. 2016). 
However, there are still many factors that regulate and participate in membrane remodeling that 
need to be understood.  
Figure 1.2 Membrane modification events in prokaryotes and eukaryotes. Dynamin protein 
assembles at the neck of an endocytic vesicle as it bulges out from the plasma membrane. GTP 
hydrolysis allows for the constriction of dynamin, and membrane scission. During exocytosis, R-SNARE 
proteins are anchored in the vesicular membrane and interact with Q-SNARES in order to form a stable 
cis-SNARE complex that drives membrane fusion. Lipid bilayers are depicted in yellow; Dynamin 
marked in blue. Figure modified from (Tan & Ramamurthi 2013). 
1.3.1 Modification of the bacterial membranes 
The cell wall of Gram-negative bacteria is the first protective barrier against the stressors of the 
surrounding environment. Bacteria have the ability to alter the structure of their envelope in 
respond to stress effectors by displaying a variety of surface antigens, changing LPS 
composition, releasing outer membrane vesicles, producing capsule structures surrounding the 
bacteria or forming nanotubes between cells (Mashburn-Warren & Whiteley 2006; Li et al. 
2012; Pande et al. 2015; Schembri et al. 2004) (Figure 1.3). In other words, the bacterial cell 
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wall is highly dynamic and undergoes reorganization as a result of changes in milieu. One way 
to remodel the envelope and adapt to stressors, such as the increased concentration of cationic 
antimicrobial peptides (cAMPs) are LPS modifications. Most LPS modifications occur on the 
lipid A portion of the molecule and include the addition of aminoarabinose moieties, 
phosphoethanolamine moieties as well as phosphorylation, deacylation and acylation events 
(Needham & Trent 2013). Changes in LPS lead to decreased affinity between antimicrobial 
peptides and outer membrane by increasing overall net negative charge of bacterial cell wall. 
Another example of the cell wall remodeling is the production of outer membrane vesicle, 
which are nanometer-sized spherical structures released by various bacteria. Vesicles have 
diverse biological functions, including the delivery of numerous proteins and toxins. Therefore, 
they can help bacteria to accommodate to changing environmental factors. However, the exact 
mechanism of OMV biogenesis and, subsequently their contribution to biological processes has 
not been fully understood. In this thesis, I address the open questions regarding the molecular 
basis for the process of OMV formation and their biological functions. The release of OMV 
and its roles as well as resistance to cAMPs in the context of Gram-negative envelope 
modifications will be viewed in the next chapters. 
Figure 1.3 The key membrane remodeling events occurring in bacteria. Membrane modifications 
are fundamental biological processes including basic events such as bacterial cell division and growth, 
or more complex behaviours such as outer membrane vesicle and nanotube formation leading to 
exchange of intracellular compartments and intercellular communication. Images modified from (Pande 
et al. 2015; Bohuszewicz et al. 2016). 
1.4 Vesiculation in Gram-negative bacteria  
The release of outer membrane vesicles from bacteria is a process described almost 50 years 
ago (Chatterjee & Das 1967). OMVs are released constitutively during the normal growth of 
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Gram-negative as well as some Gram-positive bacteria. They are defined as spherical, 
bilayered, nanometer-sized proteophospholipids with an average diameter of 20–200 nm 
(Schwechheimer & Kuehn 2015). The protein composition of OMVs resemble the proteome of 
parental bacterial cell, therefore these small particles are composed of inner and outer 
membrane proteins, lipopolysaccharides, periplasmic proteins and other bacterial membrane 
components, which get locked in the bleb lumen during the formation process. Moreover, 
vesicles may contain cytoplasmic proteins, as well as DNA and RNA, however the mechanism 
underlying the export of cytoplasmic compartments into OMVs remains elusive (Kulp & Kuehn 
2010; Kulkarni & Jagannadham 2014; Fulsundar et al. 2014). 
1.4.1 Biogenesis of outer membrane vesicle (OMV) 
Several models for OMV biogenesis have been proposed based on both experimental evidence 
as well as architectural features of the bacterial cell wall (Kulp & Kuehn 2010). However, the 
molecular mechanism leading to OMV formation is not known. It is clear that, there is no one 
mode of OMV shedding, but more likely multiple mechanisms are responsible for vesicles 
biogenesis (Roier et al. 2016). There are three main models that are deliberated within the 
scientific community. The first model suggests that an accumulation of peptidoglycan 
fragments and/or misfolded proteins in the periplasm initiates the process of bulging out and 
pinching off of the outer membrane, subsequently leading to OMV formation. Such 
accumulations can be caused by, for instance, defects in bacterial membrane synthesis or 
temperature stress (Kulp & Kuehn 2010; McBroom & Kuehn 2007). The second model 
proposes that relocation or loss of lipoproteins, which covalently link the outer membrane to 
the peptidoglycan layer, leads to a outer membrane protrusion, and thus triggers vesicle 
formation (McBroom et al. 2006). The third model is based on the structural changes of 
lipopolysaccharide that can induce the charge-charge repulsion among adjacent LPS molecules, 
leading to local deformation and budding of the bacterial cell wall. It is known that divalent 
cations cross-bridge the highly anionic LPS molecules and stabilise the whole outer membrane. 
Therefore, remodeling of LPS that leads to removal of Ca2+ and Mg2+ ions may contribute to 
increased vesicle formation (Elhenawy 2016; Kulkarni & Jagannadham 2014). In summary, it 
is currently unknown whether biogenesis of OMVs released by different Gram-negative 
bacteria is regulated by one unified, evolutionary conserved mechanism or each single bacterial 
species have their own special system to control vesiculation process. 
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1.4.2 Probably roles of OMVs 
It is advantageous for Gram-negative bacteria to release vesicles, since the production of these 
large macromolecular complexes must be accompanied with a high fitness cost. Although the 
exact mode of OMV formation remains unknown, a number of studies have highlighted the 
miscellaneous biological roles for bacterial vesicles (Figure 1.4). OMVs have been implicated 
in many processes, which include the release of virulence factors, signaling between bacterial 
and eukaryotic cells, DNA transfer, antibacterial activity and immunomodulation of the host 
(Ellis & Kuehn 2010; McBroom et al. 2006; Renelli et al. 2004). 
Figure 1.4 The functions of outer membrane vesicles derived from Gram-negative bacteria. OMVs 
can function in multiple mechanisms that promote bacterial survival and pathogenicity. They can provide 
an avenue to remove toxic compounds and unwanted metabolites, such as misfolded proteins, from 
bacterial lumen. OMVs can also contribute to dissemination of antibiotic resistance genes to recipient 
bacteria by serving as vehicles for delivery of plasmid DNA as well as they can carry hydrolysing 
enzymes that degrade antibiotics. Vesicles allows for interacting with host cells to mediate the delivery 
of various virulence factors, such as toxins. In addition, they can deliver diverse bacterial antigens to the 
host cells, which evoke inflammation. The FE-SEM image of bacterial cells releasing OMVs was taken 
as described in chapter 3.5.3. 
OMVs provide a unique, long-distance mode for the secretion of proteins and virulence factors. 
They can act as vehicles for delivery of insoluble molecules and other cellular compartments 
that cannot be easily transported across the surrounding milieu (Bomberger et al. 2009). For 
instance, OMVs have been shown to be involved in horizontal gene transfer (HGT). Recently, 
the genetic transformation potential of outer membrane vesicles and nanotubes has been studied 
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in several bacterial species. A number of research groups have shown that OMVs contain 
genetic material (both plasmid and chromosomal DNA) and can facilitate the transfer of 
plasmid DNA to other recipients (Yaron et al. 2000; Rumbo et al. 2011; Renelli et al. 2004; 
Kadurugamuwa & Beveridge 1995; Fulsundar et al. 2014; Dorward et al. 1989; Pande et al. 
2015). In this study, the involvement of vesicles in dissemination of resistance genes was 
investigated (see chapter 4.1.5 and 4.3). OMVs also contribute to defence of bacterial cells 
against antibacterial agents. The OMVs secreted by one bacterial species can provide protection 
to other bacterial species from the antibiotic stress. The presence of different peptidases, 
proteases and enzymes, such as β-lactamases has been observed in OMVs (Schaar et al. 2011). 
The OMV-mediated inactivation of antibiotics has been studied by (Ciofu et al. 2000). The 
contribution of vesicles to antibiotic resistance has been examined and described in chapter 
4.1.4. OMVs are also known to play an important role in the biofilm formation. They were 
found to be involved in delivery of exopolysaccharides and the process of cell co-aggregation. 
It has been proposed that vesicles might act as a platform for connecting of proteins, 
exopolysaccharide molecules, DNA and the attachment surface, together with the bacterial 
cells. However, the detailed mechanism underlying the involvement of OMVs in biofilm 
formation is unknown (Kulkarni & Jagannadham 2014). Furthermore, the vesicles are involved 
in modulating the host immune response, since they contain the antigenic components, such as 
OM, PG and LPS (De et al. 1959). OMVs produced by Salmonella Typhimurium elicit 
proinflammatory responses in macrophages, induce dendritic cell maturation, enhance the 
expression of MHC class II molecules and also stimulate proinflammatory cytokine secretion 
and CD4+ T-cell activation (Alaniz et al. 2007). A proinflammatory response to vesicles has 
also been reported for other pathogens, including Helicobacter pylori or Pseudomonas 
aeruginosa. The epithelial cells exposed to H. pylori or P. aeruginosa OMVs induce the 
expression of cytokine IL-8 which is a strong activator for neutrophil and monocytes in vivo 
(Ellis & Kuehn 2010; Bauman & Kuehn 2006). The OMVs can also have an anti-inflammatory 
effect on the host cells and help bacteria to evade the host immune system mechanisms. The 
vesicles derived from Porphyromonas gingivalis possess gingipain proteases that can degrade 
the membrane-bound CD14 receptors. The loss of LPS receptors results in a reduced immune 
response to P. gingivalis colonisation (Duncan et al. 2004). Moraxella catarrhalis OMVs 
contain outer membrane-bound superantigen Moraxella immunoglobulin D-binding protein 
(MID), which potentially delay the production of specific antibodies (Schwechheimer & Kuehn 
2015). Despite ubiquitous nature of OMV production and their diverse biological capabilities, 
we understand very little about mechanistic aspects of OMV formation and their biological 
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functions. Given the promiscuous character of bacteria, the role of OMVs is probably even 
more varied than is presently appreciated. 
1.4.3 Immunogenic and protective immune response of OMVs in an invertebrate larvae 
model 
Due to fact that the composition of vesicle resembles the parental bacterial cell, OMVs are the 
source of active antigens, and therefore they have a strong immunogenic properties (Mitra et 
al. 2015). A number of studies have been performed to examine the immunogenicity and 
protective immune response of OMVs in vertebrate as well as invertebrate models. 
Invertebrates, like the greater wax moth larvae, Galleria mellonella (G. mellonella), have a 
sophisticated and effective immune system that fight against all microbial and parasitic 
pathogens. Unlike vertebrates that possess both innate and adaptive immune responses, 
invertebrates rely mostly on humoral and cellular defense system to protect themselves from 
various infections (Wu et al. 2014). Humoral defenses are generated by the synthesis of 
antimicrobial peptides (AMPs), the activation of cascades that regulate coagulation and 
melanization processes, and the production of reactive oxygen and nitrogen intermediates. 
Cellular defenses include hemocyte-mediated phagocytosis, encapsulation and nodule 
formation (Strand 2008). A number of insect species have been used to study innate immunity. 
One of the most popular insects for laboratory use are G. mellonella larvae, which have many 
advantages, including suitable sizes that make them easy to handle and they are easy to culture 
in the laboratory environment. Additionally, G. mellonella has a growth optimum at 37°C and 
they contain abundance of hemolymph, which makes it convenient for performing a different 
biochemical tests (Mukherjee et al. 2010).  
In this thesis, OMVs derived from different Gram-negative bacteria were isolated and 
examined with regard to their ability to induce innate immune responses in G. mellonella model. 
The larvae priming experiments are described in chapter 4.4.3. 
1.5 Vesiculation in Gram-positive bacteria 
The release of spherical, membranous vesicles occurs not only in Gram-negative bacteria but 
is widely conserved across all prokaryotes and eukaryotes, including Gram-positive bacteria, 
archaea, parasites and fungi (Deatheragea & Cooksona 2012). Several research groups have 
reported that Gram-positive bacteria such as Bacillus anthracis, Staphylococcus aureus or 
Listeria monocytogenes also produce vesicles during their growth (Lee et al. 2009; Lee et al. 
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2013; Rivera et al. 2010). Figure 1.5 represents the cells of L. monocytogenes that secrete 
membrane vesicles (MVs). The size of MVs derived from Gram-positive bacteria has been 
found to be ranging from 50 to 150 nm in diameter, whereas proteomics studies revealed that 
they are rich in membrane lipids, cytosolic-associated proteins and different toxins. MVs are 
involved in different processes, including the delivery of many virulence-associated proteins to 
host cells. Vesicles from Bacillus anthracis have biologically active toxins, such as anthrolysin 
O (ALO) and they are capable of inducing a protective immune response in immunized mice 
(Rivera et al. 2010). MVs derived from Staphylococcus aureus can serve as a vehicle for 
virulence factors delivery and induce cytotoxicity effect in host cells (Gurung et al. 2011). Up 
to date, little is known about the mechanism underlying biogenesis of MVs derived from Gram-
positive bacteria and their associations with host cell pathology. Further studies are required to 
understand all processes that link MV formation and bacterial pathogenic potential. 
Figure 1.5 Field-emission scanning electron microscopy image of Gram-positive bacteria cells 
and their vesicles. The FE-SEM image of Listeria monocytogenes and their MVs being released from 
bacterial surface. The sample of L. monocytogenes was prepared as described in chapter 3.5.3. The 
scale bare 200 nm. 
1.6 Antibiotics and resistance 
The serendipitous discovery of the first antibiotic, penicillin made by Sir Alexander Fleming in 
1928 was a major breakthrough in the history of medicine (Ligon 2004). Since then, antibiotics 
have represented almost the only effective treatment option for life-threatening illnesses caused 
by bacterial infections (Bernal et al. 2013). Nonetheless, their efficiency has been severely 
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compromised by misuse and over-use of antibiotic drugs, which have led to the appearance of 
bacteria resistant to many frequently used antibiotics.  
There are three general categories of antibiotic resistance displayed by bacteria, such as 
intrinsic, acquired and adaptive (Alekshun & Levy 2007). Intrinsic resistance is related to the 
specific feature inherent to a bacterial species and every member of this species displays this 
resistance. For instance, Gram-negative bacteria can exhibit resistance to many antibiotics due 
to the presence of a modified lipopolysaccharide causing low permeability of outer membrane 
and functions as an extra barrier preventing the entry of drug into the cell. Moreover, many 
bacteria comprise efflux pumps that pump actively antibiotic molecules out of the cell, and thus 
decrease their concentration in the bacteria. Bacterial-acquired resistance to antibiotics is the 
consequence of the acquisition of new genetic material i.e. plasmids, integrons, transposons by 
horizontal gene transfer or mutations in chromosomal genes, leading to drug resistance. It 
provides selective advantages in the presence of antimicrobial drugs and can be transferred to 
daughter cells resulting in the appearance of antibiotic-resistant bacterial strains. In addition to 
intrinsic and acquired resistance to antibiotics, bacteria can develop an adaptive resistance, 
which involves a temporary increase in the ability of a microorganism to survive an antibiotic, 
as the result of alterations in gene and protein expression triggered by different environmental 
conditions The adaptive resistance is transient and typically reverts upon the elimination of the 
inducing condition (Olaitan, Morand & J.M. Rolain 2014). 
In addition, the antibiotic resistance in bacteria can be caused by several mechanisms, 
which can be divided into three biochemical routes: first, those that minimize the absorption of 
the antibiotic as a consequence of poor penetration into the bacterium or of antibiotic efflux, 
second, those that alter the antibiotic target by chromosomal mutation or post-translational 
modification of the target and third, those that inactivate the drug by hydrolysis or modification 
(Blair et al. 2015) (Figure 1.6). In this thesis, the major events of bacterial membrane 
remodeling (i.e., formation of outer membrane vesicle and modification of 
lipopolysaccharides), which contribute to antibiotic resistance encountered in clinical practice 
have been investigated. 
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Figure 1.6 The antibiotic target sites and molecular mechanisms of antibiotic resistance. In 
general, antibiotics target five major sites: bacterial cell wall, cell membrane, protein synthesis, DNA and 
RNA synthesis, and folic acid metabolism. These targets are very different or even do not exist in 
eukaryotic cells, which means that many antibiotics are relatively nontoxic for human being. Resistance 
to antibiotics occurs through four general mechanisms: target modification; efflux pumps, immunity and 
bypass as well as enzymatic inactivation. Figure adapted from (Wright 2010). 
1.6.1 Colistin and related peptide antibiotics 
A rapid dissemination of multidrug-resistant Enterobacteriaceae combined with the paucity of 
novel antibiotics classes able to cope with them have led to the restoration of cationic 
antimicrobial peptides (cAMPs), i.e. colistin and polymyxin B as a precious addition to the 
current therapeutic armamentarium (Falagas et al. 2006; Conly & Johnston 2006; Magiorakos 
et al. 2011). Colistin (also known as polymyxin E) is an old class of cationic, cyclic, basic 
polypeptide antibiotics that was discovered in the late 1940s from the soil bacterium 
Paenibacillus polymyxa subsp. colistinus (Laurent Poirel, Aurélie Jayol 2017). Polymyxins 
contain five chemically different compounds (polymyxins A–E), but due to their high toxicity, 
only polymyxin B and polymyxin E have been approved to use in clinical practice (Conly & 
Johnston 2006; Falagas & Kasiakou 2005). Polymyxins consist of a mixture of D- and L -amino 
acids, a heptapeptide ring, 2,4-diaminobutyric acid and a fatty acid coupled with the peptide 
through an amide bond (Figure 1.7) (Hancock 1997). In analogy to polymyxin B, Colistin is 
active predominantly against gram-negative bacteria by interacting with anionic 
lipopolysaccharide molecules in the outer leaflet of the outer membrane. It competitively 
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displace divalent cations, like Ca2+ and Mg2+ from the phosphate groups of membrane lipids, 
thus causing an increase in the permeability of the cell membranes, leakage of intracellular 
contents and ultimately bacterial death (Hancock 1997). 
Figure 1.7 The Schematic structures of a colistin and polymyxin B antibiotics. Colistin and 
Polymyxin B are cationic polypeptides composed of a cyclic heptapeptide and a tripeptide side chain, 
which is acylated at the N terminal side by a fatty acid tail. X – Fatty acid residues; Y – NH2 for colistin 
and polymyxin B; Z – D-Leu for colistin, D-Phe for polymyxin B. Figure modified from (Laurent Poirel, 
Aurélie Jayol 2017). 
1.6.2 Intrinsic, adaptive and transferable resistance to colistin  
Bacteria developed several mechanisms to protect themselves from exposure to cationic 
antimicrobial peptides (cAMPs). These strategies include intrinsic, adaptive and transferable 
resistance mechanisms (Munita et al. 2016). Intrinsic resistance to colistin is mediated by 
modification of lipopolysaccharide with amino sugars or overexpression of outer membrane 
proteins. In Serratia marcescens and Proteus mirabilis resistance to polymyxins is associated 
with expression of the eptB gene or the arnBCADTEF operon resulting in addition of 
phosphoethanolamine (pEtN) or 4-amino-4-deoxy-L-arabinose (L-Ara4N) groups to the lipid 
A domain. Such modifications lead to a decreased affinity between polymyxins and the 
bacterial cell wall by increasing the net negative charge of LPS (Laurent Poirel, Aurélie Jayol 
2017).  
Adaptive resistance involves activation of LPS-modifying operons by mutations in two-
component sensing systems (TCSs) such as PmrA/PmrB and PhoP/phoQ or expression of 
efflux pumps (Olaitan, Morand & J.-M. Rolain 2014).  In several genera of the 
Enterobacteriaceae, such as Enterobacter, Escherichia, Klebsiella and Salmonella, the 
adaptive resistance to colistin is mediated by modification of LPS with L-Ara4N and pEtN 
groups (Raetz et al. 2007). A number of genes and operons play a role in mediating resistance 
to polymyxins. The pmrC gene, pmrE gene, pmrHFIJKLM operon encode for enzymes that are 
directly responsible for LPS modifications. The mgrB gene is involved in negative regulation 
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of PhoP/phoQ system. Besides, the colistin resistance regulator (crrAB) is associated with the 
regulation of the PmrAB two-component system (Olaitan, Morand & J. M. Rolain 2014). Figure 
1.8 represents known regulatory pathways for modifications of lipopolysaccharides. 
Figure 1.8 Regulation pathways of lipopolysaccharide modifications in Gram-negative bacteria. 
In Escherichia coli, MicA and MgrB cause negative feedback on the phoP/phoQ regulatory system, 
whereas mutations in mgrB or phoP/phoQ (marked as a red-colored asterisk) usually lead to the 
induction of the phoP/phoQ two-component system (TCS). In Salmonella sp., the induction of TCS 
activates: pagL gene resulting in deacylation of lipid A, pmrD gene leading to activation of pmrA and 
additionally, eptB is repressed by the activation of MgrR. Moreover, in Klebsiella pneumoniae, the 
phoP/phoQ regulatory system activates directly the arnBCADTEF operon. All these changes in LPS 
structure mediate resistance to polymyxin. Figure adapted from (Olaitan, Morand & J. M. Rolain 2014).  
Chromosomal mutations are heritable vertically and generally considered non-transferable by 
mobile genetic elements. However, in the late 2015 Liu et al. reported an existence of a plasmid-
mediated, colistin resistance conferring gene, named mcr-1 in animal and human isolates that 
can be transmitted by horizontal gene transfer (HGT) (Liu et al. 2016). This first identified 
plasmid-borne mechanism of polymyxin resistance is mediated by phosphoethanolamine 
transferase-like enzyme (MCR-1). MCR-1 catalyzes transfer of pEtN group onto the 
glucosamine-disaccharide of lipid A at the outer leaflet of the bacterial outer membrane, and 
therefore confers colistin resistance (Figure 1.9). The detailed characterization of the mobile 
colistin resistance is presented in chapter 4.5. 
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Figure 1.9 Reaction catalyzed by MCR-1 enzyme. MCR-1 catalyses transfer of phosphoethanolamine 
group from a phosphatidylethanolamine donor substrate onto the 1′ or 4′ position of lipid A domain. 
Figure modified from (Anandan, Evans, Condic-Jurkic, O’Mara, John, Phillips, G. A. Jarvis, et al. 2017) 
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2 Thesis objectives 
The aim of this thesis was to investigate the molecular basis for remodeling of the cell envelope 
of Gram-negative bacteria and its impacts on bacterial abilities to develop resistance to 
antibiotics and the release of outer membrane vesicles. 
Specific Aims:  
▪ The development and optimization of a protocol for isolating bacterial outer membrane 
vesicles. 
▪ The investigation of the OMV formation from different Gram-negative bacterial species 
with an emphasis on the mechanism of vesicle biogenesis, its regulation and the 
immunogenic properties of bacterial blebs. 
▪ The examination of the vesicles potential ability to transfer genetic material (including 
antibiotic resistance determinants) to other bacteria. 
▪ Studying the role of LPS remodeling mediated by MCR-1 in resistance development 
towards cationic antimicrobial peptides (cAMPs). 
▪ The analysis of the conditions required for functionality of the mobile colistin resistance 
(mcr-1). 
▪ The examination of the involvement of MCR-1 in production of OMV. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Instruments 
Equipment used in this thesis is listed in Table 3.1, Appendix A.  
3.1.2 Consumables 
Consumables used in this thesis are listed in Table 3.2, Appendix A.  
3.1.3 Chemicals 
Chemicals used in this thesis are listed in Table 3.3, Appendix A.  
3.1.4 Enzymes 
Enzymes used in this thesis are listed in Table 3.4, Appendix A.  
3.1.5 Kits 
Kits used in this thesis are listed in Table 3.5, Appendix A.  
3.1.6 Buffers, media and solutions 
Buffers, media and solutions used in this thesis and their composition are listed in Table 3.6, 
Appendix A. 
3.1.7 Bacterial strains and isolates 
Strains, isolates and plasmids used in this study are listed in  Table 3.7. 
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Table 3.7 Bacterial strains, isolates and plasmids used in this dissertation. 
Bacterial isolate and strains Description Source 
A. baumannii 10 Clinical isolate; Köln outbreak Institute collection 
A. baumannii 13-B9879 Clinical isolate; Bonn outbreak Institute collection 
A. baumannii 25 Clinical isolate; Köln outbreak Institute collection 
A. baumannii 65 Clinical isolate; Kiel outbreak Institute collection 
A. baumannii ATCC 17978 Clinical isolate ATCC collection 
A. Iwoffii Clinical isolate Institute collection 
C. freundii 08698 Clinical isolate; IncN plasmid::blaKPC-2 Institute collection 
Enterobacter 247 Clinical isolate Institute collection 
E. coli BL21 DE3 GOLD Competent cells (High Efficiency) NEB, Cambrige, UK 
E. coli DH10β Competent cells (High Efficiency) NEB, Cambrige, UK 
E. coli DH5α Competent cells (High Efficiency) NEB, Cambrige, UK 
E. coli H16 Clinical isolate; ColV plasmid::ΔhlyF Institute collection 
E. coli H76 Clinical isolate; ColV plasmid::hlyF Institute collection 
E. coli H8 Clinical isolate; ColV plasmid::hlyF Institute collection 
E. coli J53 A derivative of E. coli K-12, resistant to 
sodium azide 
Institute collection 
L. monocytogenes EGD-e Wild type isolate Institute collection 
S. marcescens 2099 Clinical isolate Institute collection 
S. marcescens 2126 Clinical isolate Institute collection 
S. marcescens 273255 Clinical isolate Institute collection 
Various E. coli and K. pneumoniae Mcr-1-producing as well as colistin 
susceptible isolates, For detailed 
description, see Appendix A, Table A-1 
Institute collection 
Plasmids 
pUC19 
Description 
Insert: hlyF gene; mcr-1 gene 
Source 
This study 
pET-28a Insert: mcr-1 This study 
pAc5.1/V5-HisA Insert: EGFP-LC3 gene fusion Institute collection 
pJBA27 Insert: EGFP, pUC18 backbone Institute collection 
p002 Mcr-1 encoding plasmid of E. coli 002 Institute collection 
p002::Δmcr-1 Mcr-1 deletion mutant of p002 This study 
3.2 Bacterial techniques 
3.2.1 Bacterial growth conditions 
Bacteria were grown overnight at 37°C with shaking at 180 rpm in Lysogeny broth (LB) (BD 
Bioscience, Heidelberg, Germany) media unless otherwise noted. The composition of LB broth 
is described in  Table 3.6. For short-term storage, bacteria were plating out on a LB agar plates 
supplemented with a proper antibiotic, followed by overnight incubation at 37°C. LB plates 
were prepared using the same recipe for LB with the addition of 15 g agar per liter of broth. 
The antibiotic concentrations used are as follows: ampicillin (100 mg/L), cefotaxime (2 mg/L), 
colistin (2 mg/L), kanamycin (30 mg/L). For long-term storage, bacterial cultures were prepared 
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by mixing an overnight culture with 60% (v/v) glycerol in LB medium at ration 1:1. The 
cultures were stored in a cryovials at -80°C or in liquid nitrogen. 
3.2.2 DNA purification and quantification 
Plasmids DNA were isolated using either the Mini plasmid isolation kit (Sigma-Aldrich, 
Germany) or Maxi plasmid isolation kit (Qiagen, Germany) according to the manufacturer’s 
protocol. For Maxi plasmid isolation kit, 100 – 500 ml of an overnight culture of bacteria 
harboring plasmid DNA was centrifuged at 6000 rpm for 20 min at 4°C to harvest bacterial 
cells. The pellets were resuspended in 10 ml of P1 buffer (resuspension buffer) containing 
RNase, mixed with 10 ml of P2 buffer (lysis buffer) by inverting each tube 4-6 times and 
incubated for 5 min at RT. Afterwards, 10 ml of P3 buffer (neutralization buffer) was added to 
the lysate, mixed by inverting 4-6 times, then incubated on ice for 20 min and followed by 
centrifugation at 13000 rpm for 30 min at 4°C. Afterwards, the QIA filter column was washed 
with 10 ml of QBT buffer (equilibration buffer) and the lysate was filtered through the HiSpeed 
column. Next, the column was washed two times with 30 ml of QC buffer (wash buffer) to 
remove contaminants; the flow-through was discarded. Then, plasmid DNA was eluted with 15 
ml of QF buffer (elution buffer), precipitated with 9.5 ml of ice cold isopropanol and incubated 
for 1 h at -20°C. Plasmid DNA was centrifuged at 6000 rpm for 1 h at 4°C, washed twice with 
5 ml of 70% ethanol, air-dried and dissolved in 100 ml of TE buffer. Isolated plasmid DNA 
was stored at 4 or -80°C. For Mini plasmid isolation kit, 3 ml of an overnight bacterial culture 
was pelleted by centrifugation (6000 rpm, 5 min) and completely resuspend with 200 μl of the 
resuspension solution, followed by lysis with 200 μl of the lysis solution. Cell debris was 
precipitated by adding 350 μl of the neutralization/binding solution. Next, the cell debris was 
pelleted by centrifuging (12000 rpm, 10 min) and then the cleared lysate was transferred to the 
column and again centrifuged at 12,000 rpm 1 min. Afterwards, the column was washed with 
750 μl of the wash solution and the plasmid DNA was eluted with 100 µl of the elution solution. 
DNA was stored at 4 or -80°C. The concentration of plasmid DNA was measured by Nanodrop 
(Thermo Scientific, Waltham, USA) according to the manufacturer’s protocol. For 
quantification of OMV-associated DNA, vesicles were treated with DNase I (Thermo 
Scientific, USA) to hydrolyze surface-associated and free DNA. DNase I pretreated OMVs 
were then lysed with GES solution (5 M guanidinium thiocyanate, 100 mM EDTA, 0.5% (v/v) 
Sarkosyl) to release DNA from OMVs, and then DNA was purified by the use of a PCR product 
Materials and Methods 
 
33 
 
purification kit (Stratec molecular, Birkenfeld, Germany). Purified vesicle DNA was quantified 
using the The Qubit® 2.0 Fluorometer (Life technologies, USA). 
3.2.3 Agarose gel electrophoresis 
1% agarose gels were prepared and run according to standard procedures (Sambrook, J., 
Russell, D.W. & Laboratory. 2012). The agarose gel was prepared by dissolving agarose in 1x 
TBE buffer supplemented with 5 mg/L of ethidium bromide (Thermo Scientific, USA). The 
tray containing gel was placed in an electrophoresis apparatus (construction of the institute) 
filled with 1x TBE buffer. The DNA samples were mixed with loading buffer and loaded into 
the wells of the gel. Electrophoresis was performed at 150V, 250 mA for 1 h. Sizes of DNA-
fragments were estimated by using a 1-kb plus DNA marker (Thermo Scientific, USA). The 
agarose gel was then visualized using the gel imaging system (Bio-Rad, Hercules, USA). 
3.2.4 S1 nuclease digestion followed by pulsed-field gel electrophoresis (S1-PFGE) 
To detect and estimate the sizes of bacterial plasmids, S1 nuclease digestion followed by 
pulsed-field gel electrophoresis (S1-PFGE) was performed as described previously (Barton et 
al. 1995). Briefly, the agarose-embedded total cellular DNA was incubated with lysis buffer 
(1M NaCl, 100 mM EDTA, 50 mM Tris-HCl (pH 7.6), 0.5% N-lauroylsarcosine) supplemented 
with lysozyme for 3 hours at 55°C. Gel plugs were washed 5 times with TE buffer and milli-q 
water followed by S1 nuclease digestion for 2 hours at 37°C. Digested plugs were applied to 
wells in 1% agarose gel. Electrophoresis was conducted using a CHEF-DRIVE III apparatus 
(Bio-Rad, USA) in 0.5 x Tris–borate–ethylene diamine tetra-acetic acid (TBE) buffer; 
conditions were 6 V, with 1 s–25 s pulses for 18 hrs. Patterns were normalized using the 
molecular weight marker (PFGE Lambda or Low range Marker, Thermo Scientific, USA). 
3.2.5 Preparation of chemically competent cells 
Chemically competent bacteria were prepared according to (Sambrook, J., Russell, D.W. & 
Laboratory. 2012) with some modification. An overnight bacterial culture was diluted 1:50 in 
LB medium and grown until an OD600 of 0.4 was reached. The Cells were incubated on ice for 
20 min prior to centrifugation at 4000 x g at 4°C for 10 min. The supernatant was discarded and 
pellets were re-suspended in 17 ml ice-cold CCMB80 buffer and incubated on ice for 10 min. 
Afterwards, cells were harvested by centrifugation as previously described and resuspended in 
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4.2 ml ice-cold CCMB80 buffer. 200 μl aliquots were frozen down in liquid nitrogen and stored 
at -80°C. 
3.2.6 Transformation of chemically competent cells 
Plasmids were transformed by using the heat shock method according to standard protocols 
(Sambrook, J., Russell, D.W. & Laboratory. 2012). 5 μl of DNA (50-100 ng) were added to 
200 μl of competent cells and incubated on ice for 30 min. Cells were then heat shocked at 42°C 
for 90 seconds followed by incubation on ice for 10 min. 750 μl pre-warmed SOC medium was 
added and cells were incubated at 37°C for 1 h, with shaking 250 rpm. Bacteria were spread 
onto LB plates containing a proper antibiotic and incubated overnight at 37°C. 
3.2.7 Construction of expressing vectors 
The sequences of the primers are shown in Table 3.8 
Construction of pUC19 vector expressing hlyF gene 
The hlyF gene was PCR amplified from the E. coli V76 by using primers hlyF_F and hlyF_R. 
The resulting amplicon was digested with XbaI and HindIII, and the hlyF-containing fragment 
ligated to a multiple cloning site (MCS) of XbaI/HindIII digested pUC19 plasmid. The resultant 
plasmids pUC19::hlyF was transformed into E. coli DH10β. 
Construction of pUC19 vector expressing mcr-1 gene 
pUC19::mcr-1 was constructed by PCR amplifying mcr-1 gene using as a template E. coli V163 
and oligonucleotide primers mcr-1_F and mcr-1_R. The resulting amplicon was digested with 
SalI and EcoRI enzymes, and then the mcr-1-containing fragment was ligated to MCS of 
Sal1/EcoR1 digested pUC19 plasmid. Finally, E. coli DH10β were transformed using 
constructed plasmid. 
Construction of mcr-1 and mcr-1Δ1-214 genes for purification 
To construct plasmid pET-28a::mcr-1 and pET-28a::mcr-1Δ1-214, DNA fragments encoding 
complete or truncated mcr-1 genes and pET-28-a backbone were amplified by PCR from 
plasmids p002 and pET28-a, respectively, with a 15 bp overhang for each fragment. The pairs 
of primers: mcr-1_pET28_F, mcr-1_pET28_R and mcr-1Δ1-214_F, mcr-1Δ1-214_R were used to 
amplify mcr-1 and mcr-1Δ1-214 genes, and pairs of primers pET28a_F, pET28a_R and 
pET28a_forΔ_F, pET28a_forΔ_R were used to amplify pET28-a backbone. A Gibson 
assembly cloning kit (New England Biolabs, UK) was then used for assembly of the fragments. 
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To clone hlyF and mcr-1 genes, the translational coupling strategy was used. This 
approach is based on controlling the translation rate of an upstream protein coding sequence by 
the translation rate of a downstream protein coding sequence. In this case, the translational 
coupling occurs when there is an overlap between open reading frames of lacZ and hlyF or lacZ 
and mcr-1 genes (Figure 3.1). 
Figure 3.1 A Schematic representation of translational coupling strategy for cloning hlyF and 
mcr-1 genes. Translational coupling is defined as the codependence of translation efficiency of 
neighboring genes, which are encoded by the same polycistronic mRNA. It occurs when two open 
reading frames (in this case, lacZ-hlyF and lacZ-mcr-1) consist of overlapping stop and start codons 
(marked in red). It can help to sustain a stable ratio between proteins expressed from the same operon. 
The genes hlyF and mcr-1 were cloned into pUC19 plasmid with inducible promoter by restriction 
digestion technique. 
Table 3.8 Oligonucleotides used in this work. 
Primer name Sequence (5’->3’) Annealing temp. [C] 
hlyF_F GCGCGCAAGCTTATGAAATTATTATTACTTACAGGTGC 51.3 
hlyF_R GCGCGCTCTAGATTATTTAAAATCAACTTCCATTTGTTG 49.8 
mcr-1_pUC19_F GCGCGCGTCGACATGATGCAGCATACTTCTGTGT 62 
mcr-1_ pUC19_R GCGCGCGAATTCTCAGCGGATGAATGCGGTGC 64 
mcr-1_pET28_F CTTTAAGAAGGAGATATACCATGATGCAGCATACTTCTGTGTGG 68.2 
mcr-1_pET28_R CAGTGGTGGTGGTGGTGGTGGCGGATGAATGCGGTGCG 68.2 
pET28a_F CACCACCACCACCACCACTG 70.2 
pET28a_R GGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGGGAA
TTGTTATC 
70.2 
mcr-1Δ1-214_F TGGTGCCGCGCGGCAGCCATGCGCCAAAAGATACCATTTATCAC 65.1 
mcr-1Δ1-214_R GCCCCAAGGGGTTATGCTAGTCAGCGGATGAATGCGGTG 65.1 
pET28a_forΔ_F CTAGCATAACCCCTTGGG 63 
pET28a_forΔ_R ATGGCTGCCGCGCGGCAC 63 
3.2.8 Plasmid mutagenesis 
To remove the mcr-1 gene (1626 bp) from IncX4 plasmid (36502 bp), the mutagenesis strategy 
based on RecA-independent recombination activity of E. coli K12 DH5α was performed. 
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Briefly, plasmid amplification was performed in a way that resulting fragments did not include 
mcr-1 gene. PCR amplicons were transformed into highly competent E. coli 5α (New England 
Biolabs, Ipswich, USA), followed by the assembly of three PCR fragments. Plasmids were 
maintained by addition of 2 mg/L colistin sulfate salt (Sigma-Aldrich) or 30 mg/L of kanamycin 
(Sigma-Aldrich) to the broth. The created constructs were sequenced to verify proper assembly 
of the plasmids and to except unexpected mutations induced by DNA polymerase. The 
sequences of used PCR primers are listed in Table 3.9. The map of wild type p002 and 
p002::Δmcr-1 are depicted in Figure A-1; see Appendix C . The plasmid sequences of p002 and 
p002::Δmcr-1 are available in Genbank under the accession numbers MF381176 and 
MF381175, respectively. 
Table 3.9 The nucleotide sequences of the primers used for deletion of mcr-1 gene from IncX4 plasmid 
p002. 
Primer Sequence 5’3’ Annealing temp. [C] 
Δmcr-1_Fragment1_FOR ttccatcttcaacagatctctgattcgaaacc  60 
Δmcr-1_Fragment1_REV ttgtctgttttcgaaaagattatcgtggattgt                  60 
Δmcr-1_Fragment2_FOR gtttataacaatccacgataatcttttcgaaaacagaca            60.2 
Δmcr-1_Fragment2_REV tattttttgagtagtttctctttctccctgtattttttccaaacccacc  60.2 
Δmcr-1_Fragment3_FOR ggaaaaaatacagggagaaagagaaactactcaaaaaataaacggtggga 62.5 
Δmcr-1_Fragment3_REV tgggctgtggtttcgaatcagagatctgttga   62.5 
3.2.9 DNA sequencing, assembly and annotation 
For sequencing of plasmid DNA derived from C. freundii, the bacterial DNA was isolated from 
the overnight culture using the PureLink Genomic DNA isolation kit (Thermo Scientific, USA) 
according to instructions of the manufacturer. DNA sequencing libraries were prepared using 
the Nextera® XT kit (Illumina, San Diego, USA). Paired-end sequencing with a read-length of 
300 bp was performed using the Illumina MiSeq platform (Illumina, San Diego, USA). The 
sequences from each isolate were separately assembled de novo with SPAdes - St. Petersburg 
genome assembler or by using CLC Genomics Workbench and genome was annotated by 
GenDB (St. Petersburg Academic University, St. Petersburg, Russia (Nurk et al. 2013); 
QIAGEN Bioinformatics, Hilden, Germany and University of Giessen, Giessen, Germany for 
SPAdes, CLC Genomic and GenDB, respectively). The genetic map of the resulting contigs 
was generated with MAUVE software. For sequence of p002, a long-read single-molecule real-
time (SMRT) sequencing (Pacific Biosciences, MenloPark, CA, USA) supplemented with short 
read sequencing using the Illumina platform was performed, as described earlier (Falgenhauer 
et al. 2017). For sequencing of p002::Δmcr-1, plasmid DNA was isolated using the Qiagen 
Plasmid Maxi Kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions. A 
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Nextera XT library of the plasmid (Illumina, San Diego, USA) was sequenced on a NextSeq 
500 platform using 2x150 bp runs. Raw data was assembled using SPAdes and comparison of 
pV002 with pV002::Δmcr-1 was performed using blastn. 
3.2.10 Antibiotic susceptibility testing 
The minimum inhibitory concentration (MIC) was determined by Broth microdilution (BMD) 
and E-test. The BMD with cation-adjusted Mueller-Hinton broth (Sigma Aldrich, Germany) 
was performed according to the Clinical and Laboratory Standards Institute (CLSI) 
recommendations (Eucast 2016). Colistin was tested over a range of dilution (0,16-256 mg/L). 
Due to lack of breakpoints for polymyxins for Enterobacteriaceae according to CLSI, I used 
the breakpoint values of the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) for reference. Enterobacterial isolates with colistin MICs <2 μg/mL were 
categorized as susceptible; those with MICs >2 μg/mL were categorized as resistant. As 
recommended by CLSI, microdilution method was performed in plain polystyrene microplate 
(Thermo Scientific, USA). For E-test method, the susceptibility to colistin was determined in 
accordance with the manufacturer’s instructions (Liofilchem, Roseto degli Abruzzi, Italy). The 
MIC was read where growth inhibition intersected the antibiotic strip. When small colonies 
grew within the area of inhibition or a haze of growth occurred around the MIC end-point, the 
highest MIC intersection was noted. 
3.3 Protein techniques 
3.3.1 MCR-1 expression and purification 
A starter inoculum was prepared by adding a single colony into 20 mL of LB medium 
containing 30 mg/ml of kanamycin antibiotic and grown at 37°C overnight at 180 rpm. The 
overnight culture was subculture into 1L of freshly prepared LB medium and incubated at 37°C 
in a shaking incubator set at 180 rpm until the OD600 reached 0.6. MCR-1 expression was 
induced by the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) (Sigma-Aldrich, St. 
Louis, USA) to a final concentration of 1 mM. After 3 hours of post-induction incubation, cells 
were harvested at 7000 rpm for 30 min at 4°C. The pelleted cells were resuspended in 
Phosphate-buffered saline (PBS) (Merck Millipore, Germany) and protease inhibitor cocktail 
was added (bimake.com, Houston, USA). Lysis was performed using a Mixer Mill MM 400 
(Retsch GmbH, Haan, Germany). The lysate was centrifuged at 10,000 x g for 10 min at 4°C 
to remove the non-lysed cells. Membranes were pelleted by further centrifugation of the 
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supernatant at 100,000 x g for 1 hour using an L8-60M ultracentrifuge (Beckman Coulter, Brea, 
USA). The pelleted membrane fraction was resuspended in 1 mL of the lysis buffer (20 mM 
sodium phosphate pH 7.4, 500 mM NaCl, 10 mM imidazole, 1% n-Dodecyl β-D-maltoside 
(DDM) (Sigma-Aldrich, USA)). The mixture was then sonicated by B-12 Cell Disruptor 
(Branson Sonic Power Company, St. Louis, USA) and centrifuged at 40,000 x g for 10 min. 
The resultant supernatant containing the MCR-1 solubilized in DDM detergent micelles was 
filtered using an 0.22 µm syringe filter (Merck Millipore, Darmstadt, Germany) and applied 
onto a HisTrap HP 5ml affinity chromtagraphy column (GE Healthcare, Chicago, USA) 
equilibrated with binding buffer (20 mM sodium phosphate pH 7.4, 500 mM NaCl, 5 mM 
imidazole and 0.023 % DDM) using an ÅKTApurifier FPLC system (GE Healthcare, USA). 
The unbound protein was washed from the column with binding buffer until the absorbance at 
280 nm reached a stable baseline value. The bound MCR-1 was eluted from the column using 
an increasing gradient of elution buffer (20 mM sodium phosphate pH 7.4, 500 mM NaCl, 500 
mM imidazole, 0.023 % DDM). A peak corresponding to MCR-1 eluted between 40 % and 50 
% elution buffer. The collected eluent fractions were pooled and applied onto a PD-10 desalting 
column (GE Healthcare, USA), equilibrated in 20 mM sodium phosphate pH 7.5, 500 mM 
sodium chloride and 0.023 % DDM. The final purified MCR-1 protein was resuspended in 
phosphate-buffered saline (PBS) containing 0.023% DDM. Then, SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) was performed to assess the purity of the eluted peak fractions. 
Fractions of pure protein were pooled and concentrated using a 10 kDa molecular weight cut 
off centrifugal filter unit (Amicon Ultra-15, ultracel 10K, Merck Millipore, Germany) to 5 
mg/mL as determined by the Bradford protein assay (Thermo Scientific, USA). 
3.3.2 Outer membrane vesicles and whole cell fraction isolation 
OMVs were isolated from bacterial liquid cultures as previously described (Kadurugamuwa & 
Beveridge 1995) with some modifications. Briefly, 10 ml of an overnight culture was used to 
inoculate 1 L of LB broth containing a proper antibiotic. Bacterial culture was grown at 37°C 
with shaking 180 rpm to the beginning of stationary phase. Cells were removed by 
centrifugation at 6,000 x g at 4°C for 30 min (Sorvall, Newtown, USA) and the culture 
supernatant was filtrated through a Stericup bottle top vacuum filter (0.2 µm size; Merck, USA). 
The supernatants were concentrated via a 100-kDa tangential filtration concentration unit (Pall 
Corporation, USA) or cross-flow filtration system (Spectrum labs, USA). The retentate was 
filtered through a 0.22 µm pore size, PVDF syringe filter (Merck, Germany) to remove the 
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remaining bacteria. OMVs were pelleted from the concentrates by ultracentrifugation at 
100,000 x g for 3 hours at 4°C (Beckman Instruments, Canada; SW 40 Ti rotor). The pelleted 
OMVs were resuspended in PBS and once again filtered through 0.22 µm pore size syringe 
filters (Merck, USA). The absence of viable cells in OMVs suspensions was determined by 
spreading aliquots on LB agar plates to test for bacterial growth. Additionally, crude vesicles 
were purified on OptiPrep gradients according to method adapted from Susanne J. Bauman 
(Bauman & Kuehn 2006). The vesicles were stored at -80°C until further use. The whole cell 
lysate fraction was isolated from bacterial overnight culture. Cells were harvested by 
centrifugation at 13 200 x g for 5 min and re-suspended in 50 μl of two-times concentrated 
sample loading buffer. Samples were stored at - 80ᵒC. 
3.3.3 Protein Quantification 
The protein concentration was determined according to the Bradford assay (Bio-Rad, USA) or 
β-Lactamase enzymes activity by using Nitrocefin (Thermo Scientific, USA). For Bradford 
assay, 10 µl pf protein sample was mixed with 200 μl of Bradford dye reagent (Bio-Rad, UK) 
and the mixture was incubated at room temperature for 5 min followed by the absorbance 
measurement at 595 nm. Samples were measured in triplicate and compared with a standard 
curve plotted using serial dilutions of bovine serum albumin (BSA). For spectrophotometric 
assay, the β-Lactamase activity of proteins was measured by the ability of the enzyme to 
hydrolyze the β-lactam Nitrocefin, leading to a change in absorbance from OD390 to OD486. 
Enzyme activity was directly proportional to the intensity of Nitrocefin color. 
3.3.4 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were resolved by SDS-PAGE method using polyacrylamide gels prepared according 
to Table 3.10. Resolving gel was prepared using a protean gel casting apparatus (Biometra, 
Goettingen, Germany) and allowed to polymerize at RT. Afterwards, the stacking gel was 
poured on top of resolving gel and a comb was inserted to allow the formation of sample wells. 
Once polymerized, the protein gel was assembled in the electrophoresis chamber filled with 1x 
SDS running buffer. Protein samples were denatured in 2x protein loading buffer for 10 min at 
95°C, cooled on ice and loaded onto the gel. Protein Marker was loaded alongside the samples 
and electrophoresis was performed at 150 V for 90 min. 
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Table 3.10 Composition of stacking and resolving gels. 
Component (10ml) 8%  
Resolving 
10% Resolving 12% Resolving 5,7%  
Stacking 
MQ water 4.6 3.8 3.2 5.95 ml 
Tris HCl (pH 8.8; 1.5 M) 2,6 ml 2,6 ml 2,6 ml  
Tris HCl (pH 6.8; 0.5 M)    2.5 ml 
30% Polyacrylamide 2.6 ml 3.4 ml 4 ml 1.34 ml 
10% SDS 100 µl 100 µl 100 µl 100 µl 
10% APS*  100 µl 100 µl 100 µl 100 µl 
TEMED 10 µl 10 µl 10 µl 10 µl 
*APS and TEMED were added right before use. 
3.3.5 Vesicles-mediated transformation 
Transformation experiments were performed using E. coli J53 (plasmid-free) as a recipient 
strain and outer membrane vesicles harvested from bacterial culture as donor molecules. The 
overnight culture of E. coli J53 was subcultured to fresh LB medium and incubated at 37°C at 
180 rpm until optical density at 600 nm reached 0.4. Bacterial culture was mixed with purified 
vesicles, which have been pretreated with DNase I enzyme. The mixtures were then incubated 
at 37°C for 18 hours with shaking (100 rpm). Control experiments were carried out without 
vesicles or with 1 µg purified plasmid DNA. The bacterial cells that had acquired antibiotic 
resistance were selected on LB agar supplemented with a proper antibiotic and 200 mg/L of 
sodium azide. The plates were incubated for 48 h at 37°C and evaluated by colony counting. 
The antibiotic-resistant isolates were screened for the presence of the resistance gene by PCR. 
The size of transferred plasmid was evaluated by S1 nuclease digestion followed by pulsed-
field gel electrophoresis (PFGE) as described in chapter 3.2.4. 
3.3.6 Mass spectrometry analysis 
For identification vesicular proteins, an Orbitrap Velos Pro mass spectrometer (Thermo 
Scientific, USA) was used. An ultimate nanoRSLC-HPLC system (Thermo Scientific, USA) 
was equipped with a nano C18 RP column and connected to the mass spectrometer through a 
nanospray ion source. 5 µL of the tryptic digest were injected onto a C18 column. Automated 
trapping and desalting of the sample was performed at a flowrate of 6 µL/min using 
water/0.05% formic acid as solvent. Separation of the tryptic peptides was attained with the 
following gradient of water/0.045% formic acid (solvent A) and 80% acetonitrile/0.05% formic 
acid (solvent B) at a flow rate of 300 nL/min: holding 4% B for five minutes, followed by a 
linear gradient to 45%B within 30 minutes and linear increase to 95% solvent B in additional 5 
minutes. The column was connected to a stainless steel nanoemitter (Thermo Scientific, USA) 
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and the eluent sprayed directly to the heated capillary of the mass spectrometer using a potential 
of 2300 V. A survey scan with a resolution of 60000 within the Orbitrap mass analyzer was 
combined with at least three data-dependent MS/MS scans with dynamic exclusion for 25 s 
either using CID with the linear ion-trap or using HCD and orbitrap detection at a resolution of 
7500.  The analysis of data was done using Proteome Discoverer (Thermo Scientific, USA) 
with SEQUEST and MASCOT (version 2.2; Matrix science) search engines using a user 
defined database comprising the sequence of the protein of interest.  
For analysis of lipid A fractions, an Ultraflex I TOF/TOF mass spectrometer (Bruker 
Daltonics, Bremen) equipped with a nitrogen laser and a LIFT-MS/MS facility was used. The 
instrument was operated in the positive-ion reflectron mode using 2.5-dihydroxybenzoic acid 
and methylendiphosphonic acid as matrix solution. Sum spectra consisting of 200-400 single 
spectra were acquired. For data processing and instrument control the Compass 1.1 software 
package consisting of FlexControl 2.4, FlexAnalysis 3.0 and BioTools 3.0 was used. External 
calibration was performed with a peptide standard (Bruker Daltonics). 
3.3.7 Nuclear Magnetic Resonance (NMR) spectroscopy analysis 
One- and two-dimensional 1H-NMR spectra were acquired on a Bruker AV600 spectrometer 
at temperatures between 280 and 310 K in DMSO-d6. Samples contained a 1-5 mM peptide 
antibiotic mixed with 0-300 mM calcium chloride dihydrate (Sigma Aldrich, Germany). 
3.3.8 MCR-1 activity assay 
The activity of MCR-1 was determined by using a substrate containing a fluorescent label, 1-
acyl-2-{12-[(7-nitro-2-1,3- benzoxadiazol-4-yl)amino]dodecanoyl}-sn-glycero-3 phospho-
ethanolamine (Acyl-NBD-PE) (Avanti Lipids, Alabaster, USA). To evaluate cleavage of pEtN 
group from acyl-NBD-PE catalyzed by MCR-1, 1µg of purified enzyme was added to 2µg of 
lipid substrate and incubated for 20 hours at RT. The reactions were applied to a TLC Silica gel 
60 plate (Merck Millipore, Germany) and developed using ethyl acetate:methanol:water 
(7:2:1). The fluorescence signal on the plate was visualized in the Molecular Imager Gel Doc 
XR System (Bio-Rad, Hercules, USA). For confirmation of product formation (1-acyl-2-{12-
[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl}-sn-glycerol) the appropriate material 
was scraped off from the TLC plate and washed with methanol. The concentrated eluent was 
analyzed by mass spectrometry. 
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3.4 Cell culture techniques 
Human cervical adenocarcinoma cells (HeLa) were used in this thesis. The eukaryotic cells 
were handled under a sterile laminar flow hood. Only sterile buffers, media, glassware, and 
consumables were used during working with cells. 
3.4.1 Media and solution 
Table 3.11 Media and solution used in this thesis. 
DMEM Dulbecco’s Modified Eagle medium containing Earle's Salts, 1g/l D-glucose, L-
glutamine and pyruvate 
FBS 100% foetal bovine serum, inactivated at 56°C for 30 min 
Freezing medium 90% FBS, 10% DMSO 
HBSS Hank’s balanced salt solution without Ca2+, Mg2+, phenol red 
NEA 100x non-essential amino acids 
Opti-MEM Reduced serum Eagle’s minimum essential medium with HEPES, sodium bicarbonate, 
hypoxanthine, thymidine, sodium pyruvate, L-glutamine, trace elements and growth 
factors 
PBS Phosphate-buffered saline; without Ca2+ and Mg2+ 
Trypsin/EDTA 1x trypsin/EDTA; 0.05%/0.02% (w/v) in PBS; without Ca2+ and Mg2+ 
3.4.2 Culture of eukaryotic cells 
Human cervical adenocarcinoma cells (HeLa) were maintained in 10 cm plates containing 
DMEM (Gibco, Thermo Scientific, USA) supplemented with 10% fetal bovine serum (FBS) at 
37°C in a humid atmosphere of 5% CO2. Cells were split every two to three days or whenever 
they attained 80–90% confluency. For splitting, the medium was removed and the cells were 
washed once with 4 ml of HBSS. To detach the adherent cells from the bottom of the plates, 
cells were incubated with 1.5 ml trypsin at 37°C in a CO2-incubator for 3 min. The enzymatic 
reaction of trypsin was stopped by adding 1.5 ml of DMEM with 10% FBS, and the cells were 
then transferred into new cell culture plate containing the fresh medium. The total volume of 
medium in each petri dish was 10 ml. For storage, the detached cells were transferred into 15 
ml tubes and centrifuged (700 rpm, 3 min, RT, Heraeus Megafuge 1.0 R centrifuge). The pellets 
were resuspended in freezing medium and placed into a 2 mL cryovials. The cells were either 
store at -80°C or in liquid nitrogen. To thaw frozen cells, cryovials were warmed up at 37°C 
and cells were transferred to a 10 ml dish containing 10 ml of fresh medium. 
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3.4.3 Transfection of eukaryotic cells 
Cells were split approximately 18h prior to DNA transfections, and the confluency was between 
60-75% at the time of transfection. For plasmid transfections, the cells (̴ 5x105) were plated in 
12-well plates and incubated at 37°C. Prior to transfection, the cells were washed three times 
with HBSS and the culture medium was changed to DMEM without FBS. HeLa cells were 
transfected with EGFP-LC3-plasmid. The plasmid DNA and lipofectamine 2000 were diluted 
in Opti-MEM medium and incubated for 5 min at RT (1 μg of plasmid DNA and 5 μl of 
lipofectamine 2000 per well). Diluted DNA and diluted lipofectamine were combined at a 1:1 
ratio and incubated for 5 min at RT. The DNA-lipid complex was added to the cells and 
incubated at 37°C for 4h. Afterwards, fresh DMEM supplemented with 10% FBS was added 
and the cells were incubated for 24h. 
3.4.4 Infection of eukaryotic cells 
On the day of experiment, the HeLa cells were washed once with HBSS, the fresh DMEM 
medium was added and the cells were incubated at 37°C for 2h. Afterwards, the cells were 
washed carefully three times with prewarmed HBSS and the cells were kept in DMEM 
containing 0.5% FBS. The cells were then ready to be used for infection assays. For OMVs 
infections, the bacterial vesicles were prepared as described in chapter 3.3.5 and were added to 
the cells (1 or 3 µg of OMVs per well). The cell culture plates were incubated for 4 h at 37°C 
and 5% CO2. The formation of autophagic vacuoles was observed by fluorescence microscopy 
(FM). Sample preparation for FM is described in chapter 3.5.1. 
3.4.5 Immunoblotting 
Following SDS-PAGE separation, protein sample were blotted onto a PVDF membrane for 1.5 
hours at 72 mA by using an electroblotting apparatus (construction of the institute) in the 
presence of transfer buffer. Afterwards, membranes were blocked for one hour in blocking 
buffer (5 % milk powder in wash buffer). The membranes were then incubated with primary 
antibody followed by incubation with secondary antibody conjugated with horseradish 
peroxidase for overnight and 2 hours, respectively. Antibodies were diluted in blocking buffer. 
Then, the membranes were washed 3 times with TBST for 5 min per wash. The membranes 
were incubated with the enhanced chemiluminescence (ECL) detection system (Thermo 
Scientific, USA) for 1 min. Finally, the films were developed using a chemiluminescence 
imaging system (Syngene, Cambridge, UK). 
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3.5 Microscopic techniques 
3.5.1 Fluorescence microscopy 
For autophagy detection, the HeLa cells expressing GFP fused to LC3 gene were used to 
visualize the formation of autolysosomes observed as green puncta by fluorescence 
microscopy, BZ-8000K (Keyence, Neu-Isenburg, Germany). After the incubation of cells with 
OMVs, the culture medium was completely removed, and the cells were fixed with 500 μl of 
3.7% formaldehyde in PBS for 10 min at RT. The coverslips were washed three times with PBS 
and were mounted on glass slides by using ProLong droplets with the cells facing down. The 
clear nail polish was used to seal the coverslips to the microscopic slides and then the samples 
were analyzed under the fluorescence microscope. 
3.5.2 Transmission electron microscopy 
The OMV or bacterial cell samples were applied on the formvar coated copper grids, negatively 
stained with 1% ammonium heptamolybdate or 1% uranyl acetate and subsequently decanted. 
Stained grids were allowed to air dry and then the samples were observed and imaged using a 
Zeiss EM900 transmission electron microscope (Carl Zeiss, Oberkochen, Germany). For 
ultrathin sectioning, the HeLa cells were seeded in a plastic chamber (Nunc Lab-Tek Chamber 
Slide system 2 wells, Permanox® slide) containing 2 ml of DMEM medium per well. After 
exposer to OMVs, the cells were rinsed with sodium cacodylate buffer (pH 7.4) and fixed with 
2% glutaraldehyde in 0.1 M sodium cacodylate buffer for 1 h at room temperature, followed by 
post-fixation with 1% osmium tetroxide (OsO4) in 0.1 M sodium cacodylate buffer. The 
samples were then dehydrated in a graded series of ethanol (10%, 30%, 50%, 70%, 90% and 
twice 100%) for 10 min each and embedded in Epon resin (Pelco, USA) before ultrathin 
sections (70-100 nm) were applied to collodion-coated copper grids. The samples were then 
observed under Leo 912 transmission electron microscope (Carl Zeiss, Germany) at 80 kV 
accelerating voltage and combined with a TRS Sharpeye slow scan dual speed CCD camera 
(Albert Troendle Prototypentwicklung, Germany). 
3.5.3 Field-emission scanning electron microscopy 
The overnight bacterial culture was fixed with 5% formaldehyde and 1% glutaraldehyde in 
growth medium and dehydrated in a graded series of acetone (10%, 30%, 50%, 70%, 90% and 
twice 100%) on ice for 10 min each. Samples were then subjected to critical-point drying 
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apparatus with liquid CO2 (CPD 030, Balzers, Liechtenstein). Dried samples were covered with 
a gold-palladium film by sputter coating (SCD 500, Balzers, Liechtenstein) before examination 
by field emission scanning electron microscope (FE-SEM) Zeiss Merlin (Carl Zeiss, Germany) 
with an accelerating voltage of 20 kV. Images were taken by the high efficiency SE2 detector. 
Contrast and brightness were adjusted by imageJ software. 
3.6 Galleria mellonella infection assay 
G. mellonella larvae were bred on an artificial diet containing 22% maize meal, 22% wheat 
germ, 17.5% bees wax, 11% dry yeast, 11% honey, and 11% glycerin at RT in darkness prior 
to infection. Bacterial inoculums were injected dorsolaterally into the hemocoel by using 1 ml 
hamilton syringe mounted on a microapplicator (Figure 3.2). After injection, larvae were 
incubated at 37°C in dark. Larvae were considered dead when they exhibited no movement in 
response to touch. No mortality of G. mellonella larvae was noted when they were injected with 
0.85% sodium chloride solution. For cfu counting, infected Galleria larvae were homogenized 
in LB medium with 1% Triton X-100. Homogenates were plated onto LB agar plate and 
colonies were counted after incubation at 37°C for 24 h. For priming of G. mellonella, the larvae 
were injected with 3µg of bacterial OMV to trigger immune responses. 24 h after the 
administration of vesicles, different amount of various bacterial species were injected into each 
larva for determination of survival rates. 
Figure 3.2 Infection of G. mellonella larva with bacterial inoculum. The larvae were infected by 
intrahemocoelic injection of bacterial inoculum through the last left pro-leg by using an injection 
apparatus. The survival rate of larvae was monitored for 7 days post bacterial challenge. 
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3.7 Bioinformatics tools used in this study 
Cytoscape software (Institute for Systems Biology, USA) was used for visualizing protein-
protein interaction networks and integrating these networks with annotation data. CBS 
Prediction Servers (Center for biological sequence analysis, Technical University of Denmark) 
including transmembrane helices prediction method based on a hidden Markov Model 
(TMHMM) was used to predict the presence of transmembrane helices in proteins of interest. 
The RaptorX structure prediction server (Källberg et al. 2012a) was used to predict tertiary 
structure of a protein sequence using known structure as a templates. The Pfam library of 
annotated protein domains (European Bioinformatics Institute, UK) was used to identify the 
domain architecture of analysed proteins. The Prosite and Myhits database (SIB Swiss Institute 
of Bioinformatics, Switzerland) were used to find the domains, families and functional sites 
within investigated proteins. The list of all bioinformatics tools used in this thesis is presented 
in Table 3.12. 
 
Table 3.12 Bioinformatic softwares used in this study. 
Software Company 
Brig Open Source 
Cytoscape Institute for Systems Biology, USA 
SeqBuilder DNASTAR, USA 
Easyfig Beatson Microbial Genomics Lab. 
EggNog 4.5 database Embl, Germany 
NEBcutter V2.0 New England Biolabs, UK 
NEBuilder Assembly Tool New England Biolabs, UK 
Snapgene GSL Biotech, USA 
Construction of the protein - protein interaction network (PPIN) 
To map the identified proteins of OMVs into the PPI network, all vesicular proteins were 
converted to gene symbols. Protein interaction data were gathered from the database of binary 
protein-protein interaction landscape of Escherichia coli (Rajagopala et al. 2014), which 
contains 2,234 high-quality PPIs among 1,269 proteins. Using the protein interaction data, the 
PPI networks for the vesicular proteins were constructed. The PPIN was visualized using 
Cytoscape software version 3.5.1 with self-interactions being removed prior to analysis. 
3.8 Statistical analysis 
The data were calculated and represented as mean +/- standard deviation (SD) from at least 
three independent trials. The statistical analysis toolkit included in the MS Excel 2016 
(Microsoft, USA) package was used to test variances between experimental sets and 
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subsequently run the t-test. For all statistical operations P < 0.05 were considered as significant 
p-values. The graphs were plotted with Excel (Microsoft, USA) computer software. 
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4 Results 
Section I 
4.1 Isolation of outer membrane vesicles and their contribution to spread of bacterial 
intracellular constituents 
4.1.1 Optimization of method for isolation of outer membrane vesicles 
A main limitation in studying the OMVs is the great effort and the lack of standardization for 
already challenging procedures to isolate these nanometer-sized structures (Momen-Heravi et 
al. 2013). The current gold standard and most commonly used technique for OMVs purification 
is differential centrifugation and filtration, which involve a number of centrifugation, 
ultracentrifugation and filtration steps followed by quantification of vesicular proteins using 
e.g., Bradford assay and their quality control by electron microscopy. In this thesis, the outer 
membrane vesicles were isolated according to a previously described method with 
modifications (Kadurugamuwa & Beveridge 1995). I recommend this optimized protocol for 
everybody else as it results in a higher yield of bacterial blebs with greater purity and quantity.  
 The workflow of OMVs isolation used in this study is shown in Figure 4.1 and detailed 
described in chapter 3.3.2. 
Figure 4.1 Workflow of OMV isolation. Vesicles purification protocol includes the following steps: 
Cultivation of bacterial isolates – the type of medium, incubation time and addition of antibiotics might 
influence the vesiculation rate and composition of OMVs; Removal of intact bacteria – low speed 
centrifugation followed by sterile filtration remove any residual bacterial cells; Concentration of the 
supernatant – ultrafiltration approach is usually used to preconcentrate the filtrate prior to 
ultracentrifugation; Purification – sterile filtration or density gradient centrifugation can by carried out to 
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remove any non-OMV-associated contaminants, such as flagella and pili structures. The final step 
should include the quantification of vesicular protein by e.g., Bradford assay and quality control 
assessed by electron microscopy. Additionally, the absence of viable bacteria is confirmed by plating 
out the aliquots of OMV samples onto LB agar plates to test bacterial growth. 
In order to isolate bacterial vesicles, the OMVs were harvested from liquid culture after 
appropriately long incubation time. Too short cultivation results in very low OMVs yield, 
whereas too long bacterial growth leads to vesicles contamination through the broken 
membranes, debris and cytoplasmic proteins (Klimentová & Stulík 2015). Therefore, to keep 
possibly high vesicle yield and low impurity level, bacteria were grown until early-stationary 
phase. The next step in OMVs isolation included removal of intact bacteria by centrifuging at 
6000 x g for 30 min at 4°C. The supernatant was further sterile filtrated through 0.22 μm, PVDF 
membrane (with low protein binding properties) to remove any residual cells. As a total amount 
of vesicles in the media is very low, a subsequent concentration step by e.g., ultrafiltration (UF) 
is very required and constitutes a crucial stage in OMVs purification. Supernatants were 
concentrated using two types of UF systems. Initially, the tangential flow filtration (TFF) device 
(Pall Corporation, USA), in which the solution flows through the system under gentle pressure 
in a parallel direction to the membrane was used (Figure 4.2A). Although, Pall TFF system 
exhibit highly predictable performance characteristics and yields, its throughput is very 
compromised, resulting in filtration speed only up to 1 L of culture per hour. Thus, I switched 
to cross-flow (CF) based filtration system (Spectrum Labs, USA), which has higher overall 
liquid removal rate compare to Pall TFF filtration (Figure 4.2B).  
Figure 4.2 Ultrafiltration devices used for OMVs isolation.  Ultrafiltration (UF) methods depend on 
the use of polymeric membranes with highly defined pores to separate molecules according to their size. 
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The tangential flow filtration (TFF) systems produced by Pall Corporation (A) and Spectrum Labs (B) 
were used. In UF process during OMVs isolation, a sterile filtrated bacterial supernatant was passed 
through a membrane with an appropriate molecular weight cut-off (100 kDa) to remove most of non-
OMV-associated proteins and concentrate the OMVs-containing retentate prior to ultrafiltration.  
By using Spectrum Labs filtration unit equipped with 100 kDa (molecular weight cut-off) 
hollow fiber membranes, proteins and other contaminants under 100 kDa were removed from 
supernatant and concentration time of 1 L of medium was reduced to approximately 10 min. 
The OMVs were afterwards pelleted from 50 times concentrated retentate by ultracentrifugation 
at 150,000 x g for 3 h at 4°C and resuspended in phosphate buffered saline. In order to exclude 
the other extracellular materials from the OMV preparations, it is extremely important to filter 
the retentate and then again pelleted crude vesicles through 0.22 μm syringe filter.  
The protocol for OMVs isolation was optimized based on a very motile Enterobacter 
247 isolate. To purify vesicles from highly flagellated bacteria and separate them from other 
contaminants including flagella, fimbria and pili, density gradient centrifugation (DGC) needs 
to be employed (Dauros Singorenko et al. 2017). OMVs are composed of lipids, and therefore 
their density is lower than that of flagella, pili and various soluble secreted proteins. The crude 
OMVs obtained after ultracentrifugation were mixed with high density OptiPrep solution, 
overlaid with step gradients of lower-density solutions and centrifuged 20 hours at 150,000 x 
g. Equal volume fractions were collected from the top of each gradient and analyzed by CBS 
SDS-PAGE and TEM microscopy (Figure 4.3). According to TEM micrographs, the 
purification technique utilizing DGC allowed for removing flagella-like contaminants. 
Optimized here method for isolation and purification of sufficient amounts of OMVs from 
bacterial cultures represents a pivotal step for the subsequent analyses. 
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Figure 4.3 Purification of OMVs derived from Enterobacter 247 by OptiPrep density gradient 
centrifugation (DGC). OMVs were resuspended in 45% OptiPrep solution in 50 mM HEPES - 150mM 
NaCl, pH 6.8 and layered below OptiPrep density gradient (2 ml of 40%, 35%, 30%, 25% and 20% in 
HEPES) followed by centrifugation for 20 hours at 150,000 x g. Equal volume fractions (0.75 ml) were 
obtained sequentially from the top of each gradient and analyzed by Coomassie-stained SDS-PAGE 
(A) and TEM analysis (B) (fraction 3 shown). WCL - whole-cell lysate fraction, OMV - outer membrane 
vesicle fraction; Scale bar, 200 nm. 
4.1.2 Involvement of the OMVs in antibiotic resistance 
OMVs can mediate resistance to antibiotics through a diverse set of mechanisms. In some cases, 
they can serve as a vehicle for the transport of plasmids encoding antibiotic resistance. This 
mechanism of vesicles-mediated antibiotic resistance is discussed in chapter 4.3. In other cases, 
OMVs can carry active β-lactamases, and therefore provide protection against antibiotic-
induced killing. 
To detect the presence of active β-lactamase enzymes in OMVs, the chromogenic 
cephalosporin substrate Nitrocefin was used. OMVs derived from Enterobacter 247 and E. coli 
DH10β harboring pUC19 plasmid that encodes β-lactamase gene were mixed with Nitrocefin 
followed by spectrophotometric measurement (Figure 4.4A). The β-lactamase activity of 
vesicles was measured by the ability of the enzyme to hydrolyze the β-lactam Nitrocefin, 
leading to a change in absorbance from OD390 to OD486. OMVs isolated from both Enterobacter 
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247 and E. coli carrying pUC19 were β-lactamase positive as Nitrocefin’s color changed from 
yellow to red within 30 min. 
To reveal whether vesicles derived from β-lactamase-producing bacteria can protect 
ampicillin-susceptible isolates, the E. coli DH10β (103 CFU/ml) was exposed to 10 µg of 
Enterobacter OMVs containing active β-lactamases, followed by streaking out the suspension 
onto LB agar plate supplemented with 100 mg/L of ampicillin. A significant increase in the 
number of CFU was noted for ampicillin-susceptible E. coli culture that had been preincubated 
with β-lactamase-carrying OMVs as compared to the control bacteria exposed to PBS (Figure 
4.4B). Furthermore, when antibiotic-susceptible E. coli DH10β was incubated with β-
lactamase-negative OMVs, bacteria were not able to grow on the ampicillin plate. The addition 
of vesicles in the absence of ampicillin did not interfere with bacterial growth (data not shown). 
Figure 4.4 OMVs-mediated protection against Ampicillin antibiotic. (A) β-lactamase activity of 
bacterial OMVs was assessed by spectrophotometric assay using a chromogenic cephalosporin 
substrate (Nitrocefin, Thermo Scientific, USA). Nitrocefin has changed its color from yellow to red in the 
presence of active β-lactamases that are present inside outer membrane vesicles. (B) OMVs-mediated 
protection against Ampicillin-induced killing. Antibiotic-susceptible E. coli DH10β was protected against 
ampicillin in the presence of OMVs carrying β-lactamases, as determined by plating of the mixture of 
OMVs and bacteria onto LB agar plates supplemented with 100mg/L of ampicillin. Data are expressed 
as the mean value ± SEM of at least three independent experiments.  
4.1.3 OMVs-mediated transfer of metabolites 
To examine the ability of bacterial vesicles to mediate the exchange of cytoplasmic 
components, a pair of two amino-acid auxotrophs of E. coli was assembled. E. coli DH10β is 
auxotrophic for leucine (Leu), while strain of E. coli J53 is auxotrophic for methionine (Met) 
and proline (Pro). Therefore, both strains are unable to grow in the absence of an external supply 
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of either Leu or Pro and Met. Consequently, their growth in the coculture is indicative of the 
amino acid synthesis of the respective other strain. The scheme of the experimental setup for 
the analysis of the metabolites transfer mediated by OMVs is depicted in Figure 4.5A. 
Moreover, the cytoplasm of one partner in the pair of E. coli was labelled with a plasmid that 
encoded resistance to ampicillin (blaTEM-116) and constitutively expressed the enhanced 
green fluorescent protein (EGFP). The ability of OMVs to spread both green fluorescent protein 
and plasmid DNA encoding resistance to ampicillin was investigated. The transfer of EGFP 
was evaluated by observing via fluorescence microscopy the population of recipient E. coli J53 
that have been preincubated with vesicles derived from donor E. coli DH10β cells and were 
able to fluoresce in green colour. A strong selection pressures for limiting resources was 
induced by culturing the autotrophs in M9 minimal medium. This experiment provided 
evidence for transfer of cytoplasmic protein mediated by OMVs, which was observed by a 
significant increase of EGFP-labelled E. coli J53 cells (Figure 4.5B). Additionally, in order to 
assess the transfer of plasmid DNA from OMVs to recipient cells, the mixture of donor-vesicles 
and recipient-E. coli J53 was plating out on ampicillin-containing plates after 1, 6 and 24 h of 
incubation. However, there was no indication for a transfer of plasmid DNA between cells 
under the given conditions, as not a single colony formed on the ampicillin-containing plates 
was detected.  
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Figure 4.5 Transfer of cytoplasmic marker mediated by outer membrane vesicles. (A) A scheme 
of the experimental setup used for analysis of the OMV potential to transfer metabolites. (B) The outer 
membrane vesicles isolated from E. coli DH10β, ΔLeu were co-incubated with strain of E. coli J53, which 
is auxotrophic for Met and Pro. The donor of OMVs contained an EGFP-expressing plasmid that 
conferred resistance to the ampicillin antibiotic, while the recipient E. coli J53 was unlabeled and 
susceptible to ampicillin. Fluorescence pictures show E. coli J53 (I), E. coli DH10β expressing EGFP (II) 
and the mixture of E. coli J53 preincubated with OMVs derived from E. coli DH10β harboring EGFP-
pJBA27 plasmid (III, IV). Exposure time, 0.5 s; Magnification, 600x; Scale bars, 2 and 2.8 µm. 
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4.2 HlyF-induced formation of outer membrane vesicles in E. coli 
To date, a number of models for OMV biogenesis have been proposed (see chapter 1.4.1), yet 
the exact molecular mechanism leading to OMV formation and regulation remains unknown. 
By analyzing plasmid sequences of different highly virulent E. coli ST131 outbreak isolates, I 
found the strains that naturally harbor ColV plasmids encoding several virulence factors, such 
as iss, tsh, iroN, sitA, cavB, iutA as well as two variants of hemolysin F (hlyF) gene. The hlyF 
gene is mainly located on ColV plasmids and is epidemiologically associated to the most 
virulent strains of Avian Pathogenic E. coli (APEC) and Neonatal Meningitis E. coli (NMEC) 
(Morales et al. 2004; Johnson et al. 2006). An in silico analysis demonstrated that the hlyF gene 
would have a NAD-dependent epimerase/dehydratase activity and may therefore be involved 
in the remodeling of the bacterial outer membrane, triggering increased OMV formation. In this 
study, I examined two E. coli isolates that possess complete and naturally truncated hlyF genes 
in the context of their vesiculation capabilities and the involvement of hlyF in cell wall 
modification. 
4.2.1 Comparative genomics reveals truncation in hlyF gene on ColV plasmid of E. coli 
H16 strain 
Whole genome sequencing analysis of E. coli isolates collected from samples of clinically ill 
patients revealed two strains including E. coli H8 and E. coli H16 that harbour ColV plasmids. 
The ColV plasmids are known to encode for virulence genes and pathogenicity islands (PAIs), 
which are linked to the high virulence capability. Therefore, to detect such a conserved 
virulence gene cluster, I screened different virulence genes on ColV plasmids derived from 
these two strains. The analysis could identify a cluster of conserved virulence genes located on 
ColV plasmid of both the strains (Figure 4.6). In gene by gene comparative analysis between 
H8 and H16 strains, the hlyF gene of the E. coli H16 was observed to be truncated. Further 
nucleotide comparisons revealed loss of 231 nucleotides at the 5’ end of the gene. 
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Figure 4.6 The comparison of ColV plasmids present in E. coli H8 and H16. The different rings 
represent (from inner to outer) deviation from average G+C content (ring 1), GC skew ((G2C)/(G+C); 
ring 2), pJIE186-2 reference plasmid (ring 3) and all genes and insertion elements, which are present 
on ColV plasmids isolated from E. coli H8 and H16 (rings 4 and 5, respectively). The map was generated 
by BLAST Ring Image Generator (BRIG) software. As a reference pJIE186-2 plasmid was used (Zong 
2013). 
4.2.2 The E. coli isolate carrying a complete hlyF exhibits a hypervesiculation phenotype 
compare to isolate with truncated version of the gene 
The production of OMVs derived from the isolates of E. coli H8 expressing complete hlyF and 
E. coli H16 carrying a truncated version of this gene was accessed by quantification methods, 
including Bradford and β-lactamase activity assays. The protein concentration of OMVs 
determined by Bradford assay was 68.6 µg/L and 3.9 µg/L for E. coli H8 and H16, respectively 
(Figure 4.7A). The β-lactamase activity of vesicles amount to 1.4 and 0.4 for H8 and H16 
(Figure 4.7B). Moreover, the vesicles were examined by transmission electron microscopy 
(TEM). Quantification of the OMVs revealed that the amount of bacterial blebs was 
significantly higher for the isolate expressing a full-length hlyF gene (Figure 4.7C). Together, 
these data indicated that an intact HlyF contributes to the overproduction of OMVs. 
Additionally, these results indicate that bacteria can not only overproduce, but also 
underproduce the outer membrane vesicles via modification of hemolysin F. Therefore, hlyF is 
the first virulence factor, which may serve as a natural biological switch that regulates 
vesiculation rate in bacteria, and consequently may contribute to the bacterial pathogenic 
properties. 
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Figure 4.7 The quantification of the OMV production derived from isolates of E. coli H8 and H16.  
The OMVs were isolated from the bacterial culture by differential centrifugation and filtration steps 
followed by quantification using Bradford assay (A), β-lactamase activity test (B) and transmission 
electron microscopy (TEM) (C). All three quantification methods revealed that isolate of E. coli H8 
harboring complete hlyF gene secreted significantly more OMVs compare to ΔhlyF E. coli H16. The 
outcomes (figure A and B) are presented as the mean ± SEM from three independent experiments. 
4.2.3 Truncated HlyF lost an essential coenzyme NAD(P) binding site 
BLAST analysis of a complete amino acid sequence of HlyF indicates strong similarity to the 
extended short-chain dehydrogenase/reductase (SDRs) that constitute a large NADB-
Rossmann protein superfamily. This structural motif is found in enzymes including isomerases 
(e.g., glycosyl epimerases), lyases (e.g., glycosyl dehydratases) and some oxidoreductases (e.g., 
enzymes with both isomerase/dehydrogenase activities) (Kallberg et al. 2002; Kavanagh et al. 
2008). A number of functionally defined SDRs play a role in LPS biosynthesis, such as WbpM 
and WbpK (Charter & Lam 1996) as well as carbohydrate, amino acid, and cofactor metabolism 
(Murase et al. 2016). Therefore, HlyF is likely to act as a fatty acyl CoA reductase or putative 
nucleoside-diphosphate-sugar (NDS) epimerase, and thus be involved in LPS synthesis or 
biogenesis of bacterial cell wall. An in silico analysis revealed the absence of 231 nucleotides 
at 5' end of hlyF gene in E. coli H16 (Figure 4.8). This mutation results in N-terminal deletion 
of 77 amino acids that leads to a loss of an essential coenzyme (NAD-(P)) binding site of HlyF 
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protein. As described above, vesiculation rate of E. coli H16 was significantly decreased 
compare to OMV levels released by E. coli H8 expressing a complete hlyF gene. Based on this 
data, it can be speculated that the loss of N-terminal part of HlyF including NAD-(P) binding 
site caused a defect in enzymatic activity, resulting in hypovesiculation mode of E. coli H16. 
These outcomes suggest that hemolysin F protein contributes to modulation of outer membrane 
vesicle formation and that the N-terminal domain is required for functional active this enzyme. 
Figure 4.8 A Schematic representation of HlyF protein and its truncation. E. coli H16 expresses 
truncated version of hlyF gene, leading to protein synthesis with N-terminal deletion of 77 amino acids 
that results in a loss of an essential coenzyme (NAD-(P)) binding site. Due to the mutation, E. coli H16 
released decreased amount of OMVs. 
4.2.4 Overexpression of hlyF results in hypervesiculation in E. coli K12 DH10β 
To further examine the relationship between expression of hemolysin F and production of 
OMV, complete hlyF gene was cloned into pUC19 in accordance with translational coupling 
strategy and recombinantly expressed in E. coli K12 DH10β.  Subsequently, the resulting E. 
coli recombinant strain was analyzed for its vesiculation phenotype. OMVs isolated from E. 
coli harboring recombinant and empty plasmid were purified and quantified via Bradford, β-
lactamase activity assay and transmission electron microscopy (TEM). The indirect analysis of 
vesicle formation determined by Bradford and β-lactamase activity assays demonstrated 
substantial increase in OMVs production, for recombinant of E. coli harboring pUC19::hlyF as 
compared to an empty vector control (Figure 4.9). 
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Figure 4.9 The quantification of the OMV production in E. coli DH10β expressing hlyF. OMVs were 
isolated from E. coli DH10β harbouring either no plasmid, empty pUC19 or pUC19::hlyF. Following the 
vesicles purification, the level of OMVs was estimated by Bradford assay (A) and β-Lactamase activity 
test (B). Data are expressed as the mean value ± SEM of at least three independent experiments.  
Additionally, the elevated production of OMV was further confirmed by transmission electron 
microscopy analysis, which revealed high numbers of OMVs in hlyF positive E. coli (Figure 
4.10 and Figure 4.11). 
Figure 4.10 Transmission electron micrographs of pelleted OMVs derived from E. coli DH10β 
expressing hlyF. OMVs have been isolated from E. coli DH10β harboring either empty pUC19 plasmid 
or pUC19::hlyF. Following negative staining with 1% ammonium heptamolybdate (pH 7.0), OMVs were 
applied to 0.5% Formvar-coated 300-mesh copper grids and visualized by Zeiss EM900 transmission 
electron microscope. Photo A shows OMVs isolated from empty vector control. Photo B and C represent 
vesicles extracted from E. coli producing HlyF. Sample depicted in image C was diluted 1:100 in 
phosphate-buffered saline (PBS) for better visibility of OMVs. 
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Figure 4.11 Transmission electron micrographs of E. coli DH10β cells along with their OMVs. 
Bacterial culture was fixed with 1% glutaraldehyde and applied intact to 0.5% Formvar-coated 300-mesh 
copper grids followed by negative staining and visualizing by Zeiss EM900 transmission electron 
microscope. Micrographs A and B represent E. coli harboring empty pUC19 plasmid, Micrographs C 
and D show E. coli expressing hlyF gene. A 1% ammonium heptamolybdate was used as a negative 
counterstain. 
To gain different perspective on OMVs that are being released from bacterial cells, a field 
emission scanning electron microscopy (FE-SEM) analysis was performed. The FE-SEM 
indicated the significant increase of protruding OMVs from the cell surface of E. coli expressing 
recombinant hlyF gene as compared to E. coli harboring an empty plasmid. (Figure 4.12) 
Altogether, these outcomes showed that hlyF contributes to augmented OMVs formation in E. 
coli DH10β. 
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Figure 4.12 The field-emission scanning electron micrographs of E. coli DH10β secreting 
vesicles. Bacterial cells were fixed by incubation with 2.5% glutaraldehyde followed by post-fixation 
with 1% osmium tetroxide and dehydration in a graded series of acetone. After drying in a critical point 
dryer, the bacterial cells were mounted on specimen stubs, and gold/palladium-coated using a sputtering 
device. Images were acquired by Zeiss Merlin field-emission scanning electron microscope with an 
accelerating voltage of 20 kV. Micrographs A, B present E. coli harboring empty pUC19 plasmid. 
Micrographs C, D show E. coli expressing hlyF gene. 
4.2.5 hlyF-induced OMVs trigger formation of autophagic vacuoles in eukaryotic cells 
To examine the biological effects of hlyF-induced OMVs on eukaryotic cells, human epithelial 
carcinoma cell line (HeLa) had been transfected with a GFP-LC3 expressing plasmid and 
exposed to OMVs derived from hlyF-positive or negative E. coli. The expression of fusion gene 
followed by OMVs treatment revealed formation of autophagosomes, observed under 
fluorescence microscopy as green punctate structures in HeLa cells (Figure 4.13).  
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Figure 4.13 hlyF-OMVs induced autophagy in HeLa cells. HeLa cells expressing GFP-LC3 fusion 
protein were cultured on glass coverslips and treated with OMVs. The relocation of GFP-LC3 from a 
diffuse staining pattern in the cytoplasm and nucleus to a cytoplasmic punctuate structure was used to 
detect autophagy. Images (A-C) show autophagosome formation in response to hlyF-induced OMV. 
Images (D-E) present HeLa cells exposed to PBS, hlyF negative OMVs and Rapamycin, respectively. 
Rapamycin was used as positive control of LC3 conversion. 
Autophagy induced by hlyF-OMVs was further investigated by transmission electron 
microscopy of ultrathin sections of HeLa cells. As shown in (Figure 4.14) upon the treatment 
with vesicles, an abundance of vacuoles were found in the cytoplasm of HeLa cells. Under high 
magnification, autophagic vacuoles were observed in hlyF-induced OMVs treated host cells. 
Rapamycin-treated cells were included as an autophagy control. These results suggest that hlyF-
positive bacterial vesicles distinctively induce formation of autophagic vacuoles in HeLa cells. 
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Figure 4.14 TEM images of ultrathin sections of HeLa cells after OMV treatment. HeLa cells 
showing the formation of autophagic vacuoles upon the treatment with hlyF-induced OMVs isolated from 
E. coli DH10β. The ultrathin sections (70-100 nm) of cells pretreated with vesicles were cut with ultra-
microtome and applied to collodion-coated copper grids. Subsequently, the stained sections were 
analyzed using Leo 912 transmission electron microscope (Carl Zeiss, Germany) at an accelerating 
voltage of 80 kV equipped with a TRS Sharpeye slow scan dual speed CCD camera. Images (A and B) 
present HeLa cells exposed to Rapamycin and hlyF-induced OMVs, respectively. Images (C-E) show 
cells treated with PBS as a negative control. Rapamycin was used as positive control of LC3 conversion. 
(N = nuclear; arrows indicate the presence of autophagic vacuoles. Magnification was x500 for A, C, 
x3150, x31500 for B and x5000 for D, E. 
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4.3 Outbreak-causing, Citrobacter freundii carrying KPC-2 Carbapenemase gene and its 
vesicles-mediated genetic transformation potential 
I analyzed a repertoire of carbapenemase-encoding Enterobacteriaceae, including multiple 
species of Citrobacter genus in the context of transferring of carbapenemase-encoding plasmids 
to other bacteria. I found several outbreak isolates of C. freundii harbouring plasmids that 
encodes KPC-2 resistance gene and were able to release vesicles into milieu. One particular 
isolate of C. freundii NRZ 08698 had a unique property of secreting the OMVs containing 
antibiotic resistance genes.  This feature might play a pivotal role in success of this opportunistic 
pathogen and help bacteria to accommodate to the hostile environment. Therefore, I assessed 
the potential contribution of OMVs derived from the isolate of C. freundii to disseminate the 
carbapenem resistance genes into other members of the Enterobacteriaceae family. 
4.3.1 C. freundii releases OMVs to surrounding environment 
I first investigated whether C. freundii shed vesicles during in vitro growth. The OMVs were 
isolated from bacterial culture according to above-mentioned protocol (chapter 3.3.2). 
Thereafter, the FE-SEM and TEM microscopy were used to visualize the purified OMVs as 
well as vesicles that are being released from the surface of C. freundii cells. According to 
electron microscope images, Citrobacter isolate constantly spread vesicles into extracellular 
environment and they were clearly visible on the bacterial cells (Figure 4.15). There was no 
one place on the bacterial cell surface, which was involved in formation of OMVs, but the entire 
membrane of the bacterium was taking part in releasing of these molecular structures into the 
environment.  
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Figure 4.15 The field-emission scanning electron micrographs of C. freundii NRZ 08698 cells 
secreting vesicles. Intact bacterial culture was fixed with 1% glutaraldehyde followed by dehydration 
in a graded series of acetone. After drying in a critical point dryer, the samples were mounted on 
specimen stubs, and gold/palladium-coated using a sputtering device. Images were acquired by Zeiss 
Merlin field-emission scanning electron microscope with an accelerating voltage of 20 kV. Micrographs 
(A-F) represent C. freundii and its vesicles being released from the bacterial membranes. Bar, 200 nm. 
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OMV secreted from C. freundii were spherical, mono-, bi- layered, closed membranous 
structures, and no external material seemed to be associated with the vesicles (Figure 4.16).  
Figure 4.16 Transmission electron micrographs of pelleted OMVs derived from C. freundii. NRZ 
08698. OMVs were extracted from isolate of C. freundii harboring KPC-2-encoding IncN plasmid. 
Following negative staining with 1% ammonium heptamolybdate, OMVs were applied to 0.5% Formvar-
coated 300-mesh copper grids and visualized by Zeiss EM900 transmission electron microscope. Bar, 
200 nm. 
The size distribution of OMV was measured using imageJ software (Fiji). The diameter of C. 
freundii OMV (n = 500) was ranging from 15 to 103 nm, which is consistent with the size of 
OMV secreted by other Gram-negative bacteria (Figure 4.17). No bacteria, membrane whorls 
and cell debris were detected in analyzed vesicle samples, however fragments of flagella were 
visible among OMVs. Moreover, SDS-PAGE analysis of the vesicular proteins revealed that 
C. freundii OMVs have distinct protein band pattern compared to the WCL fraction (see chapter 
4.4.2; Figure 4.26E), indicating that special protein sorting mechanisms are employed when 
OMVs are being released. 
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Figure 4.17 The size distribution of outer membrane vesicles isolated from C. freundii NRZ 08698. 
The OMVs were visualized by transmission electron microscopy and measured using ImageJ software. 
The diameter of C. freundii vesicles (n = 500) was ranging from 15 to 103 nm. The x axis presents the 
OMVs diameter in nanometers against their number. 
4.3.2 Proteomic profiling of outer membrane vesicles from C. freundii 
I conducted the proteomic analysis of purified C. freundii-derived OMVs to identify proteins 
that are present in vesicles, and consequently obtain insights into molecular mechanisms 
involved in OMV cargo sorting and biogenesis. Additionally, the study of vesicle proteome 
should provide clues for better understanding the pathophysiological roles of these 
macromolecular structures. Besides, MS analysis allowed us to confirm the purity of extracted 
blebs and exclude possible contamination from the phage particles, which have the comparable 
size to bacterial OMVs. A total of 706 vesicular proteins were identified in the OMV samples 
during three independent trials (see Table A-2, Appendix B). It is noteworthy that the three 
independent proteomic analyses exhibited high reproducibility. Of the total proteins from all 
trials, 85, 87 and 88%, respectively, were common to the first, second and third trial. By using 
the normalized spectral abundance factor (NSAF) approach (Zybailov et al. 2006), I determined 
the relative amounts of proteins within the OMV samples. All identified proteins were 
annotated by their subcellular localization based on the PSORTb algorithm. As shown in Figure 
4.18A, 79 (50.4%), 45 (1.8%), 127 (12.1%), 451 (33.3%) and 5 (2,4%) proteins were classified 
as outer membrane, inner membrane, periplasmic, cytoplasmic and secreted, respectively. 
Compared with the theoretical proteome of Citrobacter freundii strain CFNIH1, 79 proteins out 
of theoretical 164 outer membrane and 451 out of 3367 cytoplasmic proteins were significantly 
enriched in the OMVs, whereas only 45 out of theoretical 926 inner membrane proteins were 
identified. These results indicate that the release of OMVs, which has been observed in all 
Gram-negative bacteria investigated to date may represent a novel avenue for protein secretion. 
Notable, many cytoplasmic proteins were detected in Citrobacter vesicles, most were metabolic 
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and ribosomal proteins, which is analogous to the observation of the several others researcher 
groups (Pérez-Cruz et al. 2015; Pérez-Cruz et al. 2013; Bai et al. 2014; Schwechheimer & 
Kuehn 2015). However, it is not surprising that OMVs are composed of cytoplasmic proteins. 
It is known that vesicles derived from Gram-negative bacteria can contain plasmid or 
chromosomal DNA (Jan 2017), suggesting there is a sorting mechanism, which is responsible 
for packaging intracellular compartments including cytoplasmic proteins into vesicles. 
Furthermore, the functions of identified proteins present in OMVs were categorized according 
to the Clusters of Orthologous Groups (COG) annotation with regard to the molecular function. 
Based on COG annotation, the vesicular proteins of C. freundii are involved in diverse 
processes, including cell wall/membrane/envelope biogenesis (13.2%), translation, ribosomal 
structure and biogenesis (12.6%), energy production and conversion (9.8%), carbohydrate 
transport and metabolism (9.6%), amino acid transport and metabolism (9.1%), 
posttranslational modification, protein turnover, chaperones (5.8%), and coenzyme transport 
and metabolism (4.7%), whereas the functions of 26 proteins (3.7%) are poorly characterized 
(Figure 4.18B).  
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Figure 4.18 Distribution of C. freundii-derived vesicular proteins based on their predicted 
subcellular locations and COG functional classes. A total of 706 proteins were identified in outer 
membrane vesicles of C. freundii NRZ 08698 by MALDI-TOF-MS analysis. The vesicular proteins were 
grouped into families according to the predicted subcellular localization (A) and COG functional classes 
(B). The subcellular localization was predicted based on the protein subcellular localization (SCL) 
prediction tool (Yu et al. 2010). The annotation of the Clusters of Orthologous Groups of proteins (COGs) 
was performed by COGsoft, a software for making Clusters of Orthologous Groups (Kristensen et al. 
2010). 
In addition, protein-protein interaction networks (PINs) for OMVs derived from C. freundii 
were constructed and analyzed in order to elucidate physical and functional interactions 
between vesicular proteins. Using experimentally verified data on the landscape of physical 
protein-protein interactions in E. coli (Rajagopala et al. 2014), I was able to map 337 of the 706 
vesicular proteins into the PIN. The Figure 4.19 presents the constructed PIN of the vesicular 
proteins, comprising 337 nodes and 2976 interactions. 
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Figure 4.19 Graphical representation of protein - protein interaction (PPI) network of outer 
membrane vesicle (OMV) isolated from C. freundii NRZ 08698. Nodes represent proteins of 
Results 
  
71 
 
Citrobacter-derived OMV. Edges represent experimentally determined interactions. The PPI network 
has 337 nodes with 2976 edges. The PPI network was visualized by using Cytoscape software version 
3.5.1 with self-interactions being removed prior to analysis. 
Based on clustering algorithm MCODE (Bader & Hogue 2003) that detects densely connected 
regions in large protein-protein interaction networks and functional enrichment analyses, I 
identified subnetworks within PPI network of Citrobacter-derived OMV. Proteins with related 
functions were linked to each other, forming functional modules in the protein-protein networks 
(Figure 4.20). Within the PPI network of OMV, 12 subnetworks were detected. Cluster A 
represents proteins involved in metabolic processes, consisting of NADH oxidoreductases 
(NuoA, NuoB, NuoC), succinate dehydrogenase (SdhA, SdhB), nitrate reductase (NarH, NarZ) 
and other proteins associated with glycerol metabolism (GlpA, GlpD, GlpK, GlpT, GlpQ). 
Cluster B shows proteins linked to translation, including miscellaneous ribosomal proteins such 
as RpsQ, RpsP, RplA, RplC. Subnetwork C comprises proteins connected to membrane 
biogenesis (BamB, BamC, BamD, SurA), protein export (SecB, SecD, yajC), glycolysis 
(GpmA, Pgi, Eno) and unfolded protein binding (groL). Cluster D represents proteins involved 
in response to temperature stimulus (HtpG, HslU, HtpX, ClpB, DnaJ). Subnetwork E is 
composed of proteins associated with translation process, including methionyl-tRNA 
synthetase (MetG), cysteinyl-tRNA synthetase (CysS), isoleucyl-tRNA synthetase (IleS), 
tryptophanyl-tRNA synthetase (trps) or phenylalanine tRNA synthetase (PheT). Module F 
presents proteins linked to cell division, such as FtsX, FtsL, ZipA, MurE, DdlB and AmiC. 
Finally, clusters (G-L) include protein networks composed below of 6 nodes and include 
proteins connected to fatty acid biosynthetic process (FabA, FabG, FabZ), amino sugar 
metabolic process (GlmM, GlmS, NagA, NagB) and protein transport by the Tat complex (TatA 
and TatB). 
In conclusion, by interrogating proteomic data obtained from MS analysis and by using 
systems approaches, I have built a protein interaction network of Citrobacter OMVs. Based on 
PIN, I defined how these macromolecular, extracellular protein structures are organized, 
revealing that vesicular proteins are closely interconnected via different interactions and group 
into functional modules likely involved in their functions and biogenesis. 
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Figure 4.20 Subnetworks detected in the protein-protein interaction (PPI) network of Citrobacter-derived outer membrane vesicles (OMVs). A large 
number of proteins are involved in building of OMVs. To extract meaningful information from such a highly interconnected network, clustering of the proteins 
according to their functional classes may be of use. The highly dense nodes (proteins) and their interconnected nodes were identified and extracted from the 
PPI network of OMVs to construct new small sub-PPI networks (A to L). Clustering of proteins was done by the MCODE algorithm (Bader & Hogue 2003). The 
PPI networks were visualized by using Cytoscape software version 3.5.1 with self-interactions being removed prior to analysis. 
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4.3.3 OMVs derived from C. freundii contain blaKPC-2 gene. 
To date, several research groups have reported the presence of chromosomal and plasmid DNA 
inside the OMVs secreted from various isolates of Acinetobacter, Escherichia, Pseudomonas 
and Neisseria (see chapter 1.4.2). The encapsulation of DNA within vesicles would suggest that 
pathogens can transport genetic material to other bacterial cells in a long-distance manner. 
Therefore, in order to determine whether plasmid DNA coding for carbapenem resistance gene 
blaKPC-2 is associated with OMVs derived from KPC-2-positive C. freundii NRZ08698, 
vesicle fraction was purified and the presence of blaKPC-2 gene was analysed by PCR. The 
carbapenemase gene was detected using primers targeting blaKPC-2, as indicated by a band at 
570bp (Figure 4.21). The positive PCR amplification result indicates that plasmid DNA was 
internally associated with OMVs as the PCR product was produced after DNase I treatment of 
intact OMVs. In contrast, the blaKPC-2 gene was not detected in negative sample prepared 
from E. coli DH10β cells, which did not harbour any plasmid DNA. This outcome suggests that 
plasmid DNA or its part was packaged into C. freundii OMVs and then was released out of the 
bacterial cell into milieu. 
Figure 4.21 PCR detection of blaKPC-2 gene in OMV isolated form C. freundii NRZ 08698. Agarose 
gel showing detection of plasmid DNA by PCR reaction specific for blaKPC-2. Plasmid DNA for PCR 
amplification has been isolated from intact DNase I pretreated OMVs.  
4.3.4 OMVs isolated from C. freundii facilitate transfer of plasmid DNA to neighboring 
bacteria 
The packaging of DNA into OMVs might be an additional mechanism by which C. freundii 
disseminates genetic material, including different resistance genes to neighboring bacteria. The 
ability of vesicles derived from C. freundii for transferring a plasmid DNA to other bacterial 
cells was investigated by performing OMVs-mediated transformation. Cefotaxime-susceptible, 
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non-competent E. coli J53 was mixed with outer membrane vesicles, which have been 
pretreated with DNase I, and the transfer of the KPC-2-encoding plasmid from OMVs to 
bacterial cells was quantified after 24 h of incubation (Table 4.1 and Table 4.2). The results of 
these experiments indicate that vesicles-transformed E. coli J53 acquired cefotaxime resistance 
at an average rate of 41 OMVs-transformants (transformed bacteria by exposure to OMVs) per 
10µg of OMVs. In contrast, the gene transfer events obtained with OMVs, which have not been 
pretreated with DNase I were significantly higher (126 transformants), suggesting either DNase 
I prohibits transfer of free DNA or enzyme treatment can affect the integrity of the bacterial 
blebs, and consequently influence vesicle-mediated transfer. In parallel, no OMVs-
transformants were found when E. coli J53 was incubated with 1,000 ng of free plasmid DNA 
isolated from isolate of C. freundii NRZ 08698 or when the recipient strain was incubated in 
the absence of vesicles.  
Table 4.1 OMVs-mediated transformation obtained after 24 h of incubation with OMVs derived from C. 
freundii NRZ 08698 in LB plates supplemented with 1 mg/L of cefotaxime (CTX) and 200 mg/L of sodium 
azide. 
Treatment No. of transformants* 
E. coli J53 + C. freundii’s OMVs 126 
E. coli J53 + C. freundii’s OMVs pretreated with DNase I 41 
E. coli J53 + Exogenous DNA 0 
LB + C. freundii‘s OMVs 0 
*The OMV-mediated transformation experiments were carried out in three time-independent assays. Data are expressed as the 
mean ± SEM from three experiments. 
Table 4.2 Efficiency of C. freundii’s OMVs transformation. 
Number of 
Recipients [cfu] 
Number of 
OMVs transformants [cfu] 
Efficiency of 
OMVs-mediated transformation* 
4,0 x 107 41                1 x 10-6 
* The gene transfer efficiency is calculated as the number of OMV-transformants per the number of recipient cells. 
In order to confirm whether OMVs-transformed recipient J53 selected on LB plate 
supplemented with cefotaxime contained plasmid DNA, PCR targeting blaKPC-2 gene was 
carried out. Figure 4.22 presents the amplification of KPC-2 gene detected in OMVs-
transformed E. coli J53. These results support the previous reports that Gram-negative bacteria 
can harness their OMVs as a vehicle for transferring the plasmid DNA into other bacterial cells. 
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Figure 4.22 E. coli J53 transformed with OMVs from C. freundii NRZ 08698 harbors KPC-2 gene. 
Agarose gel presents detection of plasmid DNA by PCR reaction specific for blaKPC-2. Plasmid DNA 
for PCR amplification was isolated from E. coli J53 that has been transformed with OMVs derived from 
isolate of C. freundii. 
4.3.5 S1-PFGE and sequencing analysis of plasmid DNA transferred by C. freundii OMVs 
To visualize and determine the size of plasmids in OMVs-transformants, S1 nuclease digestion 
followed by pulsed-field gel electrophoresis was performed. As shown in Figure 4.23, the 
presence of plasmid DNA that varied in length from ~60 kb to ~90 kb was detected in case of 
vesicles-transformed E. coli J53. This data confirms the transfer of a complete plasmid between 
OMVs secreted from C. freundii and recipient J53 cells. According to my best knowledge, it 
has been shown for the first time that C. freundii OMVs can serve as a vehicle to transfer such 
a large-sized plasmid (~90 kb) encoding carbapenem resistance gene blaKPC-2. 
Figure 4.23 Detection and size determination of plasmids transferred by C. freundii OMVs. 
Plasmids were digested by S1 nuclease and visualized on a pulsed-field gel. The sources of plasmid 
DNA were E. coli J53 (lane 1), OMVs-transformed E. coli J53 (lanes 2, 3, 4 and 5) and C. freundii NRZ 
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08698 (lane 6). The markers which were used are Lambda marker (the first lane) and low range marker 
(the last lane). 
In addition, the plasmids from three OMVs-transformed E. coli J53 were extracted and 
subsequently sequenced to determine their origin using the MiSeq benchtop sequencer 
(Illumina, USA). The genetic similarity of the sequenced plasmids is depicted in Figure 4.24. 
As indicated in the map, the sequencing analysis confirmed that all OMVs-transformed E. coli 
J53 harboured IncN plasmids that descend from C. freundii NRZ 08698. The ancestor IncN 
plasmid (pCF08698_KPC2) has 78.021 bp and is harboured by donor C. freundii cells. 
Plasmids found in recipient J53 differ in size due to recombination events that occurred in 
regions encoding antibiotic resistance genes leading to insertion and deletion of different DNA 
fragments. In case of two smaller plasmids (68 kb), a deletion of approximately 10 kb fragment 
has taken place due to the presence of the insertion sequence IS26 flanking region B. The larger 
plasmid identified in E. coli J53 has a duplicated region C (28 kb) compare to original 
pCF08698_KPC2, therefore its size exceeds 90 kb. However, the mechanism underlying 
duplication of region C remains elusive. Taken together, this analysis confirmed that all 
plasmids identified in E. coli J53 are from C. freundii origin and the release of OMVs can 
contribute to a long-distance delivery of plasmids encoding KPC-2 resistance genes. 
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Figure 4.24 Comparison of plasmids present in E. coli J53 transformed with C. freundii OMVs. (A) Reference pCF0869_KPC2 plasmid harbored by C. 
freundii NRZ08698. (B) KPC-2 positive plasmids found in OMVs-transformed E. coli J53, including deletion of region B. (C) KPC-2-positive plasmid found in 
OMVs transformed E. coli J53 including duplicated of region C. Plasmid 1 and 3 have identical sequences. Insertion and deletion region are marked with orange 
C and green B line, respectively. Gray ribbons between panels mark regions of 100% sequence similarity. Transposase genes are colored green, antibiotic 
resistance genes are red, tra genes are dark blue, other genes are orange and black. 
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4.4 Formation of OMV in other tested Gram-negative bacteria 
4.4.1 Gram-negative bacteria continuously release OMVs into milieu  
Previous reports indicated that OMVs are secreted ubiquitously from all Gram-negative and 
some Gram-positive bacteria investigated to date (Deatheragea & Cooksona 2012; Gurung et 
al. 2011). Accordingly, I wanted to confirm by using the optimized OMV isolation protocol 
(see chapter 4.1.1) that all Gram-negative pathogens examined in this thesis were able to release 
vesicles during in vitro growth. Vesicles were harvested from cell-free supernatant of overnight 
culture as described in chapter 3.3.2. The purified OMV were re-suspended in phosphate-
buffered saline and then examined using transmission electron microscopy (TEM). As shown 
in Figure 4.25, vesicles were spherical-shaped, mono- and bi- layered structures, uniform in 
size. When I examined the diameters of OMVs (n = 500, for each isolate), I found that their 
diameter was ranging from 15 to 120 nm, and most of the vesicles (70%) had a diameter of 20 
to 50 nm. This range is similar to previously described for OMVs, which have been isolated 
from other Gram-negative bacteria (Jang et al. 2014; Yáñez-Mó et al. 2015; Pérez-Cruz et al. 
2013). No bacteria contamination was observed in OMV samples. 
Figure 4.25 Transmission electron micrographs of negatively stained bacterial outer membrane 
vesicles. OMVs were isolated by different filtration and centrifugation steps from Acinetobacter sp., (A); 
Serratia sp., (B); Citrobacter sp., (C) and Escherichia sp. (D) followed by staining with 1% ammonium 
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heptamolybdate (pH 7.0) and OMVs were applied directly to 0.5% Formvar-coated 300-mesh copper 
grids. Vesicles samples were observed with a Zeiss EM900 transmission electron microscope (Carl 
Zeiss, Germany). Electron micrographs were taken at an accelerating voltage of 80 kV. 
4.4.2 Vesicles exhibit a different protein profile compared to whole cell lysate fraction 
It has been demonstrated that OMV derived from E. coli have a different protein distribution 
pattern compared to whole cell lysate fraction (WCL) of bacteria they originate from (Lee et al. 
2007). I investigated whether OMV cargo packaging occurs in bacteria which have been 
analysed in this thesis. To study protein sorting process, both WCL and OMV proteins were 
isolated and separated by SDS-PAGE followed by Coomassie Blue staining (Figure 4.26). The 
OMV fraction demonstrated differences in protein profile compared to the WCL of the studied 
bacteria. The proteins of 24 to 45 kDa were enriched, whereas others were excluded. The 
different protein pattern suggests that specific protein sorting mechanisms exist when OMVs 
are released. 
Figure 4.26 A representative of Coomassie Brilliant Blue-stained SDS-PAGE of whole-cell lysates 
(WC) and outer membrane vesicle (OMV) fractions. The protein content of WC and OMV 
preparations was isolated from A. baumannii 13 (A), A. baumannii 65 (B), E. coli DH10β (C), S. 
marcescens 2099 (D), C. freundii 08698 (E). A portion of each fraction was analysed by SDS-PAGE in 
combination with 10% polyacrylamide gels using the Prestained Protein Marker Broad Range 
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(Invitrogen, USA) as a molecular mass standard. Protein bands were visualized by a staining with 
Coomassie Brilliant Blue G250. Molecular weight standards are indicated on the left (kDa). 
4.4.3 OMVs induce protective immune responses in invertebrate Galleria mellonella 
model 
In this study, I evaluated the protective efficacy of OMVs isolated from Enterobacter sp. and 
Serratia sp. isolates against bacteria-induced lethality in G. mellonella infection model. It has 
been previously reported that OMV derived from Gram-negative bacteria are composed of 
abundant immunogenic proteins, such as outer membrane proteins (OMPs), protective capsular 
polysaccharide (CPS) and lipopolysaccharide (LPS) antigens. Therefore, vesicles can 
presumably induce protective immune response in vertebrates and invertebrates. To determine 
the contribution of OMVs to the activation of the innate immune response in G. mellonella, I 
primed larvae with 100 ng of OMV derived from either Enterobacter 247 and S. marcescens 
2099 24 h prior bacterial infection. G. mellonella were challenged by injecting a dose of 106 or 
101 cfu/larva of Enterobacter 247 or S. marcescens 2099 isolates, respectively. OMV-mediated 
activation of immune system provided potent protection against subsequent infection by a lethal 
dose of bacteria (Figure 4.27). These results indicate that G. mellonella invertebrate model 
possess inducible immune defense molecules (i.e. antimicrobial peptides, AMPs) that provide 
long-lasting antimicrobial responses to bacterial challenge. 
Figure 4.27 The effect of priming Galleria mellonella larvae with OMVs on immune protection 
against bacterial challenge. Activation of the immune system by injecting 100 ng of OMV derived from 
Enterobacter 247 (A) or S. marcescens 2099 (B) 24 h prior bacterial challenge. Priming of G. mellonella 
resulted in a significant increase of survival of larvae compare to untreated larvae. Negative control 
represents larvae injected with 10 µl of PBS. Positive control is larvae challenged with bacteria, without 
prior OMV injection. Data are expressed as the mean ± SEM for 10 larvae per treatment from three 
independent experiments. 
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To examine the basis for increased survival rates of G. mellonella primed with OMVs, 
individual wax worms were homogenized in LB medium containing 1% Triton X-100 and then 
plated for bacterial enumeration. As expected, the larvae that have been pretreated with OMVs 
prior bacterial challenge were free of bacteria at 7 days post-infection, indicating that the 
immune defenses of G. mellonella were highly effective in killing the pathogens (Figure 4.28). 
No activation of innate immunity was observed when I used PBS instead of OMV as a priming 
agent. 
Figure 4.28 Determination of bacterial load from infected larvae.  G. mellonella larvae infected with 
Enterobacter 247 at 106 cfu/larva (A) and S. marcescens at 101 cfu/larva (B) were homogenized in LB 
medium supplemented with 1% Triton X-100, followed by plating onto LB agar plates. Bacterial colonies 
were counted after 24 h of incubation at 37°C. No bacteria detected in OMVs pretreated larvae, 
suggesting that the constitutive immune defenses of G. mellonella were highly effective in killing injected 
pathogens. Data are expressed as the mean ± SEM for 3 larvae per counting from three independent 
experiments 
.
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Discussion - Section I 
The cell wall is a rigid, yet dynamic structure that is essential for viability in all Gram-negative 
and Gram-positive bacteria. It does not only constitute a barrier between the extracellular and 
intracellular milieu, but also plays a fundamental role in many physiological processes, such as 
bacterial growth, communication between cells and their environment as well as survival and 
pathogenesis (Bohuszewicz et al. 2016; de Pedro & Cava 2015). Changes in the cell wall are 
one of the ways by which bacteria can adapt to constantly changing milieu. In this section of 
the thesis, I investigated the influence of the remodeling of bacterial cell membranes on 
antibiotic resistance and OMV formation. I chose different species of Acinetobacter, 
Citrobacter, Enterobacter, Escherichia and Serratia, which represent common opportunistic 
pathogens that are clinically significant for immunocompromised individuals. All tested 
bacteria were able to secrete vesicles during in vitro growth and some of the blebs could serve 
as vectors for dissemination of the enzymatically active enzymes (e.g., β-lactamases) and 
antibiotic resistance genes (e.g., KPC-2) in a long-distance manner. Furthermore, I discovered 
that a hemolysin F (hlyF) gene, which is associated with ColV plasmids harbored by invasive 
strains of E. coli, contributes to increased vesicle production. I demonstrated that hlyF is the 
first virulence factor, which may act as a natural biological switch that regulates vesiculation 
rate in bacteria. In the following sections of this chapter, the overview of obtained outputs is 
given to summarize and discuss the data from the first part of this thesis. 
Vesiculation in Gram-negative bacteria 
The cell wall of Gram-negative bacteria has dynamic features that facilitate adaptation to unique 
surroundings. The modification of the bacterial membranes are involved in acquiring nutrients, 
defending against other microbes, or evading the host immune system (Bohuszewicz et al. 
2016). Formation of outer membrane vesicles is one of the membrane remodeling events that 
are constantly ongoing at the surface of the bacterial cells.  
One aim of this thesis was to investigate the secretion of outer membrane vesicles 
derived from different clinically important Gram-negative pathogens. The OMVs were 
examined with respect to their ability to transfer various bacterial intracellular compartments 
e.g., active β-lactamase or metabolites and to induce protective immune responses in wax moth 
larva, Galleria mellonella. I validated the production and release of OMVs in all investigated 
bacterial species. These observations are consistent with others in the literature (Yáñez-Mó et 
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al. 2015; Deatheragea & Cooksona 2012) and confirmed that the secretion of vesicles into the 
extracellular milieu is an evolutionally conserved, universal process that occurs not only in 
complex multicellular organisms but also in simple bacteria. Examination of purified OMVs 
by TEM revealed spherical, mono- and bilayer structures with size ranging from 15 to 200 nm 
in diameter. As reported in previous studies (Lee et al. 2007; Frias et al. 2010; Sharpe et al. 
2011; Kulkarni & Jagannadham 2014), my analysis of the vesicular proteins by SDS-PAGE 
demonstrated that OMVs fraction exhibits distinct protein profile compare to whole cell lysate 
fraction, suggesting that specific protein sorting mechanisms are in effect when OMVs are 
secreted.  
Moreover, a MALDI-TOF-MS-based proteomic study was conducted to identify 
proteins, which were present in the isolated vesicles. Proteomic analyses have shown that 
OMVs are composed of not only outer membrane and periplasmic proteins, but also inner 
membrane and cytoplasmic proteins. The most abundant were outer membrane and cytoplasmic 
proteins. However, when compared with a total bacterial proteome, outer membrane proteins 
were significantly enriched in the OMVs, whereas cytoplasmic proteins were deprived. While 
outer membrane and periplasmic proteins are considered as a natural component of bacterial 
vesicles, the presence of cytoplasmic and inner membrane proteins still lacks a clear 
explanation. Nevertheless, detection of cytoplasmic components, such as ribosomal proteins, 
chaperones, and elongation factors in OMVs should not be surprising. The fact that OMVs 
contain DNA and RNA molecules, and that translation of outer membrane proteins may take 
place simultaneously with their integration into the vesicles, indicates that ribosomal and 
transcriptional proteins might be exported into bacterial blebs. The presence of intracellular 
proteins in OMVs has also been confirmed by many other research groups (Toyofuku et al. 
2012; Pérez-Cruz et al. 2015; Kwon et al. 2009; Choi et al. 2011). The incorporation of 
cytoplasmic and inner membrane proteins into bacterial vesicles can be only explained by the 
presence of double-bilayer membranes in OMVs, which was previously supported by 
Kadurugamuwa et al. and Pérez-Cruz et al. (Pérez-Cruz et al. 2013; Kadurugamuwa & 
Beveridge 1995). The formation of vesicles that contain both inner and outer membranes could 
also result in trapping cytoplasmic constituents such as plasmids, fragments of chromosomal 
DNA and different ribosomal proteins. Due to the fact that OMVs are composed of not only 
outer membrane and periplasmic proteins but also cytoplasmic compartments, the nomenclature 
for the outer membrane vesicles should be changed to vesicles only as these macromolecular 
structures represent more than only blebs of bacterial membrane. 
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Additionally, in this thesis, the potential of OMVs as immunogens was examined. Since 
vesicles contain abundant outer membrane proteins and lipoproteins, they can be regarded as 
representing bacterial surfaces and an acellular source of bacterial antigens (Irving et al. 2014; 
Alaniz et al. 2007; Ellis & Kuehn 2010). Therefore, I assessed the protective immune response 
of OMVs using larva G. mellonella as a non-vertebrate model organism. Priming moth larvae 
with OMVs significantly conferred immune protection against bacterial-induced lethality. The 
increase in survival rates of G. mellonella that have been pretreated with OMVs was 80% 
compared to PBS injected larvae as negative controls. These results suggest that bacterial 
membrane vesicles are potent immunogenic structures, which are effective inducers of 
protective immunity. My outcomes add to the growing body of literature indicating that OMVs 
are important in stimulation of immune responses and bacterial infection events, consistent with 
what was previously reported (Kaparakis-Liaskos & Ferrero 2015; Kulkarni & Jagannadham 
2014).  
Furthermore, I have shown the protective role of bacterial outer membrane vesicles 
against antibiotics. The nitrocefin based spectrophotometric assay determined active β-
lactamases in OMVs isolated from β-lactam resistant isolates of E. coli and Enterobacter sp. 
Their vesicles were able to protect ampicillin-susceptible bacteria, against ampicillin-induced 
killing. The detection of active β-lactamases in OMVs can be considered as a novel mechanism 
by which bacteria not only enhance survival of their own species but also promote existence of 
co-inhabiting pathogens which might be antibiotic-susceptible. It was previously described that 
S. pneumoniae cells growing in the presence of β-lactamase-positive M. catarrhalis were 
protected against killing when they were treated with amoxicillin antibiotic (Budhani & 
Struthers 1998). Schaar V. et al. (Schaar et al. 2011) noted that preincubation of amoxicillin 
with purified M. catarrhalis OMVs fully rescued amoxicillin-susceptible M. catarrhalis, S. 
pneumoniae, and H. influenzae from β-lactam-induced killing. These results, along with the 
outcomes from this thesis indicate that OMVs can serve as an additional mechanism by which 
bacteria can evade antibiotic-induced killing by hydrolyzing antimicrobial agents.  
Additionally, I investigated whether bacteria can secrete OMVs into the extracellular 
environment in order to exchange metabolites between bacterial communities. The 
preincubation of OMVs derived from leu auxotroph of E. coli harboring a EGFP-pJBA27 
plasmid with Δpro, Δmet E. coli J53 strain resulted in exchange of nutrients and proteins. 
Transfer of the enhanced green fluorescent protein (EGFP) mediated by OMVs was evaluated 
by quantifying the population-level proportion of J53 cells that fluoresced in green colour via 
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fluorescence microscopy. However, the fluorescence of recipient bacteria was transient, 
suggesting that vesicles only contributed to the transfer of already expressed green fluorescence 
protein, yet OMVs provided no evidence for a transfer of plasmid DNA under the given 
conditions. Pande S. et al. (Pande et al. 2015) demonstrated the transfer of metabolites in 
nanotube-dependent manner but in their experiment, the functional role of OMV in exchange 
of proteins remained elusive. Although, all Gram-negative bacteria investigated to date are 
known to produce membrane vesicles and our knowledge of OMV functions and biogenesis 
has increased substantially in recent years, so far, the mechanistic proof of principle for their 
roles remains unclear. The formation and shedding of OMVs are rapid processes and extremely 
difficult to capture, therefore only employment of cutting-edge microscopy approaches for 
cellular and molecular visualization will enable us to unambiguously determine their functions 
in bacterial communities. 
Regulation of vesicle production by hlyF gene 
The multidrug (MDR) resistant isolates of E. coli constitute an emerging threat to healthcare 
institutions and their patients worldwide, and are therefore being extensively investigated 
(Kempke et al. 2016; Johnson et al. 2010). The collection of MDR E. coli originated from 
human and animal clinical cases were examined in the context of their virulence properties. 
Whole genome sequencing and comparative genomics-based approaches revealed the presence 
of ColV plasmids among a few analyzed isolates. The ColV plasmid has been shown to be 
implicated in the virulence of Avian Pathogenic E. coli (APEC) and of Neonatal Meningitis E. 
coli (NMEC) (Mellata 2013). These plasmids harbor many virulence genes, including hlyF, a 
putative hemolysin; tsh, a temperature-sensitive hemagglutinin; iss, the serum survival gene 
contributing to complement resistance; ompT, an outer membrane protease; the ColV operon, 
encoding ColV bacteriocin and several iron-related genes (Schouler et al. 2012; Johnson et al. 
2006). Several studies demonstrated that hlyF is an important virulence factor for pathogenicity, 
although no protein domain responsible for a hemolytic activity of hlyF was identified (Mellata 
et al. 2009; Johnson et al. 2006; Morales et al. 2004). In this work, an in silico analysis 
demonstrated that the hlyF gene encodes for protein belonging to NADB-Rossman family, 
thereby most probably functioning as fatty acyl coenzyme A (CoA) reductase or nucleoside-
diphosphate-sugar epimerase. Therefore, this virulence factor may be involved in the 
modification of the Gram-negative cell envelope. It was previously observed that remodeling 
of cell wall can affect formation of OMVs that originate from the cell wall by a process of 
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bulging out and pinching off a portion of the membranes (McBroom et al. 2006; Kulkarni & 
Jagannadham 2014; Roier et al. 2016). Taken collectively, these facts indicate the probable 
connection between hlyF gene and vesiculation process.  
In this thesis, I examined the involvement of hlyF gene in production of outer membrane 
vesicles. The vesiculation rate of two E. coli ST131 isolates expressing normal and truncated 
version of hlyF genes were compared. The truncation of hlyF resulted in decreased OMVs 
formation compare to E. coli harboring a complete gene, suggesting that this virulence factor 
could be associated with the OMV biogenesis. The blast analysis of amino acids sequences 
revealed the deletion of 77 amino acids from N-terminal side of the truncated hemolysin F gene, 
leading to loss of NADP-binding motif ‘TGXXGXXG’ and therefore result in expression of a 
non-functional protein. To exclude the contribution of other genes located on ColV plasmid to 
vesicles formation and confirm that only hlyF is involved in modulation of OMVs production, 
I cloned the complete hemolysin F gene into pUC19 vector, followed by transformation of 
constructed plasmid into E. coli K12 DH10β. The resulting recombinant strain exhibited 
significantly increased vesiculation rates compared to control E. coli harboring an empty 
pUC19 plasmid as was shown by TEM, β-lactamase activity and Bradford assays. These 
outcomes clearly demonstrated that the expression of hlyF triggers increased production of 
outer membrane vesicle, whereas the mutation of this gene leads to hypovesiculation 
phenotype. Therefore, this is the first identified virulence factor which may serve as a natural 
biological switch that controls OMV formation in E. coli.  
Additionally, I showed that the OMVs derived from E. coli expressing hlyF gene have 
a potential to induce autophagy in eukaryotic epithelial cells. It was reported previously that 
bacterial OMVs trigger autophagosome formation associated with inflammatory interleukin 8 
responses in epithelial cells via NOD1 and RIP2 signaling pathway (Irving et al. 2014). Hence, 
due to the fact that OMV are involved in a number of biological functions, the induction of 
vesicle production mediated by hlyF may contribute to a wide range of processes in bacterial 
communities. It is important to pass a remark that I encountered isolates exhibiting 
hypervesiculation phenotype but did not harbor the hlyF gene. It has been previously noted that 
various proteins which are involved in LPS modification, cell wall integrity and peptidoglycan 
synthesis may affect the process of vesicle formation (Cascales et al. 2000; McBroom et al. 
2006; Elhenawy et al. 2016), indicating that there is not one mechanism underlying vesiculation 
but rather multiple events can lead to the production of vesicles in bacteria. Taken together, this 
data indicates that the presence of hlyF gene in E. coli not only triggers increased OMVs 
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formation but also induces autophagosome formation in HeLa cells exposed to hlyF-induced 
vesicles. However, bioinformatics analysis does not give an exact hint towards the molecular 
basis underlying this process and further work is required to precisely understand this 
mechanism. My study is parallel and supportive to recently published. investigation (Murase et 
al. 2016), which provided the first evidence for the contribution of hlyF to vesicle production. 
Murase et al. observed that the culture supernatant of E. coli expressing hlyF induced 
autophagosome formation in eukaryotic cells, and this phenomenon concurred with the 
increased formation of vesicle, which led them to speculate the role of hlyF protein. 
My discovery that bacteria utilize hemolysin F gene to regulate production of OMVs 
has significant implications for microbial ecology and physiology. By expression of hlyF, 
bacteria can modulate the formation of OMV, and therefore meaningfully extends their ability 
to interact with surrounding milieu in long-distance manner without the need for direct contact. 
Dissemination of antibiotic resistance genes via bacterial vesicles 
The capability of bacteria to extend their influence in a long-distance manner is crucial to their 
activity and survival, and can be achieved by formation of nanotubes or release of small 
macromolecular structures, such as outer membrane vesicles (Dubey et al. 2016; Shetty et al. 
2011; Kulkarni & Jagannadham 2014). OMVs are highly versatile and mediate a variety of 
processes, including delivery of small molecules for signaling and various proteins that effect 
virulence (Kadurugamuwa & Beveridge 1995; Ellis & Kuehn 2010). Additionally, several 
groups observed that OMVs are composed of double-stranded DNA, and therefore might be 
involved in transferring of genetic material to milieu (Yaron et al. 2000; Rumbo et al. 2011; 
Renelli et al. 2004; Kadurugamuwa & Beveridge 1995; Dorward et al. 1989). Since multidrug 
resistant Enterobacteriaceae, in particular those producing carbapenemases are a worrying 
problem in hospital settings in Europe and beyond, I wanted to know whether the vesicles 
secreted by these microorganisms could serve as vectors for the spread of antibiotic resistance 
genes. Genetic material can be transferred between bacteria by several mechanisms including 
transformation, conjugation or transduction (Thomas & Nielsen 2005). Transformation is the 
process that occurs when a bacterial cell takes up foreign DNA from its surroundings. The 
bacteria which are able to ingest naked DNA are called recipients and after transformation, 
microorganisms that have taken up foreign DNA are termed transformants. During the 
transformation process, donor cells need to be lysed to release the free DNA molecules in order 
for it to be taken up by the recipient. In this thesis, I revealed that C. freundii isolates secrete 
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vesicles containing the blaKPC-2 carbapenemase gene without a loss of viability, hence 
representing a novel avenue of spreading plasmids with antibiotic resistance genes that are 
clinically important. Moreover, I provided evidence of DNA transfer, which has been mediated 
by OMVs derived from of C. freundii cells.  
Initially, the release of vesicles by isolates of C. freundii was confirmed by electron 
microscopy. According to SEM analysis, the OMVs were visible uniformly on the entire 
surface of a bacterial cell, suggesting that whole Gram-negative envelope is involved in 
vesiculation process. The OMVs size measurements revealed that C. freundii secrete vesicles 
of different sizes during growth. However, the biological consequence of this observation needs 
to be determined. The various range of OMV size indicates that vesicle production is a 
physiologically regulated and reproducible event. Vesicle diameter diversity may depend on 
different growth phases of bacterial blebs. 
Moreover, the vesicles were also further characterized for their protein composition by 
comprehensive mass spectrometry analysis. According to the normalized spectral abundance 
factor (NSAF), the most abundant were membrane proteins, but cytoplasmic compounds were 
also detected. It is known that OMVs contain inner and outer membrane, and consequently trap 
underlying cytoplasmic compartments, such as plasmids, cytosolic proteins or even fragmented 
chromosome (Kadurugamuwa & Beveridge 1995). To obtain insights into the interrelationships 
between proteins identified by MS analysis, I constructed and analyzed a protein - protein 
interaction (PPI) networks for OMVs derived from C. freundii isolate. PPIs revealed that 
vesicular proteins were closely interconnected via physical interactions and cluster into 
functional modules. According to constructed PPI networks, I was able to identify functional 
modules that appear to be involved in bacterial cell wall and membrane biogenesis, amino acid 
transport and metabolism, translation, ribosomal structure and biogenesis and cell division. 
Since recent studies have drawn attention to the importance of OMVs in bacterial pathogenesis, 
a better understanding of interrelationships between vesicular proteins will be useful in finding 
a novel, promising antimicrobial targets (Schwechheimer & Kuehn 2015; Lim & Yoon 2015). 
One such potential virulence target has been detected in C. freundii OMVs (Figure 4.20, 
subnetwork C) and is called survival protein A (SurA). This protein has been shown to be 
pivotal for outer membrane biogenesis in several species of bacteria and its loss leads to 
hypersensitivity to hydrophobic antibiotics and a reduction in outer membrane protein 
production (Southern et al. 2016). Investigating the function of SurA in OMVs might contribute 
to development of novel therapeutic strategies for the inhibition of the vesicle biogenesis and 
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consequently attenuate bacterial virulence potential. Another interesting antimicrobial target, 
which has been also identified in Citrobacter’s OMV, is filamentous temperature-sensitive 
protein Z (FtsZ). It is an essential cell-division protein involved in formation a highly dynamic 
cytokinetic ring at the septum site. As inactivation of FtsZ or an alteration in its assembly leads 
to the inhibition of Z-ring, septum formation and likely OMV formation, the FtsZ constitutes a 
very promising factor for novel antimicrobial drug development (Kumar et al. 2011). 
Members of the Enterobacteriaceae are known to disseminate genes horizontally, 
mainly via conjugation. However, my results reinforce another possible pathway of horizontal 
gene transfer (HGT). I showed that KPC-2-producing C. freundii secretes vesicles containing 
KPC-2 gene. Further, I demonstrated that non-competent E. coli J53 exposed to KPC-2-
containing OMVs results in an intergenus gene transfer mediated by a DNA transport 
mechanism that did not rely on the bacterial cells. The frequency of vesicle-mediated gene 
transfer between C. freundii OMVs and recipient E. coli J53 cells was low and yielded 41 
vesiculants per 10 µg of OMVs, which was four orders of magnitudes lower comparable to 
conjugation efficacy. Additionally, the presence of plasmid DNA in OMVs-transformants was 
confirmed by positive amplification of blaKPC-2 gene. To further verify the origin of DNA inside 
OMVs-transformed E. coli J53, the plasmid was isolated and sequenced. The sequencing 
analysis confirmed that the DNA found in E. coli J53 that has been preincubated with OMVs 
originated from C. freundii cells. My results correspond to previous reports indicating that 
OMVs can act as an additional mechanism for transferring genetic material to other bacteria 
(Fulsundar et al. 2014; Yaron et al. 2000; Klieve et al. 2005; Rumbo et al. 2011; Dorward et al. 
1989). However, not all OMV containing DNA have been found to allow vesicle-mediated 
horizontal gene transfer (Renelli et al. 2004). The molecular mechanism leading to 
encapsulation of DNA into vesicles and subsequently delivery of genes into the host cell surface 
is not completely known yet. The observations of previous research groups suggest that OMVs 
utilize various endocytic routes to enter the cells, but the exact action mode need to be 
determined (Kaparakis-Liaskos & Ferrero 2015; Kulp & Kuehn 2010). 
Taken together, my outcomes provide evidence that C. freundii produces OMVs of 
distinct-size populations that offer a nuclease-resistant mechanism of gene transfer within 
unrelated bacteria. Further investigations should be conducted to determine the biological 
relevance of this transfer as well as the surface and adherence properties of OMVs. Nonetheless, 
the prospect that OMVs provide a unique, long-distance manner for the secretion of cytoplasmic 
constituents, including plasmid DNA sheds completely new light on the interaction between 
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bacterial communities and their environment. Collectively, my discovery that outbreak isolates 
utilize, along with conjugation, vesicles to transfer antibiotic resistance genes, and thus convert 
susceptible isolates to resistant, has significant implications for the current understanding the 
interplay between microbial populations. The possibility that by the release of OMVs pathogens 
can significantly extend their spread beyond the limitations of traditional conjugation 
machinery indicates that bacteria may act as multicellular, indirectly connected elements 
without the need for immediate cell-cell contact.
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Section II 
4.5 Examination of mechanism of colistin resistance conferred by the mobile, plasmid-
mediated colistin resistance gene 1 (mcr-1). 
Colistin is a last-resort antibiotic against infections caused by multidrug-resistant (MDR) Gram-
negative bacteria. However, colistin treatment has resulted in the selection of MDR bacterial 
isolates with chromosomal mutations leading to polymyxin resistance and, more recently, the 
appearance of a plasmid-encoded colistin resistance mechanism (mcr-1) (Liu et al. 2015). The 
mcr-1 gene encodes a member of the family of phosphoethanolamine (pEtN) transferases that 
catalyze the transfer of pEtN group onto the glucosamine-disaccharide of lipid A in the outer 
leaflet of the bacterial outer membrane (Y. Y. Liu et al. 2017). This increases the net negative 
charge of the lipid A head group and, consequently, affinity between cationic antimicrobial 
peptides (CAMPs), such as colistin and bacterial membrane. The mcr-1 gene is encoded on 
nonrelated types of plasmid replicons such as IncI2, IncX4, IncHI2 and IncP and was rarely 
detected to be located on the chromosome (Zurfluh, Kieffer, et al. 2016; Zurfluh, Tasara, et al. 
2016). It is a part of a highly conserved operon that includes an additional open reading frame 
encoding a putative membrane-bound phosphatase belonging to PAP2 protein superfamily 
according to conserved domain blast analysis. Although mcr-1 gene has been discovered in the 
late 2015, so far, the detailed mechanism for MCR-1 colistin resistance in not fully understood, 
mainly due to the lack of the biochemical analysis and the crystal structure of complete MCR-
1 enzyme. 
4.5.1 The structure of MCR-1 
The structure of MCR-1 closely resembles two members of the pEtN transferases derived from 
Neisseria meningitides, LptA and Campylobacter jejuni, EptC, which belongs to the alkaline 
phosphatase protein super-family. The MCR-1 contains two discretely folded domains: one N-
terminal transmembrane (TM) domain and one C-terminal presumably periplasmic-facing 
catalytic domain (Ma et al. 2016). Transmembrane helices prediction method (TMHMM) 
(Sonnhammer et al. 1998) predicted that the TM domain is composed of five transmembrane 
helices (TMH1-TMH5; Figure 4.29A) located approximately parallel to one another and 
crossing the inner membrane. The computer modeling of the complete MCR-1 protein structure 
performed by a web portal for protein structure and function prediction (RaptorX) (Källberg et 
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al. 2012) indicated that the catalytic domain of MCR-1 has a hemispherical shape and includes 
seven β-strands flanked by α-helical structures (Figure 4.29B). Its α/β/α fold is characteristic 
for the alkaline phosphatase protein superfamily, therefore MCR-1 enzyme may act similarly 
to other pEtN transferases (Stojanoski et al. 2016). Genetic studies revealed that both the TM 
region and a catalytic domain are essential for MCR-1 activity (Gao et al. 2016). However, to 
date only the C-terminal, soluble domain has been crystallized and the catalytic mechanism of 
MCR-1 still needs to be elucidated (Hinchliffe et al. 2017). 
Figure 4.29 In silico characterization of full-length MCR-1 protein. (A) The transmembrane helices 
prediction method (TMHMM) predicted 5 transmembrane α-helices at the N-terminus of MCR-1 amino 
acids sequence (Sonnhammer et al. 1998). (B) Predicted 3D structure of MCR-1 protein based on 
RaptorX protein structure prediction tool (Källberg et al. 2012). MCR-1 contains two regions annotated 
as a transmembrane domain (TM) at N-terminus and a catalytic domain at C-terminus. The crystal 
structures of MCR-1 catalytic domain (PDB code: 5K4P) and eukaryotic phosphate transporter (PDB 
code: 4J05) were used as templates for 3D structure prediction.  
4.5.2 Functional analysis of MCR-1 mediated colistin resistance 
As yet, the contribution of the MCR-1 enzyme to polymyxin resistance has been examined by 
cloning the mcr-1 gene into expression vectors followed by determination of MICs towards 
colistin and analysis of structural changes in lipid A. However, this gene is encoded on different 
plasmids and is a part of an operon including an open reading frame (ORF) predicted to encode 
a membrane-bound phosphatase. So far, the association of the putative phosphatase and other 
plasmid-encoded factors with the expression of the mcr-1 gene and subsequently with colistin 
resistance is not known. Therefore, I aimed to address this concern by performing a mutagenesis 
of mcr-1-encoding IncX4-type plasmid. Initially, to investigate the level of protection mediated 
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by MCR-1 and assess the involvement of other plasmid-borne genes in colistin resistance, the 
mcr-1 was removed from a wild type (WT) IncX4 plasmid of E. coli 002 (p002) to create the 
isogenic variant p002::Δmcr-1 (Figure A-0.1, Appendix C). Following the transformation of 
the mutated IncX4 plasmid into E. coli K12 DH10β, the broth microdilution method (BMD) 
was performed to determine colistin MICs for the resulting transformants (Table 4.3). The MIC 
value for E. coli DH10β, containing the WT p002 was 4 mg/L. The E. coli DH10β harboring 
p002::Δmcr-1 became susceptible to colistin at 2mg/L. These results proved the essential role 
of mcr-1 gene in conferring resistance to colistin. 
Table 4.3 Colistin susceptibility testing for E. coli DH10β. The MICs were determined by broth 
microdilution (BMD) in cation-adjusted Mueller-Hinton broth (CA-MHB). 
E. coli DH10β MIC* of colistin [mg/L] 
p002 4 
p002::Δmcr-1 2 
*The MIC is defined as the lowest concentration of the colistin that inhibits visible growth of the tested isolate as observed with 
the unaided eye. 
To further confirm that the mcr-1 gene encoded on IncX4 plasmid is functional and leads to 
modification of bacterial outer membrane and consequently to colistin resistance, a lipid A 
fractions from transformants of E. coli DH10β carrying either WT or mutated IncX4 
(p002::Δmcr-1) were isolated and analyzed by MALDI-TOF-MS. The MS results revealed that 
unlike the negative-control DH10β with p002::Δmcr-1 or without any plasmid, the pEtN-
modified lipid A occurs consistently in the strain carrying mcr-1 gene (Figure 4.30). The 
addition of pEtN group to lipid A domain of LPS was confirmed in E. coli harboring p002 by 
detection of the mass shift (Δm/z 123) in the spectrum of lipid A structure, which corresponds 
to a molecular weight (MW) of pEtN in negative ion mode (Figure 4.30B). No changes in mass 
spectra of lipid A were noted for E. coli carrying no or a mutated plasmid (Figure 4.30A, C). 
The mass differences of m/z  ̴ 28 (m/z 1768 and 1823) and  ̴ 43 (m/z 1839) correspond to 
heterogeneity of the length in fatty acid chain. The peak at m/z 1716 was assigned to the 
structure of lipid A with a monophosphate group. These outcomes indicate that neither the 
phosphatase gene nor any components of the IncX4 plasmid could confer resistance to colistin 
in the absence of the mcr-1 gene. 
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Figure 4.30 MALDI-TOF-MS analysis of lipid A fractions isolated form E. coli. The Lipid A was 
extracted from E. coli DH10β (A) and E. coli DH10β harboring either WT p002 (B) or mcr-1 deletion 
mutant (p002::Δmcr-1) (C). The pEtN-modified species are represented in red (m/z 1919). Asterisk (*) 
represents lipid A structure that varies in acyl chain length. 
4.5.3 Purification and activity of MCR-1 enzyme 
To further gain detailed insights into biochemical properties of full-length MCR-1, the mcr-1 
was engineered as a C-terminal hexahistidine gene fusion by cloning into pET-28a expression 
vector under an inducible T7 promoter. Subsequently, the protein was overexpressed by IPTG 
induction for 3 hours at 37°C, and then the membrane-bound MCR-1 was extracted from the 
collected membrane fraction in the presence of the 1% detergent dodecyl-β-D-maltoside 
(DDM). The protein-DDM micelles were loaded onto an immobilized metal-affinity 
chromatography (IMAC) Ni-NTA column and the MCR-1 bound protein was eluted with an 
increasing concentration of imidazole in elution buffer containing DDM, yielding 
approximately 2.6 mg/L. The homogeneity of the purified enzyme, as evaluated by SDS–
PAGE, was 98% (Figure 4.31). MCR-1 polypeptide was visible as a single protein band of 
about 55 kDa, similar to the expected molecular mass of MCR-1. MS analysis further confirmed 
the identity of the recombinant MCR-1 transmembrane protein (Figure 4.33A). 
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Figure 4.31 Purification of full-length MCR-1. (A) Coomassie blue stained 10% SDS-PAGE of purified 
MCR-1. Mass spectrometry analysis verified the identity of the recombinant MCR-1 protein (Figure 
4.33A). (B) Elution profile of MCR-1 on HisTrap HP column, equilibrated with binding buffer (BB) (pH 
7.4). Elution of proteins with linear gradient of imidazol (0 – 500mM) in BB, column volume: 5ml, flow 
rate: 2.5 mL/min, time of elution: 80 min. 
Additionally, a deletion mutant of the gene (mcr-1Δ1-214) was engineered and cloned into pET-
28a vector in order to have a negative control for MCR-1 activity assay. The MCR-1Δ1-214 
protein was overexpressed and puriﬁed under native conditions with yield of up to 27 mg/L as 
previously described (Stojanoski et al. 2016) (Figure 4.32, Figure 4.33B). 
Figure 4.32 Purification of catalytic domain of MCR-1 (MCR-1Δ1-214). (A) Coomassie blue stained 
10% SDS-PAGE of purified MCR-1Δ1-214. Mass spectrometry analysis verified the identity of the 
recombinant MCR-1 protein (Figure 4.3B). (B) Elution profile of MCR-1Δ1-214 on HisTrap HP column, 
equilibrated with binding buffer (BB) (pH 7.4).  Elution of proteins with linear gradient of imidazol (0 – 
500mM) in BB, column volume: 5ml, flow rate:  2.5 mL/min, time of elution: 50 min. 
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Figure 4.33 MS analysis of purified MCR-1.  (A) The full-length MCR-1. (B) The catalytic domain of 
MCR-1 (MCR-1Δ1-214). The proteins were identified based on matches to their sequences resulting from 
comparing of observed peptide MS/MS spectra to theoretical spectra. 
To assess the activity of the purified MCR-1 and soluble domain (MCRΔ1-214) used as a negative 
control, a fluorescence-based TLC enzyme assay was performed using a lipid substrate tagged 
with a fluorescent label (Acyl-NBD-PE). As shown in Figure 4.34A, the MCR-1 was able to 
successfully remove pEtN group from the lipid substrate, confirming that the purified enzyme 
adopted a proper conformational state in DDM detergent micelles and was enzymatically 
active. The product formed by reaction with the full-length MCR-1 was confirmed by MS to 
be 1-acyl-2-{12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl}-sn-glycerol (Figure 
4.34 B). In contrast, a MCRΔ1-214 construct was unable to catalyze pEtN hydrolysis, confirming 
that the transmembrane domain of MCR-1 is required for its activity on a lipid substrate. 
Figure 4.34 Activity of purified MCR-1 enzyme. (A). The fluorescence-based TLC enzyme assay of 
recombinant MCR-1 purified in n-Dodecyl β-D-maltoside (DDM) detergent micelles. (B) MS analysis of 
the product formed by reaction of acyl-NBD-PE with the MCR-1 enzyme. The substrate is labeled as an 
acyl 12:0 NBD-glycerol-3-phosphoethanolamine and the product is labeled as an acyl 12:0 NBD-
glycerol. 
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4.5.4 Calcium-dependence of mcr-1-mediated resistance to colistin 
Although the expression of mcr-1 gene leads to the modification of the outer leaflet of the outer 
membrane and results in increased resistance to colistin,  many MCR-1 producers show a MIC 
of 2 mg/L for colistin, and therefore are categorized as sensitive according to EUCAST 
guidance (Chew et al. 2017). This suggests that the mcr-1 gene is able to confer resistance to 
colistin but clearly only under defined conditions. These observations have encouraged a joint 
CLSI-EUCAST subcommittee to announce warnings related to the overall poor credibility of 
colistin susceptibility testing (Eucast 2016). Therefore, all methods to simplify and improve 
determination of MIC towards polymyxins, i.e. colistin are highly wanted. By analyzing the 
minimum inhibitory concentration of colistin for mcr-1-producing Enterobacteriaceae isolates, 
we observed that MCR-1 producers exhibited increased resistance to colistin when they were 
grown in the presence of heat-inactivated serum (Table 4.4).  
Table 4.4 The colistin MIC susceptibility for subset of mcr-1-producing E. coli isolates. The MICs were 
determined by microdilution method in the reference cation-adjusted Mueller Hinton broth (CA-MHB) 
containing 20% of heat-inactivated normal human serum (iNHS). 
 
Isolate (Inc group) 
Broth microdilution MIC* [mg/L] 
CA-MHB CA-MHB supplemented with 20% 
NHS 
E. coli _001 (IncHI2) 4 6 
E. coli _002 (IncX4) 4 6 
E. coli _006 (IncX4) 4 6 
E. coli _018 (chromosomal) 4 6 
E. coli _055 (ND) 4 6 
E. coli DO14** (NA) 0.5 0.5 
E. coli DO21** (NA) 0.5 0.5 
E. coli_017** (NA) 0.5 0.5 
*The MIC is defined as the lowest concentration of the colistin that inhibits visible growth of the tested isolate as observed with 
the unaided eye. ** mcr-1-negative isolate; ND – not determined; NA – not applicable. 
Since serum comprises high levels of calcium ions, I evaluated whether addition of Ca2+ to 
broth could be used as an enhancing agent for the detection of mcr-1-encoding 
Enterobacteriaceae. I noted that elevated concentrations of Ca2+ in the media are optimal for 
the reliable detection of mcr-1-positive isolates. Therefore, I formulated the calcium-enhanced 
medium (CE-MHB) containing 200 mg/L Ca2+ and compared it to the reference broth (CA-
MHB) by using microdilution and Etest methods. Initially, a subset of mcr-1-positive isolates 
was examined by microdilution and Etest methods. A pronounced difference in MIC values 
between CA-MHB and the CE-MHB was observed. The MIC for colistin ranged from between 
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4 mg/L and 8 mg/L in CA-MHB, and increased to between 16 and 32 mg/L in CE-MHB (Table 
4.5). 
Table 4.5 Colistin susceptibility results for a subset of mcr-1-positive E. coli isolates. The MICs were 
determined in cation-adjusted Mueller-Hinton broth (CA-MHB) and calcium-enhanced Mueller-Hinton 
broth (CE-MHB) by broth microdilution and Etest. 
 
Isolate (Inc type) 
Broth microdilution MIC* [mg/L] Etest MIC* [mg/L] 
CA-MHB CE-MHB CA-MHB CE-MHB 
E. coli_017** (NA) 0.5 0.5 1.5 1.5 
E. coli_020 (IncHI2) 4 16 3 12 
E. coli_041 (IncX4) 4 16 4 16 
E. coli_044 (IncHI2) 8 32 4 24 
E. coli_053 (ND) 8 32 4 24 
E. coli_055 (ND) 4 32 4 24 
E. coli_059 (IncX4) 4 32 4 24 
*The MIC is defined as the lowest concentration of the colistin that inhibits visible growth of the tested isolate as observed with 
the unaided eye. ** mcr-1-negative isolate; NA – not applicable; ND – not determined. 
I also detected a significant increase in MIC values for colistin with CE-MHB, compared to the 
reference CA-MHB when using Etest (Figure 4.35). Therefore, CE-MHB clearly determines 
mcr-1-positive bacteria regardless of the assay format (liquid, solid) used. It is noteworthy that 
isolates lacking mcr-1 gene and being susceptible to colistin did not exhibit an increased MIC 
towards colistin in CE-MHB. Moreover, the concentration of Ca2+ used has no adverse effects 
on bacterial growth (results not shown). 
Figure 4.35 The effect of increased calcium concentration on the minimum inhibitory 
concentration (MIC) of colistin for MCR-1 producers. (A) The colistin MIC values of colistin-
susceptible and a representative mcr-1-positive isolate. (B) Colistin susceptibility testing of 49 isolates 
expressing mcr-1 gene. A significant upward shift in colistin MIC values was observed in CE-MHB, as 
compared to the reference CA-MHB. The MICs were determined in cation-adjusted Mueller Hinton broth 
(CA-MHB) and calcium-enhanced Mueller Hinton broth (CE-MHB) by Etest. 
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To directly confirm the contribution of the mcr-1 gene to calcium-induced resistance to colistin, 
the gene was removed from the IncX4-plasmid p002 in order to create the isogenic variant 
p002::Δmcr-1 (Figure A-0.1, Appendix C). The MICs towards colistin of E. coli DH10β, 
containing either the wild type p002 or p002::Δmcr-1 was determined in CA-MHB to be 4 mg/L 
and 2 mg/L, respectively. However, the MIC values of the strain harboring p002 increased to 
32 mg/L when grown in CE-MHB broth. The isogenic E. coli DH10β strain harboring 
p002::Δmcr-1 remained susceptible to colistin at 2mg/L, demonstrating an essential role of mcr-
1 gene in calcium-induced colistin resistance (Figure 4.36). 
Figure 4.36 The image of microtiter plate presenting the results of MIC determination to colistin. 
Colistin susceptibility testing for E. coli DH10β harboring p002 or p002::Δmcr-1 determined by broth 
microdilution in cation-adjusted Mueller-Hinton broth (CA-MHB) and calcium-enhanced Mueller-Hinton 
broth (CE-MHB). The MIC is defined as the lowest concentration of the colistin that inhibits visible growth 
of the tested isolate as observed with the unaided eye and was marked in red X. 
4.5.5 Analysis of interaction between colistin and calcium ions   
The observations of previous research groups (Sud & Feingold 1970; Chen & Feingold 1972; 
Newton 1954) suggest that divalent cations may antagonize the bactericidal effect of polymyxin 
antibiotics. However, the exact mechanism of these antagonism events is not known yet. To 
exclude the interactions between calcium ions and colistin molecules, the NMR-spectroscopy 
analysis was carried out. The NMR method is useful for studying the complexation of small 
molecule ligands, e.g. peptide antibiotics with metal ions by recording the chemical shift of 
analyzing particles. I started with a NMR spectral profiling of intact colistin followed by 
measuring NMR spectra of a mixture of colistin and calcium chloride dehydrate. In order to 
analyse the colistin-calcium interactions, the peptide was dissolved in DMSO-d6 either 
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separately or along with increasing concentration of CaCl2 x 2H2O. The spectra of colistin in 
the presence or absence of calcium ions were measured (Figure 4.37).  No change in the proton 
chemical shift of the peptide in presence of calcium was observed, suggesting that colistin 
complexation by calcium ions did not occur. 
Figure 4.37 1H-NMR spectra of colistin peptide preincubated with and without different 
concentration of calcium salt taken at 28°C. A complexation or binding of colistin by calcium ions 
would lead to a change in the chemical shift of the side chain signals of the colistin antibiotic but they 
are identical in the presence/absence of Ca2+. The 1H-NMR analysis of changes in chemical shifts has 
not identified the sites susceptible to interactions with calcium ions. 
4.5.6 Differentiation between MCR-1 and non-MCR-1 producers based on Ca2+ 
deprivation 
The discovery that mcr-1-mediated resistance to colistin is calcium inducible (see chapter 4.5.4) 
encourage me to evaluate the effects of calcium depletion on MCR-1 activity in situ as 
measured by growth curve determination for representative mcr-1-producing E. coli and isolate 
intrinsically resistant to colistin. Removal of calcium through addition of the increasing 
concentration of chelating agent selective for Ca2+, EGTA inhibited the growth of E. coli isolate 
expressing mcr-1 gene in the presence of colistin (Figure 4.38A). Surprisingly, the growth of 
isolates exhibiting a mcr-1-indepentent resistance mechanism to colistin was not repressed by 
the addition of a chelating agent (Figure 4.38B).  
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Figure 4.38 Growth curves of representative MCR-1 and non-MCR-1 producers in the presence 
of increasing concentration of EGTA and 2 mg/L of colistin. (A) The growth curves of mcr-1-
producing E. coli and (B) Providencia rettgeri exhibiting mcr-1-independent resistance mechanism to 
colistin. In the presence of colistin, EGTA inhibits the growth of MCR-1 producers, whereas intrinsically-
resistant isolates are not affected. Data are expressed as the mean ± SEM from three independent 
experiments. 
Profound growth inhibition due to EGTA exposure was also observed when MIC values 
towards colistin were determined for 48 mcr-1-expressing E. coli (Figure 4.39) supporting the 
theory for calcium being a requirement in MCR-1 function. These outcomes imply that divalent 
cations, specifically calcium ions, are important to resistance mediated by MCR-1 mechanism.  
Figure 4.39 The effect of calcium depletion on the minimum inhibitory concentration (MIC) of 
colistin for MCR-1 and non-MCR-1 producers. (A) The colistin MIC values for representative mcr-1-
producing and intrinsically resistant isolates determined by Etest. (B) Colistin susceptibility testing of 48 
isolates expressing mcr-1 gene determined by broth microdilution (BMD). A significant drop in colistin 
MIC values was observed in Ca2+ depleted medium for all tested MCR-1 producers. The colistin MICs 
were measured in cation-adjusted Mueller Hinton broth (CA-MHB) and Mueller Hinton broth 
supplemented with 10 mM EGTA (MHBEGTA). 
On the basis of the aforementioned results, which are indicating that the mcr-1-dependent 
colistin resistance mechanism requires calcium for its activity, I developed a simple method for 
differentiation between MCR-1 and non-MCR-1 producers. This test is based on the broth 
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microdilution (BMD) in MHB supplemented with 10 mM EGTA (MHBEGTA) and standard CA-
MHB as recommended by the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) and Clinical Laboratory Standard Institute (CLSI) guidelines. For each tested 
isolate, bacterial suspension was inoculated in parallel into all wells of 2 rows in 96well 
microplate, including CA-MHB and MHBEGTA (Figure 4.40). 
Figure 4.40 Representative results of the EGTA-based test for distinguishing of MCR-1 and non-
MCR-1 producers. Intrinsically resistant isolates exhibit the same MIC towards colistin in both CA-MHB 
and MHBEGTA, whereas mcr-1-producing E. coli have decreased colistin MIC values in MHBEGTA 
compare to CA-MHB. 
The parallel analysis of MIC of colistin in CA-MHB and MHBEGTA allowed for simultaneous 
colistin susceptibility testing and differentiation between MCR-1 and non-MCR-1 producers. 
All isolates intrinsically resistant to colistin had the same MIC towards colistin in both CA-
MHB and MHBEGTA, whereas MCR-1 producers exhibited a decrease in colistin MICs in 
MHBEGTA compared to CA-MHB. The mechanisms leading to this effect remain to be 
elucidated. 
The test described here is simple to perform and is based on the requirement of the 
MCR-1 relating to the presence of Ca2+. It provides not only detection of colistin-resistant 
Enterobacteriaceae but also enable for determination of different types of colistin resistance 
mechanisms (i.e. intrinsic and transferable) and therefore may contribute to containment of 
mobile colistin resistance. 
4.5.7 LPS modification triggers formation of OMV  
Modification of bacterial outer membrane mediated by mcr-1 gene not only results in increased 
resistance to cationic antimicrobial peptides, such as colistin but also may contribute to other 
events important for bacterial survival, colonization and host inception. Recent study have 
revealed links between remodeling of lipid A domain of LPS and the delivery of proteins and 
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toxins that are associated with outer membrane vesicles (Elhenawy et al. 2016). Elhenawy at 
al. discovered that changes in LPS mediated by deacylation of lipid A play a role in OMV 
biogenesis. Divalent cations intercalate between LPS molecules and stabilize the negatively 
charged bacterial membranes. Modification of lipopolysaccharides can alert LPS packing order 
by replacing structurally important cations leading to charge - charge repulsion, and therefore 
trigger local deformation of outer membrane, causing increase formation of the OMV. Thus, I 
tested the effect of LPS remodeling mediated by mcr-1 colistin resistance mechanism on OMV 
formation employing recombinant E. coli DH10β strain expressing mcr-1 gene as well as 
transconjugants of E. coli J53 carrying different mcr-1-encoding plasmids (Figure 4.41). 
Expression of mcr-1 in recombinant E. coli resulted in 2-fold increase in vesiculation phenotype 
compare to empty vector control. The same profound augmentation of OMV levels was 
observed for transconjugants of E. coli J53 harboring mcr-1 in different Inc-type plasmids. 
Taken together, these results suggest that the mcr-1 gene can trigger elevated releases of OMVs 
by modification of outer membrane through addition of phosphoethanolamine group to lipid A 
domain of LPS.  
Figure 4.41 Expression of mcr-1 gene induces OMV production in E. coli. The mcr-1 gene cloned 
into pUC19 vector or encoded on different Inc-type plasmids was transferred into E. coli DH10β and E. 
coli J53, respectively. Vesiculation phenotype of E. coli was assessed by OMVs isolation followed by 
vesicular proteins quantification based on Bradford assay. Control strains carrying either the empty 
vector control or no plasmid are marked in white and red chequers. Bar graph represents data obtained 
from single trial analysis. 
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Discussion - Section II 
In the second section of this thesis, I investigated the modification of the bacterial membranes 
at the level of lipopolysaccharides mediated by plasmid-borne colistin resistance mechanism 
(mcr-1). I confirmed that the expression of this gene confers resistance to colistin by catalyzing 
the addition of phosphoethanolamine (pEtN) group to lipid A. Moreover, full-length MCR-1 
protein was purified and characterized in terms of its biochemical properties. Based on 
discovered conditions required for functionality of MCR-1, I devised a novel calcium-enhanced 
medium for improved determination of mcr-1-producing Enterobacteriace as well as a new 
EGTA-based assay for distinguishing of MCR-1 and non-MCR-1 producers. In the following 
chapter, the overview of obtained outputs is given to summarize and discuss the data from 
second section of this thesis. 
The effect of membrane remodeling mediated by MCR-1 on resistance to colistin and 
OMV formation 
The increasing occurrence of multidrug-resistant (MDR) Gram-negative bacteria (GNB) is a 
serious threat to global healthcare system due to the severely limited treatment options. In 
particular, the ESBL-producing GNB that are resistant to carbapenems pose the greatest 
challenge for successful therapy (World Health Organization 2017). Progressively, colistin is 
used as a last-line antibiotic for GNB infections as the spread of plasmids encoding antibiotic 
resistance led to increased treatment failure rates for carbapenems or third generation 
cephalosporins (Biswas et al. 2012). However, colistin treatment has resulted in the selection 
of MDR bacterial isolates with chromosomal mutations leading to polymyxin resistance and, 
more recently, the appearance of a plasmid-encoded resistance to colistin (mcr-1) (Liu et al. 
2016). This first transferable colistin resistance mechanism might contribute to an even faster 
spread of colistin resistance among Enterobacteriaceae isolates leading to nosocomial 
outbreaks of untreatable infections. The mcr-1 gene codes for phosphoethanolamine (pEtN) 
transferase enzyme that catalyze the transfer of pEtN group onto the glucosamine-disaccharide 
of lipid A in the outer leaflet of the bacterial outer membrane (Anandan, Evans, Condic-Jurkic, 
O’Mara, John, Phillips, G. a. Jarvis, et al. 2017). However, its exact mode of action remains to 
be understood. One of the objectives of this thesis was to investigate the impact of MCR-1 on 
bacterial membrane remodeling and consequently resistance to colistin.  
Homology modelling of the complete MCR-1 with the RaptorX protein structure 
prediction server identified the soluble portions of two pEtN transferases, LptA and EptC, as 
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the closest relatives of known structure. The MCR-1 contains two discretely folded domains: 
one N-terminal transmembrane (TM) domain and one C-terminal presumably periplasmic-
facing catalytic domain (Ma et al. 2016). I experimentally validated that the expression of the 
complete mcr-1 gene augments colistin resistance in E. coli, as assessed by determination of 
MIC towards colistin for a recombinant strain expressing mcr-1 gene, as well as analysis of 
structural changes in lipid A extracted from a transconjugant of E. coli harboring wild type or 
mutated IncX4 plasmids. This supports the previous findings indicating that mcr-1 confers 
resistance to colistin by masking the negative charges of the 1 and 4' phosphate groups on lipid 
A, thereby reducing its affinity for cationic peptides (Y. Y. Liu et al. 2017; Y. Y. Liu et al. 
2017). To get insights into biochemical properties of MCR-1, the mcr-1 gene was cloned into 
a pET-28a expression vector, followed by protein overexpression and purification in the 
presence of the 1% detergent dodecyl-β-D-maltoside (DDM) by a metal-affinity 
chromatography (IMAC). Furthermore, the purified full-length MCR-1 was found to be 
enzymatically active, as determined by cleavage of the Acyl-NBD-PE substrate using 
fluorescence-based thin layer chromatography (TLC) enzyme assay. In addition, the truncated 
version of MCR-1 (MCR-1Δ1-214) was not able to successfully hydrolysis of pEtN group from 
the lipid substrate, suggesting that membrane anchoring region is essential for proper function 
of the MCR-1 enzyme. This result is consistent with the previous findings indicating that 
transmembrane domain may play a key role in substrate and lipid A binding (Gao et al. 2016; 
Hinchliffe et al. 2017; Hu et al. 2016; Ma et al. 2016; Stojanoski et al. 2016). To the best of my 
knowledge, this is the first report on purification of complete MCR-1, which is enzymatically 
active. 
The mcr-1 gene is highly conserved and is capable of conferring resistance to colistin 
but clearly only under defined conditions. Thus, even though the presence of the mcr-1 gene 
results in increased resistance to polymyxin antibiotics, many isolates exhibit an MIC of 2 mg/L 
towards colistin, just below the clinical breakpoint of EUCAST, and are therefore categorized 
as sensitive despite harboring the plasmid-borne colistin resistance gene (Chew et al. 2017). An 
analysis of minimum inhibitory concentration (MIC) towards colistin for mcr-1-producing 
Enterobacteriaceae isolates revealed an increased resistance to colistin in the presence of heat-
inactivated human serum, which contains high amounts of calcium ions. This led us to the 
discovery that elevated Ca2+ level is required for the functionality of mcr-1-mediated resistance. 
Therefore, I devised a calcium-enhanced medium (CE-MHB) based on MHB that mimics 
conditions required for the mobile colistin resistance and allows for solving current problems 
associated with colistin susceptibility testing for isolates exhibiting low MICs towards colistin 
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(EUCAST 2016). All mcr-1-encoding isolates tested in this thesis that grown in CE-MHB 
exhibited increased MIC values as compared to growth in the reference CA-MHB. There was 
a clear separation of MIC values between resistant- and susceptible- bacteria when using CE-
MHB. Importantly, the isolates that are colistin susceptible or do not carry the mcr-1 gene 
remain colistin-sensitive regardless of the presence of increased calcium concentrations in the 
medium. Additionally, the use of a strain harboring an isogenic IncX4 plasmid lacking mcr-1 
confirms its contribution to calcium-dependent resistance towards colistin. However, the 
mechanisms leading to this effect remain to be understood, but because there is no increased 
resistance of colistin-sensitive strains, Ca2+ does not antagonize the bactericidal effect of 
colistin by preventing binding of the peptide to the bacterial cell wall. 
In order to exclude the interactions between calcium ions and colistin, which could lead 
to increased MIC towards colistin, the NMR-spectroscopy analysis was performed. No change 
in the proton chemical shift of the peptide in presence of calcium was observed, suggesting 
there is no complexation of colistin by calcium ions. However, the previous reports suggest that 
divalent cations may antagonize the bactericidal effect of polymyxin antibiotics, but exact 
mechanism of these antagonism events is not known yet (Sud & Feingold 1970; Chen & 
Feingold 1972; Newton 1954). 
The effects of calcium depletion on MCR-1 activity were evaluated by growth curve 
analysis as well as determination of MICs towards colistin for mcr-1-positive E. coli. Removal 
of calcium through addition of the 5 - 15 mM chelating agent selective for Ca2+, EGTA inhibited 
the growth of E. coli isolates expressing mcr-1 gene in the presence of colistin. Surprisingly, 
the growth of isolates intrinsically resistant to colistin has not been suppressed by calcium 
chelation. These outcomes imply that divalent cations, specifically calcium ions, are important 
to mcr-1 mediated colistin resistance and their depletion can be used for simple differentiation 
between mobile and intrinsic/adaptive colistin resistance mechanisms. Based on my 
knowledge, there is no existing literature that describes the effect of chelation of calcium ions 
on mcr-1 mediated resistance to colistin. However, there are recent publications indicating that 
use of metalloenzyme chelators, such as EDTA and dipicolinic acids inhibits the MCR-1 by 
binding zinc ions, which are present in the catalytic side of this enzyme (Esposito et al. 2017; 
Coppi at al. 2017).  From a transmission analysis standpoint, an easy distinguishing of intrinsic 
and transferable resistance mechanism is an important healthcare parameter, which can prevent 
form further dissemination of colistin resistance, and consequently promote better treatment 
options. 
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In this thesis, I investigated the effect of membrane remodeling on OMV formation by 
the structural changes in lipid A mediated by mcr-1 colistin resistance mechanism. To evaluate 
the involvement of MCR-1 in regulating of bacterial vesiculation phenotype, the mcr-1 gene 
was recombinantly expressed in E. coli DH10β and OMVs were isolated followed by Bradford 
quantification assay. Expression of mcr-1 has led to 2-fold increase in the amounts of OMV, as 
compared to empty vector control. The same profound increase of OMV levels was noted for 
transconjugants of E. coli J53 harboring mcr-1 in different Inc-type plasmids. These results 
suggest that the release of vesicles may depend on net charge/integrity of bacterial membranes. 
This hypothesis is supported by Elhenawy et al. and Mashburn-Warren et al. who argued that 
changes in the structure of the lipid A and the loss of divalent cations stabilizing cell wall 
contribute to generate membrane curvature, and thus OMV production (Elhenawy et al. 2016; 
Mashburn-Warren et al. 2008). Although there are increasing number of compelling studies on 
the vesiculation phenomenon occurring in Gram-negative bacteria, the mechanisms of OMV 
formation remain still enigmatic (Bonnington & Kuehn 2017). Based on the current models for 
OMV production accepted by the scientific community (Schwechheimer & Kuehn 2015) as 
well as the aforementioned involvement of mcr-1 and hlyF (which has been investigated in first 
section of this thesis) in the vesiculation process, it is rational to think that more than one 
mechanism is responsible for vesicles biogenesis. I agree with the hypothesis proposing that 
the induction of charge-charge repulsion triggered by the structural changes of 
lipopolysaccharide can lead to local membrane deformation, and consequently vesicle 
formation. The existence of such a LPS-dependent OMV formation mechanism, would be a 
convincing evidence that all Gram-negative bacteria have one unified, evolutionary conserved 
mode of vesicle biogenesis. In addition, a bilayer-couple model of OMV production is 
appealing to me as well (Schertzer & Whiteley 2012). It suggests that the increased 
concentration of an amphiphilic molecules causes expansion of the outer bacterial leaflet 
relative to the inner leaflet, thus triggering localized membrane curvature and consequently 
formation of double membranes vesicle. The release of OMVs composed of both outer and 
inner membranes would explain the presence of DNA and other cytoplasmic molecules, which 
could be packed into bacterial blebs along with cytoplasmic membrane.  
In conclusion, the data in this section of the thesis evaluates the role of mcr-1 gene with 
respect to colistin resistance, outer membrane vesicle formation and its involvement in altering 
the structure of lipid A. This study provides a biochemical analysis of purified full-length MCR-
1 and reports on the elevated Ca2+ level that is required for mcr-1-mediated colistin resistance. 
The possibility that bacteria utilize the fluctuation in calcium ions to regulate the mobile colistin 
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resistance has significant implications for currently recommended colistin susceptibility testing. 
The Ca2+-enhanced medium devised here will make surveillance of mcr-1-producing 
Enterobacteriaceae much easier and will improve our understanding of the true prevalence of 
mcr-1 expressing isolates. Differentiation between MCR-1 and non-MCR-1 producers based 
on calcium deprivation will contribute to constrain dissemination of the mobile colistin 
resistance. 
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Appendix 
Appendix A - Colistin MIC values for mcr-1-producing isolates 
Table A-1 The list of isolates and their properties used in the MCR-1 study (Chapter 4.5). Colistin MIC 
values were determined by Etest in cation-adjusted Mueller-Hinton broth (CA-MHB) and calcium-
enhanced Mueller-Hinton broth (CE-MHB).  
Species Source Incompatibility group of the 
mcr-1-positive plasmids 
Colistin MIC [mg/L] 
CA-MHB CE-MHB 
E. coli_001 Human IncHI2 2 24 
E. coli_002 Pig IncX4 2 12 
E. coli_003 Pig IncHI2 4 16 
E. coli_004 Pig IncHI2 4 24 
E. coli_005 food (beef) IncX4 2 16 
E. coli_006 food (poultry) IncX4 2 16/24 
E. coli_013 Cattle IncHI2 4 32 
E. coli_018 food (poultry) chromosomal 2 16 
E. coli_020 food (poultry) IncHI2 3 12 
E. coli_021 Pig IncX4 6 32 
E. coli_022 Pig IncX4 3 16 
E. coli_023 Pig IncX4 3 24 
E. coli_024 Pig ND 3 24 
E. coli_025 Pig IncHI2 4 24 
E. coli_026 Pig IncHI2 3 24 
E. coli_027 Pig IncX4 3 24 
E. coli_028 Pig IncHI2 3 12 
E. coli_029 Pig IncX4 3 24 
E. coli_030 Pig IncX4 4 16 
E. coli_031 food (poultry) IncHI2 4 16 
E. coli_032 food (poultry) IncHI2 4 16 
E. coli_033 food (poultry) IncX4 3 16 
E. coli_034 food (poultry) ND 4 24 
E. coli_035 food (poultry) ND 4 24 
E. coli_037 pig IncX4 3 6 
E. coli_038 pig IncX4 4 24 
E. coli_039 pig IncHI2 3 16 
E. coli_040 pig IncX4 4 12 
E. coli_041 pig IncX4 4 16 
E. coli_042 pig IncX4 4 24 
E. coli_043 pig IncHI2 4 12 
E. coli_044 pig IncHI2 4 24 
E. coli_045 pig ND 6 24 
E. coli_046 pig IncX4 3 16 
E. coli_047 pig IncX4 4 16 
E. coli_048 pig IncX4 3 24 
E. coli_049 pig IncX4 4 16 
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E. coli_050 pig IncX4/IncN 4 16 
E. coli_051 pig IncX4 4 16 
E. coli_052 pig IncX4 6 24 
E. coli_053 pig ND 4 24 
E. coli_054 poultry IncHI2 4 16 
E. coli_055 poultry ND 4 24 
E. coli_056 poultry IncX4 6 24 
E. coli_057 poultry IncX4 4 24 
E. coli_058 poultry ND 6 32/48 
E. coli_059 poultry IncX4 4 24 
E. coli_060 poultry IncHI2 4 16 
K. pneumoniae_002 poultry ND >128               >128 
E. coli_010* poultry NA 2 2 
E. coli_017* companion animal NA 1.5 1.5 
E. coli CAE02* cattle NA 1.5 1.5 
E. coli CAE07* cattle NA 1.5 1.5 
E. coli CAE13* cattle NA 2 2 
E. coli CLO28* poultry NA 1.5 1.5 
E. coli CLO29* poultry NA 2 1.5 
E. coli CLO47* cattle NA 2 2 
E. coli DO14* companion animal NA 1.5 1.5 
E. coli DO21* companion animal NA 1.5 1.5 
E. coli DH10β* laboratory strain NA 2 2 
p002/DH10β transconjugant IncX4 4 32 
p002 Δmcr-1 Δmcr-1 of p002 in E. coli 
DH10β  
IncX4 2 2 
t004/J53 transconjugant of E. coli 
J53 harboring p004 
IncHI2 2 16 
t002/J53 transconjugant of E. coli 
J53 harboring p002 
IncX4 2 24 
t003/J53 transconjugant of E. coli 
J53 harboring p003 
IncHI2 2 12 
t001/J53 transconjugant of E. coli 
J53 harboring p001 
IncHI2 2 12 
* mcr-1-negative isolates; ND - not determined; NA - not applicable  
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Table 3.1 The equipment used in this study. 
Instrument Manufacturer 
Analytical balance Mettler, Giessen, Germany 
Autoclave Getinge, Getinge, Sweden 
Biological safety cabinets Thermo scientific, USA  
CHEF-DR II System Bio-Rad, USA 
Cell-counting chamber Brand, Wertheim, Germany 
Centrifuges Eppendorf, Hamburg, Germany 
CO2-incubator Thermo scientific, USA 
Cross flow filtration system Spectrum labs, USA 
Electroblotting apparatus Construction of the institute 
Electrophoresis apparatus 
(agarose gel electrophoresis) 
Construction of the institute 
Electrophoresis apparatus 
(SDS-PAGE) 
Biometra, Goettingen, Germany 
Electroporator Bio-Rad, USA 
Field emission scanning electron microscope Carl Zeiss, Germany 
Film developer for Western blots Agfa Healthcare, Mortsel, Belgium 
Fluorescence microscope Keyence, Japan 
Freezer (-20°C) Bosch, Stuttgart, Germany 
Freezer (-80°C) Thermo Scientific, USA 
Freezing chamber for 
eukaryotic cells 
Nalgene Sigma Aldrich, St. Louis, USA 
Fridge (4°C) Bosch, Stuttgart, Germany 
Gel Imaging Systems Bio-Rad, USA 
Hypercassette for film 
development 
Amersham Biosciences, Little Chalfont, 
Buckinghamshire, UK 
Ice machine Ziegra, Isernhagen, Germany 
Incubator Thermo Scientific, USA 
Light microscope Hund, Wetzlar, Germany 
Magnetic stirrer IKA, Staufen, Germany 
Mass spectrometer Thermo Scientific, USA 
Microliter pipettes Eppendorf, Hamburg, Germany 
Microplate reader Tecan, Maennedorf, Switzerland 
Microwave oven Sharp, Japan 
MiSeq sequencer Illumina, USA 
Multi-channel pipette Biozym, Hessisch Oldendorf, Germany 
Microapplicator  
NanoDrop Spectrophotometer Thermo Scientific, USA 
pH-Meter Knick, Berlin, Germany 
Pipetboy Integra Biosciences, Zizers, Switzerland 
Plate shaker IKA, Staufen, Germany 
Shaking-incubator Infors, Basel, Switzerland 
Tangential Flow Filtration system Pall, USA 
Thermal cycler Applied Biosystems, USA 
Thermomixer Eppendorf, Hamburg, Germany 
Transmission electron microscopy Carl Zeiss, Germany 
Ultracentrifuge Beckman, USA 
Vortex mixer VWR, Radnor, PA, USA 
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Water bath Grant Instruments, UK 
Milli-Q water purification system Merck, Germany 
Table 3.2 The consumables used in this study. 
Item Manufacturer 
96-well plates flat-bottom Greiner, Frickenhausen, Germany 
96-well plates U-bottom Greiner, Frickenhausen, Germany 
96-well plates V-bottom Greiner, Frickenhausen, Germany 
Bottle top filters VWR, Radnor, PA, USA 
Cell scraper Greiner, Frickenhausen, Germany 
Cover slips R. Langenbrinck, Germany 
Cryovials Sarstedt, Nuembrecht, Germany 
Cuvettes Ratiolab, Dreieich, Germany 
Disposable pipettes Greiner, Frickenhausen, Germany 
Disposable scalpels Feather, Osaka, Japan 
Disposable syringes Braun, Melsungen, Germany 
ECL films Amersham Biosciences, UK 
Electron microscopy grids Merck, Germany 
Electroporation cuvettes Thermo Scientific, USA 
Examination gloves Ansell, Richmond, VIC, Australia 
Films for 96-well plates Thermo Scientific, USA 
Glass slides R. Langenbrinck, Germany 
Glassware Schott, Mainz, Germany 
Hollow Fiber Filters Spectrum labs, USA 
Inoculating loops Nunc Sigma Aldrich, St. Louis, USA 
Microcentrifuge tubes, 1.5 ml Eppendorf, Hamburg, Germany 
Multiwell tissue culture plates Becton Dickinson; Franklin Lakes, USA 
Paper towels Kimberly Clark, Irwing, USA 
Parafilm Pechiney Plastic Packaging, USA 
Petri dishes Greiner, Frickenhausen, Germany 
Pipette tips Greiner, Frickenhausen, Germany 
Pipette tips (with filter) Nerbe Plus, Winsen/Luke, Germany 
Plastic tubes 50 ml, 15 ml Greiner, Frickenhausen, Germany 
PVDF membrane Roche, Basel, Switzerland 
Syringe filters Merck, Germany 
Tangential flow filtration membranes Pall, USA 
Tissue culture dishes Becton Dickinson, Franklin Lakes, USA 
Density gradient medium (OptiPrep) Sigma Aldrich, Germany 
Table 3.3 Chemicals used in this study. 
Chemical Supplier 
1 kb plus DNA ladder Thermo Scientific, USA 
Acetone Sigma Aldrich, Germany 
Acid Hydrolysate of Casein Sigma Aldrich, Germany 
Agar Sigma Aldrich, Germany 
Agarose Sigma Aldrich, Germany 
Ammonium peroxidisulphate (APS) Merck, Germany 
Ampicillin Sigma Aldrich, Germany 
Beef Extract Sigma Aldrich, Germany 
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Boric acid Sigma Aldrich, Germany 
Bovine serum albumin (BSA) Sigma Aldrich, Germany 
Bradford protein assay Bio-Rad, Germany 
Bromophenol blue Serva, Germany 
Calcium chloride dihydrate Sigma Aldrich, Germany 
Cefotaxime Sigma Aldrich, Germany 
Colistin Sigma Aldrich, Germany 
Deoxycholic acid Sigma Aldrich, Germany 
Dimethyl sulphoxide (DMSO) Merck, Germany 
Dithiothreitol (DTT) Serva, Germany 
DMEM medium Thermo Scientific, USA 
ECL detection system Thermo Scientific, USA 
EDTA Merck, Germany 
EPON Resin Pelco, USA 
Ethanol Sigma Aldrich, Germany 
Ethidium bromide Roth, Germany 
Fetal bovine serum (FBS) PAA Laboratories, Germany 
Ficoll GE Healthcare Life Sciences, Germany 
Film developer solution for Western 
blots (Unimatic D) 
Calbe Chemie; Calbe, Germany 
Film fixer solution for Western blots 
(Unimatic F) 
Calbe Chemie; Calbe, Germany 
Formaldehyde Merck, Germany 
Formic acid Sigma Aldrich, Germany 
Glucose Sigma Aldrich, Germany 
Glutaraldehyde Sigma Aldrich, Germany 
Glycerol Merck, Germany 
Glycine Merck, Germany 
Hanks´ balanced salt solution (HBSS) Roth; Karlsruhe, Germany 
Isopropanol Merck, Germany 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) Sigma Aldrich, Germany 
Kanamycin Sigma Aldrich, Germany 
Lambda PFG Ladder New england biolabs, UK 
Lipofectamine 2000 Thermo Scientific, USA 
Low Range PFG Marker New england biolabs, UK 
Magnesium chloride hexahydrate Sigma Aldrich, Germany 
Methanol Sigma Aldrich, Germany 
Nitrocefin Thermo Scientific, USA 
N-lauroylsarcosine Sigma Aldrich, Germany 
Opti-MEM I medium Thermo Scientific, USA 
Osmium tetroxide Sigma Aldrich, Germany 
Page ruler plus pre-stained protein 
Ladder 
Thermo Scientific, USA 
Paraformaldehyde Sigma Aldrich, Germany 
Phosphate-buffered saline (PBS) Biochrom AG; Berlin, Germany 
Polyacrylamide Roth, Germany 
Potassium chloride Sigma Aldrich, Germany 
Potassium dihydrogen phosphate Sigma Aldrich, Germany 
ProLong Gold Antifade with 4',6- 
diamidino-2-phenylindole (DAPI) 
Thermo Scientific, USA 
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Protease inhibitor cocktail III Merck, Germany 
SDS Sigma Aldrich, Germany 
Skimmed milk powder Sigma Aldrich, Germany 
Sodium Cacodylate Sigma Aldrich, Germany 
Sodium chloride Roth, Germany 
Sodium hydrogen phosphate Merck, Germany 
Sodium phosphate Sigma Aldrich, Germany 
Starch Sigma Aldrich, Germany 
TEMED Roth, Germany 
Tris Roth, Germany 
Triton X-100 Serva, Germany 
Trypsin/EDTA PAA Laboratories, Germany 
Tryptone Becton Dickinson; Franklin Lakes, NJ, 
Tween-20 Serva; Heidelberg, Germany 
Uranyl acetate Sigma Aldrich, Germany 
X-gal Sigma Aldrich, Germany 
Yeast extract Becton Dickinson, USA 
β-mercaptoethanol Sigma Aldrich, Germany 
Table 3.4 Enzymes used in this study. 
Enzyme Manufacturer 
DNAse I Thermo Scientific, USA 
Lysozyme Sigma Aldrich, Germany 
Q5 high fidelity DNA polymerase New England Biolabs, UK 
Restiction Endonucleases Thermo Scientific, USA, New England Biolabs, UK 
T4 DNA Ligase Thermo Scientific, USA 
Taq DNA Polymerase Thermo Scientific, USA 
Tfl DNA Polymerase Promega, USA 
Table 3.5 Kits used in this study. 
Kit Manufacturer 
Gibson Assembly® Cloning Kit New England Biolabs, UK 
Maxi plasmid isolation Kit Qiagen, Germany  
Mini plasmid isolation Kit Qiagen, Germany  
PureLink Genomic DNA isolation kit Thermo Scientific, USA 
QIAquick PCR Purification Kit Qiagen, Germany  
 Table 3.6 Buffers, media and solutions used in this study. 
Buffers, media and solutions Components 
0.2 M Sodium Cacodylate Stock Buffer 42.8g/l Sodium Cacodylate 
Set pH to 7.2 
1.5 M Tris, pH 6.8 (Stock buffer for stacking gels) 181.65 g Tris base 
dissolved in Milli-Q water to 1 L 
pH set to 6.8 
1.5 M Tris, pH 8.8 (Stock buffer for separating gels) 181.65 g Tris base 
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dissolved in Milli-Q water 1 L 
pH set to 8.8 
10x TBE buffer 121.1 g/l Tris base 
61.8 g/l Boric acid 
7.4 g/l EDTA 
10x PBS 27 mM KCl 
1.4 M NaCl 
81 mM Na2HPO4 
15 mM KH2PO4 
dissolved in Milli-Q water 
pH set to 7.4 
10x SDS-PAGE running buffer 250 mM tris 
1.92 M glycine 
1% (w/v) SDS 
dissolved in Milli-Q water 
10x Transfer buffer: 30 g/l Tris base 
144 g/l glycine 
1x TBS with Tween-20 10 mM tris-HCl (pH 8) 
150 mM NaCl 
0.1% (v/v) Tween-20 
1x TE buffer 10mM tris-HCl (pH 8) 
1 mM EDTA 
5X loading buffer 
(agarose gel electrophoresis) 
25% (w/v) ficoll type 400 
0.25% (w/v) bromophenol blue 
in 1x TE buffer 
5x SDS-PAGE loading buffer 62.5 mM tris-HCl (pH 6.8) 
2% (w/v) SDS 
20% (v/v) gycerol 
5% (v/v) β-mercaptoethanol 
0.125 % (w/v) bromophenol blue 
dissolved in Milli-Q water 
Antibiotic stock solutions Ampicillin: 100 mg/ml in mQ water 
Colistin: 50 mg/ml in mQ water 
Cefotaxime: 50 mg/ml in mQ water  
Kanamycin: 50 mg/ml in mQ water 
CCMB80 buffer 80mM Calcium Chloride  
20mM Manganese Chloride  
10mM Magnesium Chloride  
10mM Potassium Acetate 
10% Glycerol 
Cell Lysis Buffer (PFGE) 
 
50 mM Tris-HCl 
1M NaCl 
100 mM EDTA 
0,5% N-lauroylsarcosine 
Set pH to 7.6  
     Appendix 
  
132 
 
Coomassie Blue stock solution 250 mg Coomassie Brilliant Blue per 100 mL of fixing 
solution 
Destaining solution for Coomassie brilliant blue 
 
400 mL methanol 
100 mL glacial acetic acid 
500 ml Milli-Q water 
Fixing solution for Coomassie brilliant blue 600 mL methanol 
75 mL glacial acetic acid 
325 ml Milli-Q water 
GES solution 5 M guanidinium thiocyanate 
100 mM EDTA 
0.5% (v/v) Sarkosyl 
Lysogeny broth (LB) 5 g/l yeast extract 
10 g/l tryptone 
5 g/l NaCl 
Mueller Hinton medium 
 
17.5 g/l Acid Hydrolysate of Casein 
3.0 g/l Beef Extract 
1.5 g/l Starch 
Super optimal catabolite medium (SOC) 5 g/l yeast extract 
20 g/l tryptone 
0.584 g/l NaCl 
0.186 g/l KCl 
2.4 g/l MgSO4 
200 g/l Glucose 
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Appendix B - Vesicular proteins identified in C. freundii OMVs 
Table A-2 Proteins identified in Citrobacter freundii-derived OMVs. 
UniProtKB/TrEMBL 
accession number 
Protein name Function* 
Trial 
I II III 
Outer membrane 
A0A023V1S4 Capsular biosynthesis protein Function unknown + + + 
A0A023V2V4 Uncharacterized protein Cell wall/membrane/envelope biogenesis + + + 
A0A023V3K6 Phospholipase A Cell wall/membrane/envelope biogenesis + + + 
A0A023V726 Maltoporin Carbohydrate transport and metabolism + + + 
A0A023V7G6 Vitamin B12 transporter BtuB Coenzyme transport and metabolism + + + 
A0A023V7S0 Ferrichrome transporter Inorganic ion transport and metabolism + + + 
A0A023V7V2 Outer membrane protein assembly factor BamA Cell wall/membrane/envelope biogenesis + + + 
A0A023V8L6 Outer membrane receptor protein Inorganic ion transport and metabolism + + + 
A0A023V950 LPS-assembly protein LptD Cell wall/membrane/envelope biogenesis + + + 
A0A023V9K1 Membrane protein Cell wall/membrane/envelope biogenesis + + + 
A0A023V9L0 Membrane protein Cell wall/membrane/envelope biogenesis + + + 
A0A023V9Q9 Membrane protein Cell wall/membrane/envelope biogenesis + + + 
A0A023VAA1 MltA-interacting protein MipA Cell wall/membrane/envelope biogenesis + + + 
A0A023VAB7 Ion channel protein Tsx Cell wall/membrane/envelope biogenesis + + + 
A0A023VAN4 Lipid A palmitoyltransferase PagP Not in COG genes - + + 
A0A023VBV0 Membrane protein Cell wall/membrane/envelope biogenesis + + + 
A0A023VC38 Porin Cell wall/membrane/envelope biogenesis - + + 
A0A023VCF7 Membrane protein Cell wall/membrane/envelope biogenesis + + + 
A0A023VD55 Porin Cell wall/membrane/envelope biogenesis + + + 
A0A023VFD9 Outer membrane siderophore receptor Inorganic ion transport and metabolism + + + 
A0A023VFQ1 Membrane protein Cell wall/membrane/envelope biogenesis + + + 
A0A023VG07 Long-chain fatty acid outer membrane transporter Lipid transport and metabolism + + + 
A0A023V3J5 Biofilm formation protein HmsH General function prediction only + + + 
A0A023V4N3 Phospholipid ABC transporter substrate Cell wall/membrane/envelope biogenesis + + + 
A0A023V4Y1 Uroporphyrin-III methyltransferase Function unknown + + + 
A0A023V5D4 Uncharacterized protein Cell wall/membrane/envelope biogenesis + + + 
A0A023V6A0 Membrane protein Cell wall/membrane/envelope biogenesis + + + 
A0A023V6Z2 Cell division protein FtsI Cell cycle control, cell division, chr. partitioning + + + 
A0A023V8B4 Uncharacterized protein General function prediction only - + + 
A0A023V8F6 Cell division protein FtsH Posttran. modifi., protein turnover, chaperones + + + 
A0A023VB08 RND transporter Cell wall/membrane/envelope biogenesis + + + 
A0A023VCT1 Membrane protein Cell wall/membrane/envelope biogenesis + + + 
A0A023VDY1 Membrane protein Not in COG genes + + + 
A0A023V1M8 Membrane protein Cell wall/membrane/envelope biogenesis + + + 
A0A023V1V9 Murein hydrolase effector LrgB Cell wall/membrane/envelope biogenesis + + + 
A0A023V236 Uncharacterized protein Energy production and conversion + + + 
A0A023V2H3 Membrane-bound lytic murein transglycosylase C Cell wall/membrane/envelope biogenesis + + + 
A0A023V2R7 Uncharacterized protein Posttran. modifi., protein turnover, chaperones + + + 
A0A023V367 Membrane protein Cell wall/membrane/envelope biogenesis + + + 
A0A023V3F5 Membrane-bound lytic murein transglycosylase A Cell wall/membrane/envelope biogenesis + + + 
A0A023V467 Uncharacterized protein Cell wall/membrane/envelope biogenesis + + + 
A0A023V4B0 Lipoprotein NlpD Cell wall/membrane/envelope biogenesis + + + 
A0A023V4B9 Metalloprotease Posttran. modifi., protein turnover, chaperones + + + 
A0A023V4I0 Outer membrane N-deacetylase Carbohydrate transport and metabolism + + + 
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A0A023V4K7 Lipoprotein NlpI Cell wall/membrane/envelope biogenesis + + + 
A0A023V552 Membrane protein Function unknown + + + 
A0A023V5T8 Membrane protein Cell wall/membrane/envelope biogenesis + + + 
A0A023V6D6 Uncharacterized protein Function unknown + + + 
A0A023V7B4 Outer membrane lipoprotein RcsF Not in COG genes + + + 
A0A023V7E3 Membrane protein Not in COG genes + + + 
A0A023V827 Membrane protein Cell wall/membrane/envelope biogenesis + + + 
A0A023V828 Uncharacterized protein General function prediction only + + + 
A0A023V8V0 LPS-assembly lipoprotein LptE Cell wall/membrane/envelope biogenesis + + + 
A0A023V986 Copper homeostasis protein Cell wall/membrane/envelope biogenesis + + + 
A0A023V9B2 Lipoprotein Cell wall/membrane/envelope biogenesis + + + 
A0A023VAE2 Uncharacterized protein Function unknown + + + 
A0A023VAG4 Uncharacterized protein Function unknown + + + 
A0A023VAY3 Peptidoglycan-associated outer membrane lipoprotein Cell wall/membrane/envelope biogenesis + + + 
A0A023VAZ1 Curli production assembly/transport protein CsgG Cell wall/membrane/envelope biogenesis + + + 
A0A023VAZ9 Acyl-CoA thioesterase Carbohydrate transport and metabolism + + + 
A0A023VB21 Lipoprotein Not in COG genes + + + 
A0A023VB83 Penicillin-binding protein activator LpoB Cell wall/membrane/envelope biogenesis + + + 
A0A023VB86 Murein lipoprotein Cell wall/membrane/envelope biogenesis + + + 
A0A023VBP7 Uncharacterized protein Function unknown + + + 
A0A023VBT7 Endopeptidase Cell wall/membrane/envelope biogenesis + + + 
A0A023VCE6 Transcriptional regulator Cell wall/membrane/envelope biogenesis + + + 
A0A023VCV6 Lipoprotein Not in COG genes + + + 
A0A023VD27 Membrane protein Cell wall/membrane/envelope biogenesis + + + 
A0A023VDB8 Outer-membrane lipoprotein LolB Cell wall/membrane/envelope biogenesis + + + 
A0A023VDF1 Membrane-bound lytic murein transglycosylase A Cell wall/membrane/envelope biogenesis + + + 
A0A023VEG2 Membrane protein Cell wall/membrane/envelope biogenesis + + + 
A0A023VEX2 Outer membrane protein assembly factor BamD Cell wall/membrane/envelope biogenesis + + + 
A0A023VF30 Outer membrane protein assembly factor BamB Cell wall/membrane/envelope biogenesis + + + 
A0A023VF93 Lipoprotein General function prediction only + + + 
A0A023VFG1 Membrane protein Cell wall/membrane/envelope biogenesis + + + 
A0A023VG72 RpoE-regulated lipoprotein Mobilome: prophages, transposons + + + 
A0A023VG87 ABC transporter permease Cell wall/membrane/envelope biogenesis + + + 
A0A023VGJ5 Outer membrane protein assembly factor BamC Function unknown + + + 
A0A023VGX7 Membrane protein Cell wall/membrane/envelope biogenesis + + + 
Inner membrane 
A0A023V5B6 Formate dehydrogenase Energy production and conversion - - + 
A0A023V7X6 Lipoprotein Inorganic ion transport and metabolism + + + 
A0A023VA60 Multidrug transporter Cell wall/membrane/envelope biogenesis + + + 
A0A023V3J4 Sec-independent protein translocase protein TatA Intracellular trafficking, secr., vesicular 
transport 
+ + + 
A0A023V4V4 Sec-independent protein translocase protein TatB Intracellular trafficking, secr., vesicular 
transport 
+ + + 
A0A023V578 D-alanyl-D-alanine carboxypeptidase Cell wall/membrane/envelope biogenesis - + + 
A0A023V5D0 Sulfoxide reductase catalytic subunit YedY Energy production and conversion + + + 
A0A023V5Q8 ATP synthase subunit b Energy production and conversion + + + 
A0A023V7G2 Protein HflC Posttran. modifi., protein turnover, chaperones + + + 
A0A023V869 Cell division protein FtsL Cell cycle control, cell division, chr. partitioning + + + 
A0A023V8T8 D-alanyl-D-alanine carboxypeptidase Cell wall/membrane/envelope biogenesis - + + 
A0A023V946 Membrane protein Cell wall/membrane/envelope biogenesis + + + 
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A0A023VAB2 Colicin uptake protein TolR Intracellular trafficking, secr., vesicular 
transport 
+ + + 
A0A023VBI8 Peptidase M15 Cell wall/membrane/envelope biogenesis + + + 
A0A023VBJ3 Sulfoxide reductase catalytic subunit YedY Energy production and conversion + + + 
A0A023VDF8 Formate dehydrogenase Energy production and conversion + + + 
A0A023V304 Mechanosensitive ion channel protein MscS Cell wall/membrane/envelope biogenesis - + + 
A0A023V3D7 Serine/threonine protein kinase Amino acid transport and metabolism + + + 
A0A023V3L6 Protoheme IX biogenesis protein Function unknown + + + 
A0A023V5J6 Preprotein translocase subunit SecG Intracellular trafficking, secr., vesicular 
transport 
+ + + 
A0A023V5K7 ATP-dependent zinc metalloprotease FtsH Posttran. modifi., protein turnover, chaperones + + + 
A0A023V5N9 Membrane protein insertase YidC Cell wall/membrane/envelope biogenesis + + + 
A0A023V5V2 Magnesium transport protein CorA Inorganic ion transport and metabolism - + + 
A0A023V622 Uncharacterized protein Cell wall/membrane/envelope biogenesis + + + 
A0A023V649 Cell division protein FtsX Cell cycle control, cell division, chr. partitioning + + + 
A0A023V6Q2 Fumarate reductase subunit C Energy production and conversion + + + 
A0A023V6Y2 PTS system mannitol-specific transporter sub. IICBA Carbohydrate transport and metabolism + + + 
A0A023V6Z9 Topoisomerase II Not in COG genes + + + 
A0A023V792 Zinc metalloprotease Posttran. modifi., protein turnover, chaperones - + + 
A0A023V7Y3 Uncharacterized protein Function unknown + + - 
A0A023V8A6 PTS system trehalose(Maltose)-specific transporter Carbohydrate transport and metabolism + + + 
A0A023V8D1 Anaerobic C4-dicarboxylate transporter Carbohydrate transport and metabolism + + + 
A0A023V9B5 Protein translocase subunit SecD Intracellular trafficking, secr., vesicular 
transport 
+ + + 
A0A023V9D6 Cell division protein FtsK Cell cycle control, cell division, chr. partitioning + + + 
A0A023VAA8 Cytochrome d terminal oxidase subunit 1 Energy production and conversion + + + 
A0A023VAL1 Membrane protein Not in COG genes + + + 
A0A023VAS5 Apolipoprotein N-acyltransferase Cell wall/membrane/envelope biogenesis + + + 
A0A023VBB3 Colicin uptake protein TolQ Intracellular trafficking, secr., vesicular 
transport 
+ + + 
A0A023VCB6 PTS mannose transporter subunit IID Carbohydrate transport and metabolism + + + 
A0A023VCW8 Protease HtpX Posttran. modifi., protein turnover, chaperones + + + 
A0A023VDS3 UPF0259 membrane protein CFNIH1_18960 Not in COG genes - - + 
A0A023VDX7 sn-glycerol-3-phosphate transporter Carbohydrate transport and metabolism + + + 
A0A023VFQ8 Amino acid transporter Amino acid transport and metabolism + + + 
A0A023VG42 NADH-quinone oxidoreductase subunit A Energy production and conversion + + + 
A0A023VGL0 Signal peptidase I Intracellular trafficking, secr., vesicular 
transport 
+ + + 
Periplasmic 
A0A023V241 N-acetylmuramoyl-L-alanine amidase Cell wall/membrane/envelope biogenesis + + + 
A0A023V2G7 Uncharacterized protein Not in COG genes + + + 
A0A023V2P0 LacI family transcriptional regulator Carbohydrate transport and metabolism + + + 
A0A023V2X6 Protein-disulfide isomerase Posttran. modifi., protein turnover, chaperones - + + 
A0A023V337 Capsular biosynthesis protein Cell wall/membrane/envelope biogenesis + + + 
A0A023V360 Glycine/betaine ABC transporter substrate Amino acid transport and metabolism + + + 
A0A023V3B2 Cell division protein FtsB Cell cycle control, cell division, chr. partitioning + + + 
A0A023V3C2 Hydrogenase 2 large subunit Energy production and conversion - + + 
A0A023V3F9 Protease Posttran. modifi., protein turnover, chaperones - + + 
A0A023V3G2 UPF0441 protein CFNIH1_02420 Function unknown + + + 
A0A023V3H3 Uncharacterized protein Function unknown + + + 
A0A023V3S2 L-asparaginase II Translation, ribosomal structure and biogenesis + + + 
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A0A023V3Y3 Lipopolysaccharide export system protein LptA Cell wall/membrane/envelope biogenesis + + + 
A0A023V4C4 CTP synthase Nucleotide transport and metabolism + + + 
A0A023V4I4 Uncharacterized protein Not in COG genes + + + 
A0A023V4J7 Penicillin-binding protein activator LpoA Cell wall/membrane/envelope biogenesis + + + 
A0A023V4J9 Peptidyl-prolyl cis-trans isomerase Posttran. modifi., protein turnover, chaperones + + + 
A0A023V4Q2 Cell division protein FtsP Cell cycle control, cell division, chr. partitioning + + + 
A0A023V4S1 Uncharacterized protein Not in COG genes - + + 
A0A023V4S6 Glycerol-3-phosphate ABC transporter substrate Carbohydrate transport and metabolism + + + 
A0A023V4U5 Copper resistance protein Not in COG genes + + + 
A0A023V4V8 DNA recombination protein RmuC Replication, recombination and repair + + + 
A0A023V4X6 Membrane protein Function unknown + + + 
A0A023V582 Thiol:disulfide interchange protein Posttran. modifi., protein turnover, chaperones + + + 
A0A023V5F8 Beta-lactamase Defense mechanisms + + + 
A0A023V5L8 ABC transporter substrate-binding protein Lipid transport and metabolism + + + 
A0A023V5P5 Serine endoprotease DegQ Posttran. modifi., protein turnover, chaperones + + + 
A0A023V5S0 D-ribose transporter subunit RbsB Carbohydrate transport and metabolism + + + 
A0A023V5T5 Maltose-binding protein Not in COG genes + + + 
A0A023V5X8 Uncharacterized protein Signal transduction mechanisms + + + 
A0A023V656 Peptidyl-prolyl cis-trans isomerase Posttran. modifi., protein turnover, chaperones + + + 
A0A023V657 Uncharacterized protein Not in COG genes + + + 
A0A023V689 Peptidase Amino acid transport and metabolism + + + 
A0A023V6C8 Uncharacterized protein General function prediction only + + + 
A0A023V6D5 C4-dicarboxylate ABC transporter Carbohydrate transport and metabolism + + + 
A0A023V6D8 Peptide ABC transporter substrate-binding protein Amino acid transport and metabolism + + + 
A0A023V6G8 Leucine ABC transporter substrate-binding protein Amino acid transport and metabolism + + + 
A0A023V7D7 Phosphate-binding protein PstS Inorganic ion transport and metabolism + + - 
A0A023V7I5 2', 3'-cyclic nucleotide 2'-phosphodiesterase Nucleotide transport and metabolism + + + 
A0A023V7J5 Sugar ABC transporter substrate-binding protein Carbohydrate transport and metabolism + + + 
A0A023V7M8 Uncharacterized protein Not in COG genes - + + 
A0A023V7Q0 Sugar ABC transporter substrate-binding protein Carbohydrate transport and metabolism + + + 
A0A023V7U4 Cytochrome c-552 Inorganic ion transport and metabolism + + + 
A0A023V7W4 Transcriptional regulator Carbohydrate transport and metabolism + + + 
A0A023V7X5 Uncharacterized protein Function unknown + + + 
A0A023V7Y4 Lytic murein transglycosylase Cell wall/membrane/envelope biogenesis + + + 
A0A023V7Y9 Protein CreA Signal transduction mechanisms + + + 
A0A023V802 VirG Posttran. modifi., protein turnover, chaperones + - + 
A0A023V817 Transpeptidase Cell wall/membrane/envelope biogenesis - + + 
A0A023V850 Biofilm stress and motility protein A Function unknown + + + 
A0A023V8F2 N-acetylmuramoyl-l-alanine amidase II Cell wall/membrane/envelope biogenesis + + + 
A0A023V8F8 Vitamin B12-binding protein Inorganic ion transport and metabolism - + - 
A0A023V8F9 Peptidyl-prolyl cis-trans isomerase Posttran. modifi., protein turnover, chaperones - - + 
A0A023V8K4 Endopeptidase Not in COG genes + + + 
A0A023V8U3 Chaperone SurA Posttran. modifi., protein turnover, chaperones + + + 
A0A023V8Z6 Fimbrial protein FimI Cell motility + + + 
A0A023V915 Multicopper oxidase Cell cycle control, cell division, chr. partitioning + + + 
A0A023V949 Serine endoprotease Posttran. modifi., protein turnover, chaperones + + + 
A0A023V968 Disulfide isomerase Posttran. modifi., protein turnover, chaperones + + + 
A0A023V969 Chaperone protein skp Cell wall/membrane/envelope biogenesis + + + 
A0A023V984 Uncharacterized protein Not in COG genes - + + 
A0A023V997 L,D-transpeptidase Cell wall/membrane/envelope biogenesis + + + 
A0A023V9B7 Uncharacterized protein Cell wall/membrane/envelope biogenesis + + + 
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A0A023V9C8 Amino acid transporter Amino acid transport and metabolism + + + 
A0A023V9J5 5'-nucleotidase Nucleotide transport and metabolism + + + 
A0A023V9J6 Lipoprotein Function unknown + + + 
A0A023V9K9 Protein TolB Intracellular trafficking, secr., vesicular 
transport 
+ + + 
A0A023V9Q0 Adhesin Cell motility + + + 
A0A023V9S7 Glutathione ABC transporter substrate-binding 
protein 
Amino acid transport and metabolism + + + 
A0A023V9T4 Glucans biosynthesis protein G Cell wall/membrane/envelope biogenesis + + + 
A0A023V9W6 Outer-membrane lipoprotein carrier protein Cell wall/membrane/envelope biogenesis + + + 
A0A023VAA5 Uncharacterized protein Cell motility + + + 
A0A023VAK6 Putrescine-binding periplasmic protein Amino acid transport and metabolism + + + 
A0A023VAQ2 Murein L,D-transpeptidase Cell wall/membrane/envelope biogenesis + + + 
A0A023VAV2 Lysozyme inhibitor Cell wall/membrane/envelope biogenesis + + + 
A0A023VAV8 Glucose-1-phosphatase Not in COG gene + + + 
A0A023VAW8 Ferrous iron transporter Inorganic ion transport and metabolism + + + 
A0A023VAZ4 Molybdate transporter Defense mechanisms + + + 
A0A023VB05 Uncharacterized protein Intracellular trafficking, secr., vesicular 
transport 
+ + + 
A0A023VBB6 Tol-pal system protein General function prediction only + + + 
A0A023VBF1 Spermidine/putrescine ABC transporter substrate Amino acid transport and metabolism + + + 
A0A023VBG4 Glutamine ABC transporter substrate-bindnig protein Amino acid transport and metabolism + + + 
A0A023VBI6 Uncharacterized protein Carbohydrate transport and metabolism + + + 
A0A023VBM5 Sulfurtransferase Inorganic ion transport and metabolism + + + 
A0A023VBW6 Peptide ABC transporter substrate-binding protein Amino acid transport and metabolism - + + 
A0A023VC10 UPF0312 protein CFNIH1_15285 General function prediction only - + + 
A0A023VC24 Nickel ABC transporter substrate-binding protein Amino acid transport and metabolism + + + 
A0A023VC75 Probable thiol peroxidase Posttran. modifi., protein turnover, chaperones + + + 
A0A023VC81 Peptigoglycan-binding protein LysM Cell wall/membrane/envelope biogenesis + + + 
A0A023VCB5 Uncharacterized protein General function prediction only - + + 
A0A023VCD2 Peptide ABC transporter substrate-binding protein Amino acid transport and metabolism + + + 
A0A023VCD3 Conjugal transfer protein TrbG Intracellular trafficking, secr., vesicular 
transport 
+ - + 
A0A023VCF4 Formate dehydrogenase Energy production and conversion - + + 
A0A023VCR7 Uncharacterized protein Posttran. modifi., protein turnover, chaperones - + + 
A0A023VCR9 Periplasmic trehalase Carbohydrate transport and metabolism + + + 
A0A023VCU3 Uncharacterized protein Function unknown + + + 
A0A023VCZ2 Spermidine dehydrogenase Sec. metabo. biosynthe., transp. and catabo. - + + 
A0A023VD12 Peptide ABC transporter substrate-binding protein Amino acid transport and metabolism - + + 
A0A023VDI9 Lipoprotein Translation, ribosomal structure and biogenesis + + + 
A0A023VDM6 Glucans biosynthesis protein D Cell wall/membrane/envelope biogenesis + + + 
A0A023VDV0 Peptide ABC transporter substrate-binding protein Amino acid transport and metabolism + + + 
A0A023VDX8 Peptide ABC transporter substrate-binding protein Amino acid transport and metabolism + + + 
A0A023VE03 Vancomycin high temperature exclusion protein Cell wall/membrane/envelope biogenesis + + + 
A0A023VE85 Carboxy-terminal protease Posttran. modifi., protein turnover, chaperones + + + 
A0A023VEB4 Nitrate reductase Energy production and conversion + + + 
A0A023VEF0 N-acetylmuramoyl-l-alanine amidase I Cell wall/membrane/envelope biogenesis + + + 
A0A023VEK0 N-acetylmuramoyl-L-alanine amidase amid Cell wall/membrane/envelope biogenesis + + + 
A0A023VEK2 Arginine ABC transporter substrate-binding protein Amino acid transport and metabolism + + + 
A0A023VEM3 Osmoprotectant uptake system substrate Cell wall/membrane/envelope biogenesis + + + 
A0A023VER5 Zinc ABC transporter substrate-binding protein Inorganic ion transport and metabolism + + + 
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A0A023VET1 LacI family transcriptional regulator Carbohydrate transport and metabolism + + + 
A0A023VEV9 Anti-sigma E factor Signal transduction mechanisms + + + 
A0A023VEW3 L-arabinose-binding periplasmic protein Carbohydrate transport and metabolism + + + 
A0A023VEZ0 Ecotin Posttran. modifi., protein turnover, chaperones + + + 
A0A023VEZ3 Cystine transporter subunit Amino acid transport and metabolism + + + 
A0A023VF06 Uncharacterized protein Cell wall/membrane/envelope biogenesis + + + 
A0A023VF11 Beta-barrel assembly-enhancing protease General function prediction only + + + 
A0A023VF13 Glycerophosphodiester phosphodiesterase Lipid transport and metabolism + + + 
A0A023VF38 L,D-transpeptidase Cell wall/membrane/envelope biogenesis + + + 
A0A023VF68 Histidine ABC transporter substrate HisJ Amino acid transport and metabolism + + + 
A0A023VFA2 Thiosulfate reductase PhsA Energy production and conversion + + + 
A0A023VFD6 Sugar ABC transporter substrate-binding protein Carbohydrate transport and metabolism + + + 
A0A023VFF9 Acyl-CoA thioesterase Amino acid transport and metabolism + + + 
A0A023VG28 Beta-lactamase Defense mechanisms + + + 
A0A023VGE9 Thiosulfate transporter subunit Inorganic ion transport and metabolism + + - 
A0A023VFF5 zipA Cell division protein ZipA homolog + + + 
A0A023VFN3 ccmE Cytochrome c-type biogenesis protein CcmE + + + 
Cytoplasmic 
A0A023V248 Thymidylate synthase Nucleotide transport and metabolism + + + 
A0A023V2B2 6-phospho-beta-glucosidase Carbohydrate transport and metabolism - + + 
A0A023V2F0 S-adenosylmethionine synthase Coenzyme transport and metabolism + + + 
A0A023V2H1 Alanine--tRNA ligase Translation, ribosomal structure and biogenesis + + + 
A0A023V2W4 Uncharacterized protein Inorganic ion transport and metabolism - + + 
A0A023V311 Transketolase Carbohydrate transport and metabolism + + + 
A0A023V325 Uronate isomerase Carbohydrate transport and metabolism + + + 
A0A023V369 Uncharacterized protein Coenzyme transport and metabolism - - + 
A0A023V376 5-keto-4-deoxy-D-glucarate aldolase Carbohydrate transport and metabolism + - + 
A0A023V397 Polyribonucleotide nucleotidyltransferase Translation, ribosomal structure and biogenesis + + + 
A0A023V3A1 Transcription termination NusA Transcription + + + 
A0A023V3C3 UDP-N-acetylglucosamine 1-carboxyvinyltransferase Cell wall/membrane/envelope biogenesis - + + 
A0A023V3D9 Aldehyde reductase Energy production and conversion + + + 
A0A023V3E3 Cytosine deaminase Nucleotide transport and metabolism - + + 
A0A023V3E5 L-fucose isomerase Carbohydrate transport and metabolism + + + 
A0A023V3F0 50S ribosomal protein L13 Translation, ribosomal structure and biogenesis + + + 
A0A023V3F4 Malate dehydrogenase Energy production and conversion + + + 
A0A023V3H0 Acetyl-CoA carboxylase Lipid transport and metabolism + + + 
A0A023V3I0 4-deoxy-L-threo-5-hexosulose-uronate-isomerase Carbohydrate transport and metabolism + + + 
A0A023V3I5 Xaa-Pro dipeptidase Amino acid transport and metabolism + + + 
A0A023V3I9 3-octaprenyl-4-hydroxybenzoate carboxy-lyase Coenzyme transport and metabolism + + + 
A0A023V3J8 Uridine phosphorylase Nucleotide transport and metabolism + + + 
A0A023V3N2 Cell division protein ZapA Cell cycle control, cell division, chr. partitioning + + + 
A0A023V3N5 Uncharacterized protein Translation, ribosomal structure and biogenesis + + + 
A0A023V3Q9 50S ribosomal protein L17 Translation, ribosomal structure and biogenesis + + + 
A0A023V3R0 Serine dehydratase Amino acid transport and metabolism - + + 
A0A023V3R1 Glycine/betaine ABC transporter ATP-binding 
protein 
Inorganic ion transport and metabolism + + + 
A0A023V3R2 Ribosomal RNA small subunit methyltransferase E Translation, ribosomal structure and biogenesis - - + 
A0A023V3R7 Glutamate--cysteine ligase Coenzyme transport and metabolism + + + 
A0A023V3R9 50S ribosomal protein L18 Translation, ribosomal structure and biogenesis + + + 
A0A023V3S4 50S ribosomal protein L24 Translation, ribosomal structure and biogenesis - + + 
A0A023V3S9 30S ribosomal protein S3 Translation, ribosomal structure and biogenesis - + + 
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A0A023V3T5 50S ribosomal protein L4 Translation, ribosomal structure and biogenesis + + + 
A0A023V3V6 Elongation factor Tu Translation, ribosomal structure and biogenesis + + + 
A0A023V3W6 Phosphoglucosamine mutase Carbohydrate transport and metabolism + + + 
A0A023V3X2 Enolase Carbohydrate transport and metabolism + + + 
A0A023V3X9 ABC transporter ATP-binding protein Cell wall/membrane/envelope biogenesis + - - 
A0A023V3Y9 1,2-propanediol oxidoreductase Energy production and conversion + + + 
A0A023V407 Ribulose-phosphate 3-epimerase Carbohydrate transport and metabolism + + + 
A0A023V419 Aldo/keto reductase General function prediction only + + + 
A0A023V421 DNA-binding protein Fis Transcription + + + 
A0A023V422 Phosphoenolpyruvate carboxykinase [ATP] Energy production and conversion + + + 
A0A023V461 DNA-binding protein Transcription + + + 
A0A023V471 Transcriptional repressor MprA Transcription - + + 
A0A023V478 Protein RecA Replication, recombination and repair + + + 
A0A023V485 ATP-dependent RNA helicase RhlB Replication, recombination and repair + + + 
A0A023V487 Glycine dehydrogenase (decarboxylating) Amino acid transport and metabolism + + + 
A0A023V493 Proline aminopeptidase P II Amino acid transport and metabolism + + + 
A0A023V494 Putative reductase CFNIH1_03990 Lipid transport and metabolism - + + 
A0A023V498 Ribose-5-phosphate isomerase A Carbohydrate transport and metabolism + + + 
A0A023V4A3 30S ribosomal protein S21 Translation, ribosomal structure and biogenesis + + + 
A0A023V4A8 Fructose-bisphosphate aldolase Carbohydrate transport and metabolism + + + 
A0A023V4B8 DNA-directed RNA polymerase subunit alpha Transcription + + + 
A0A023V4D0 50S ribosomal protein L6 Translation, ribosomal structure and biogenesis + + + 
A0A023V4D2 50S ribosomal protein L14 Translation, ribosomal structure and biogenesis + + + 
A0A023V4D5 LOG family protein General function prediction only + + + 
A0A023V4D6 Oligopeptidase A Amino acid transport and metabolism + + + 
A0A023V4D9 50S ribosomal protein L22 Translation, ribosomal structure and biogenesis + + + 
A0A023V4E3 50S ribosomal protein L3 Translation, ribosomal structure and biogenesis + + + 
A0A023V4G2 Elongation factor G Translation, ribosomal structure and biogenesis + + + 
A0A023V4G4 Methionine gamma-lyase Amino acid transport and metabolism + + + 
A0A023V4I5 Tartronate semialdehyde reductase Lipid transport and metabolism + + + 
A0A023V4I9 Glycine--tRNA ligase alpha subunit Translation, ribosomal structure and biogenesis + - + 
A0A023V4J4 Crp/Fnr family transcriptional regulator Signal transduction mechanisms + + + 
A0A023V4K2 Lysine--tRNA ligase Translation, ribosomal structure and biogenesis + + + 
A0A023V4K5 Siroheme synthase Coenzyme transport and metabolism - + + 
A0A023V4K8 Translation initiation factor IF-2 Translation, ribosomal structure and biogenesis + + + 
A0A023V4M3 Ribosomal RNA large subunit methyltransferase E Translation, ribosomal structure and biogenesis - + + 
A0A023V4N1 Phosphoglycerate kinase Carbohydrate transport and metabolism + + + 
A0A023V4P1 Glutathione S-transferase Posttran. modifi., protein turnover, chaperones + + + 
A0A023V4Q1 Protein-export protein SecB Intracellular trafficking, secr., vesicular 
transport 
+ + + 
A0A023V4Q4 N-acetylneuraminate lyase Amino acid transport and metabolism + - - 
A0A023V4Q6 30S ribosomal protein S9 Translation, ribosomal structure and biogenesis + + + 
A0A023V4R5 3',5'-cyclic adenosine monophosphate 
phosphodiester. 
Signal transduction mechanisms + + + 
A0A023V4S4 Uncharacterized protein Function unknown + + + 
A0A023V4S5 Rod shape-determining protein MreB Cell cycle control, cell division, chr. partitioning + + + 
A0A023V4Z6 Transcription termination factor Rho Transcription + + + 
A0A023V529 30S ribosomal protein S13 Translation, ribosomal structure and biogenesis + + + 
A0A023V533 30S ribosomal protein S5 Translation, ribosomal structure and biogenesis + + + 
A0A023V536 DNA gyrase subunit B Replication, recombination and repair + + + 
A0A023V537 50S ribosomal protein L5 Translation, ribosomal structure and biogenesis + + + 
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A0A023V542 50S ribosomal protein L16 Translation, ribosomal structure and biogenesis + + + 
A0A023V544 Bifunctional protein HldE Cell wall/membrane/envelope biogenesis + + + 
A0A023V546 50S ribosomal protein L23 Translation, ribosomal structure and biogenesis + + + 
A0A023V553 Bifunctional protein GlmU Cell wall/membrane/envelope biogenesis + + + 
A0A023V581 50S ribosomal protein L21 Translation, ribosomal structure and biogenesis + + + 
A0A023V589 Glycerol dehydrogenase Energy production and conversion + - + 
A0A023V5B4 Uncharacterized protein Function unknown + + + 
A0A023V5D3 Transcription accessory protein Transcription - + + 
A0A023V5E8 Protoporphyrinogen oxidase Coenzyme transport and metabolism - + + 
A0A023V5F1 Glycerol-3-phosphate dehydrogenase Energy production and conversion + + + 
A0A023V5J2 Ribosome-binding factor A Translation, ribosomal structure and biogenesis + + + 
A0A023V5K8 50S ribosomal protein L11 Translation, ribosomal structure and biogenesis + + + 
A0A023V5L1 Deoxyribose mutarotase Carbohydrate transport and metabolism + - + 
A0A023V5L3 DNA-directed RNA polymerase subunit beta' Transcription + + + 
A0A023V5L4 Octaprenyl diphosphate synthase Coenzyme transport and metabolism + + - 
A0A023V5N2 Membrane protein Signal transduction mechanisms + + + 
A0A023V5N6 Bifunctional purine biosynthesis protein PurH Nucleotide transport and metabolism + + + 
A0A023V5P0 Stringent starvation protein A Posttran. modifi., protein turnover, chaperones + + + 
A0A023V5P1 30S ribosomal protein S4 Translation, ribosomal structure and biogenesis + + + 
A0A023V5P7 50S ribosomal protein L15 Translation, ribosomal structure and biogenesis + + + 
A0A023V5Q2 30S ribosomal protein S8 Translation, ribosomal structure and biogenesis + + + 
A0A023V5Q3 Protease TldD General function prediction only - + + 
A0A023V5Q7 30S ribosomal protein S17 Translation, ribosomal structure and biogenesis + + + 
A0A023V5R7 30S ribosomal protein S10 Translation, ribosomal structure and biogenesis + + + 
A0A023V5T2 Ferroxidase Inorganic ion transport and metabolism + + + 
A0A023V5T6 30S ribosomal protein S7 Translation, ribosomal structure and biogenesis + + + 
A0A023V5T9 Ubiquinone/menaquinone biosynthesis C-
methyltrans. 
Coenzyme transport and metabolism + + + 
A0A023V5U1 Uncharacterized protein Transcription + + + 
A0A023V5U4 Glyoxylate/hydroxypyruvate reductase B Energy production and conversion + - + 
A0A023V5X7 Cell division protein DamX Cell cycle control, cell division, chr. partitioning - + + 
A0A023V5Z2 Osmolarity response regulator Signal transduction mechanisms + + + 
A0A023V5Z7 Mannitol-1-phosphate 5-dehydrogenase Carbohydrate transport and metabolism + + + 
A0A023V600 ATP-dependent protease ATPase subunit HslU Posttran. modifi., protein turnover, chaperones + + + 
A0A023V607 30S ribosomal protein S11 Translation, ribosomal structure and biogenesis + + + 
A0A023V609 ADP-L-glycero-D-manno-heptose-6-epimerase Cell wall/membrane/envelope biogenesis + + + 
A0A023V610 Aspartate kinase Amino acid transport and metabolism + + - 
A0A023V611 50S ribosomal protein L30 Translation, ribosomal structure and biogenesis - + + 
A0A023V613 Glucose-1-phosphate adenylyltransferase Carbohydrate transport and metabolism + - + 
A0A023V625 50S ribosomal protein L2 Translation, ribosomal structure and biogenesis + + + 
A0A023V626 Argininosuccinate lyase Amino acid transport and metabolism + + + 
A0A023V647 50S ribosomal protein L1 Translation, ribosomal structure and biogenesis + + + 
A0A023V663 Uncharacterized protein Not in COG genes + + - 
A0A023V686 30S ribosomal protein S6 Translation, ribosomal structure and biogenesis + + + 
A0A023V695 Tryptophan--tRNA ligase Translation, ribosomal structure and biogenesis + + + 
A0A023V697 Universal stress protein Signal transduction mechanisms + + + 
A0A023V6A3 Glutathione reductase Energy production and conversion + + + 
A0A023V6B2 Glucose-6-phosphate isomerase Carbohydrate transport and metabolism + + + 
A0A023V6F1 Probable cytosol aminopeptidase Amino acid transport and metabolism + + + 
A0A023V6F7 Glutamine--fructose-6-phosphate aminotransferase Cell wall/membrane/envelope biogenesis + + + 
A0A023V6G1 ATP synthase subunit alpha Energy production and conversion + + + 
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A0A023V6H2 Cell division protein FtsE Cell cycle control, cell division, chr. partitioning + + + 
A0A023V6I9 GTP-binding protein TypA Signal transduction mechanisms + + + 
A0A023V6L3 Uncharacterized protein Inorganic ion transport and metabolism + + + 
A0A023V6L7 L-threonine 3-dehydrogenase Amino acid transport and metabolism + + + 
A0A023V6M5 Dihydrodipicolinate synthase Amino acid transport and metabolism + + + 
A0A023V6N4 Fumarate hydratase Energy production and conversion + + + 
A0A023V6N6 Thymidine phosphorylase Nucleotide transport and metabolism + + + 
A0A023V6R6 Transaldolase Carbohydrate transport and metabolism + + + 
A0A023V6R7 Adenylosuccinate synthetase Nucleotide transport and metabolism + + + 
A0A023V6S5 Fructose-6-phosphate aldolase Carbohydrate transport and metabolism + + + 
A0A023V6S7 30S ribosomal protein S20 Translation, ribosomal structure and biogenesis + + + 
A0A023V6T8 Peptidyl-prolyl cis-trans isomerase Posttran. modifi., protein turnover, chaperones + + + 
A0A023V6U5 Transcription termination NusG Transcription + + + 
A0A023V6V0 DNA-directed RNA polymerase subunit beta Transcription + + + 
A0A023V6V7 Ribosomal RNA small subunit methyltransferase A Translation, ribosomal structure and biogenesis + + + 
A0A023V6W8 DNA-binding protein Replication, recombination and repair + + + 
A0A023V6Y1 Trehalose-6-phosphate hydrolase Carbohydrate transport and metabolism + + + 
A0A023V6Y8 Serine acetyltransferase Amino acid transport and metabolism + + + 
A0A023V6Z1 Phosphoglycerate mutase Carbohydrate transport and metabolism + + + 
A0A023V6Z3 Arginine deiminase Amino acid transport and metabolism + + + 
A0A023V6Z6 2-amino-3-ketobutyrate coenzyme A ligase Coenzyme transport and metabolism + + + 
A0A023V704 Cell division protein ftsA Cell cycle control, cell division, chr. partitioning - + + 
A0A023V706 50S ribosomal protein L28 Translation, ribosomal structure and biogenesis + + + 
A0A023V709 DNA polymerase III subunit beta Replication, recombination and repair + + + 
A0A023V710 Orotate phosphoribosyltransferase Nucleotide transport and metabolism - + + 
A0A023V727 Pyruvate dehydrogenase E1 component Energy production and conversion + + + 
A0A023V730 ATP synthase subunit beta Energy production and conversion + + + 
A0A023V750 Single-stranded DNA-binding protein Replication, recombination and repair + + + 
A0A023V758 Dihydrofolate reductase Coenzyme transport and metabolism + + + 
A0A023V762 Penicillin-binding protein 1B Cell wall/membrane/envelope biogenesis + + + 
A0A023V768 Glutamate-1-semialdehyde 2,1-aminomutase Coenzyme transport and metabolism + + + 
A0A023V773 5'-methylthioadenosine nucleosidase Nucleotide transport and metabolism + + + 
A0A023V781 Succinyltransferase Amino acid transport and metabolism + + + 
A0A023V787 Uridylate kinase Nucleotide transport and metabolism + + + 
A0A023V799 Phosphopentomutase Carbohydrate transport and metabolism + + + 
A0A023V7A2 Lysine decarboxylase LdcC Amino acid transport and metabolism + - + 
A0A023V7A4 Superoxide dismutase Inorganic ion transport and metabolism + + + 
A0A023V7B0 ATP-dependent 6-phosphofructokinase Carbohydrate transport and metabolism + + + 
A0A023V7B6 Triosephosphate isomerase Carbohydrate transport and metabolism + + + 
A0A023V7B7 Small heat shock protein IbpA Posttran. modifi., protein turnover, chaperones + + + 
A0A023V7B9 Molybdenum cofactor biosynthesis protein MogA Coenzyme transport and metabolism + + + 
A0A023V7C1 Glycerol kinase Energy production and conversion + + + 
A0A023V7C4 Chaperone protein DnaK Posttran. modifi., protein turnover, chaperones + + + 
A0A023V7D2 ATP-dependent protease subunit HslV Posttran. modifi., protein turnover, chaperones + + + 
A0A023V7E0 Aspartate ammonia-lyase Amino acid transport and metabolism + + + 
A0A023V7E2 ATP synthase gamma chain Energy production and conversion + + - 
A0A023V7F2 Catalase-peroxidase Inorganic ion transport and metabolism + + + 
A0A023V7F7 Phosphoenolpyruvate carboxylase Energy production and conversion + + + 
A0A023V7G7 Probable GTP-binding protein EngB Cell cycle control, cell division, chr. partitioning + + + 
A0A023V7H2 Glutamine synthetase Amino acid transport and metabolism + + + 
A0A023V7H6 50S ribosomal protein L10 Translation, ribosomal structure and biogenesis + + + 
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A0A023V7J4 UDP-diaminopimelate ligase Cell wall/membrane/envelope biogenesis - + + 
A0A023V7K6 Cell division protein FtsZ Cell cycle control, cell division, chr. partitioning + + + 
A0A023V7N2 Acetyltransferase component of pyruvate 
dehydrogen. 
Energy production and conversion + + + 
A0A023V7N5 Aspartate carbamoyltransferase regulatory chain Nucleotide transport and metabolism + + + 
A0A023V7P0 Ornithine carbamoyltransferase Amino acid transport and metabolism + + + 
A0A023V7P3 Cell division protein FtsN Cell cycle control, cell division, chr. partitioning + + + 
A0A023V7S2 Soluble pyridine nucleotide transhydrogenase Energy production and conversion + + + 
A0A023V7T0 Uncharacterized protein Energy production and conversion + + + 
A0A023V7U0 50S ribosomal protein L7/L12 Translation, ribosomal structure and biogenesis + + + 
A0A023V7U5 Ribosome-recycling factor Translation, ribosomal structure and biogenesis - + + 
A0A023V7X8 Deoxyribose-phosphate aldolase Nucleotide transport and metabolism + + + 
A0A023V814 4-hydroxy-tetrahydrodipicolinate reductase Amino acid transport and metabolism + + + 
A0A023V820 DNA helicase Replication, recombination and repair + + + 
A0A023V821 10 kDa chaperonin Posttran. modifi., protein turnover, chaperones + + + 
A0A023V824 Elongation factor P Translation, ribosomal structure and biogenesis + + + 
A0A023V830 Succinate dehydrogenase iron-sulfur subunit Energy production and conversion + + + 
A0A023V834 Phosphatidylserine decarboxylase proenzyme Lipid transport and metabolism - + + 
A0A023V841 GTPase HflX Translation, ribosomal structure and biogenesis - + + 
A0A023V855 Trigger factor Posttran. modifi., protein turnover, chaperones + + + 
A0A023V860 Peptidylprolyl isomerase Posttran. modifi., protein turnover, chaperones + + + 
A0A023V862 30S ribosomal protein S18 Translation, ribosomal structure and biogenesis + + + 
A0A023V880 Cell division protein FtsQ Cell cycle control, cell division, chr. partitioning + + + 
A0A023V885 Peptidase PmbA General function prediction only + + + 
A0A023V892 GMP reductase Nucleotide transport and metabolism + + + 
A0A023V8C1 Uncharacterized protein Posttran. modifi., protein turnover, chaperones + + + 
A0A023V8D4 60 kDa chaperonin Posttran. modifi., protein turnover, chaperones + + + 
A0A023V8E4 Fumarate reductase flavoprotein subunit Energy production and conversion + + + 
A0A023V8F7 Beta-galactosidase Carbohydrate transport and metabolism + + + 
A0A023V8G0 Ribonuclease R Transcription + + + 
A0A023V8G4 Uncharacterized protein Energy production and conversion + + + 
A0A023V8G5 UPF0325 protein CFNIH1_10505 Cell wall/membrane/envelope biogenesis + + + 
A0A023V8H3 Elongation factor Ts Translation, ribosomal structure and biogenesis + + + 
A0A023V8H5 50S ribosomal protein L9 Translation, ribosomal structure and biogenesis + + + 
A0A023V8I6 3-hydroxyacyl-[acyl-carrier-protein] dehydratase Fab Lipid transport and metabolism + + + 
A0A023V8I8 Inorganic pyrophosphatase Energy production and conversion + + + 
A0A023V8J2 Acetyl-coenzyme A carboxylase carboxyl transferase Lipid transport and metabolism + + + 
A0A023V8J4 D-alanine--D-alanine ligase Cell wall/membrane/envelope biogenesis + + + 
A0A023V8M7 Purine nucleoside phosphorylase DeoD-type Nucleotide transport and metabolism + + + 
A0A023V8M9 Riboflavin biosynthesis protein RibD Coenzyme transport and metabolism + + - 
A0A023V8N8 Valine--tRNA ligase Translation, ribosomal structure and biogenesis + + + 
A0A023V8N9 Probable phosphoglycerate mutase GpmB Carbohydrate transport and metabolism + + + 
A0A023V8P2 Uncharacterized protein Replication, recombination and repair + + + 
A0A023V8Q4 Phosphoheptose isomerase Carbohydrate transport and metabolism + + + 
A0A023V8Q8 Chaperone protein DnaJ Posttran. modifi., protein turnover, chaperones + + + 
A0A023V8R2 Isoleucine--tRNA ligase Translation, ribosomal structure and biogenesis + + + 
A0A023V8R3 Tyrosine phenol-lyase Amino acid transport and metabolism + + + 
A0A023V8R6 Amino acid dehydrogenase Energy production and conversion + + + 
A0A023V8R7 Citrate lyase subunit alpha Energy production and conversion + + + 
A0A023V8V2 UPF0255 protein frsA Signal transduction mechanisms - + + 
A0A023V8W8 Transcriptional regulator MraZ Translation, ribosomal structure and biogenesis + + + 
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A0A023V8X8 Nucleoside triphosphate hydrolase Signal transduction mechanisms + - + 
A0A023V8Y4 ABC transporter ATP-binding protein General function prediction only + + + 
A0A023V8Y7 Cell division protein ZapD Cell cycle control, cell division, chr. partitioning + + + 
A0A023V8Z0 Cysteine--tRNA ligase Translation, ribosomal structure and biogenesis + + + 
A0A023V8Z3 TorR family transcriptional regulator Signal transduction mechanisms + + + 
A0A023V904 Dihydrolipoyl dehydrogenase Energy production and conversion + + + 
A0A023V906 Negative modulator of initiation of replication Replication, recombination and repair + + + 
A0A023V927 Succinate dehydrogenase flavoprotein subunit Energy production and conversion + + + 
A0A023V928 3-methyl-2-oxobutanoate hydroxymethyltransferase Coenzyme transport and metabolism - - + 
A0A023V930 Succinyl-CoA ligase [ADP-forming] subunit alpha Energy production and conversion + + + 
A0A023V956 Transcriptional regulator Transcription - + + 
A0A023V9B0 Peroxiredoxin Defense mechanisms + + + 
A0A023V9E2 Pyruvate formate-lyase Energy production and conversion + + + 
A0A023V9E3 Transcriptional regulator HU subunit alpha Replication, recombination and repair + + - 
A0A023V9E6 tRNA-dimethylallyladenosine synthase Translation, ribosomal structure and biogenesis + + + 
A0A023V9F9 30S ribosomal protein S2 Translation, ribosomal structure and biogenesis + + + 
A0A023V9G0 N-acetylglucosamine-6-phosphate deacetylase Carbohydrate transport and metabolism + + + 
A0A023V9G8 Ferric uptake regulator Inorganic ion transport and metabolism + + + 
A0A023V9H2 Phosphoglucomutase Carbohydrate transport and metabolism + + + 
A0A023V9H6 Aminoacyl-histidine dipeptidase Amino acid transport and metabolism + + + 
A0A023V9H8 Asparagine--tRNA ligase Translation, ribosomal structure and biogenesis + + + 
A0A023V9H9 Glutamate 5-kinase Amino acid transport and metabolism + + + 
A0A023V9J0 Succinate dehydrogenase iron-sulfur subunit Energy production and conversion + + + 
A0A023V9J9 Proline--tRNA ligase Translation, ribosomal structure and biogenesis + + + 
A0A023V9L2 Ribosomal RNA large subunit methyltransferase I Translation, ribosomal structure and biogenesis + + + 
A0A023V9L7 Galactokinase Carbohydrate transport and metabolism + + + 
A0A023V9L9 Uncharacterized protein Mobilome: prophages, transposons + + + 
A0A023V9N0 Urocanate hydratase Amino acid transport and metabolism + + + 
A0A023V9Q7 Peptidase T Amino acid transport and metabolism + + + 
A0A023V9R4 ABC transporter ATP-binding protein General function prediction only - + + 
A0A023V9V5 Nicotinamidase Coenzyme transport and metabolism + + + 
A0A023V9W7 Pyrroline-5-carboxylate reductase Amino acid transport and metabolism + + + 
A0A023V9Y0 Cytidylate kinase Nucleotide transport and metabolism + + + 
A0A023V9Z2 Queuine tRNA-ribosyltransferase Translation, ribosomal structure and biogenesis - + + 
A0A023VA33 ATP-dependent Clp protease ATP-binding ClpX Posttran. modifi., protein turnover, chaperones + + + 
A0A023VA47 Acyl-CoA thioesterase Lipid transport and metabolism + + + 
A0A023VA64 UMP phosphatase Nucleotide transport and metabolism + + + 
A0A023VA66 NAD(P)H dehydrogenase (quinone) Energy production and conversion + + + 
A0A023VA70 Chaperone protein HtpG Posttran. modifi., protein turnover, chaperones + + + 
A0A023VA72 Glutamine--tRNA ligase Translation, ribosomal structure and biogenesis + + + 
A0A023VA74 Delta-aminolevulinic acid dehydratase Coenzyme transport and metabolism + + + 
A0A023VA94 Recombination-associated protein RdgC Replication, recombination and repair - + + 
A0A023VAA0 Succinyl-CoA ligase [ADP-forming] subunit beta Energy production and conversion + + + 
A0A023VAB3 Preprotein translocase subunit YajC Intracellular trafficking, secr., vesicular 
transport 
+ + + 
A0A023VAB8 Phosphoglycerate mutase Carbohydrate transport and metabolism + + + 
A0A023VAE3 Ribonuclease E Translation, ribosomal structure and biogenesis + + + 
A0A023VAF6 3-oxoacyl-[acyl-carrier-protein] synthase 2 Lipid transport and metabolism + + + 
A0A023VAG2 DNA protection during starvation protein Inorganic ion transport and metabolism + + + 
A0A023VAJ3 Adenylate kinase Nucleotide transport and metabolism + + + 
A0A023VAJ7 Alkyl hydroperoxide reductase Defense mechanisms + + + 
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A0A023VAL3 Leucine-responsive transcriptional regulator Transcription + + + 
A0A023VAL4 Translation initiation factor IF-3 Translation, ribosomal structure and biogenesis + + + 
A0A023VAL6 Universal stress protein UspG Signal transduction mechanisms + + + 
A0A023VAL7 Integration host factor subunit alpha Replication, recombination and repair + + + 
A0A023VAM7 Phosphoserine aminotransferase Coenzyme transport and metabolism + + + 
A0A023VAN8 3-deoxy-manno-octulosonate cytidylyltransferase Cell wall/membrane/envelope biogenesis + + + 
A0A023VAP6 Aromatic amino acid aminotransferase Amino acid transport and metabolism + + + 
A0A023VAQ8 Pyrimidine-specific ribonucleoside hydrolase RihA Nucleotide transport and metabolism + + + 
A0A023VAU0 Glucosamine-6-phosphate deaminase Carbohydrate transport and metabolism + + + 
A0A023VAU1 Superoxide dismutase Inorganic ion transport and metabolism + + + 
A0A023VAW1 Citrate synthase Energy production and conversion + + + 
A0A023VAW4 Alkyl hydroperoxide reductase Defense mechanisms + + + 
A0A023VAX7 Oxidoreductase Energy production and conversion + + + 
A0A023VAZ0 Galactose-1-phosphate uridylyltransferase Carbohydrate transport and metabolism + - - 
A0A023VB12 Molybdenum cofactor biosynthesis protein B Coenzyme transport and metabolism + + + 
A0A023VB41 Uncharacterized protein Carbohydrate transport and metabolism + + + 
A0A023VB54 3-ketoacyl-ACP reductase Lipid transport and metabolism + + + 
A0A023VB59 Phosphoenolpyruvate synthase Carbohydrate transport and metabolism + + + 
A0A023VB85 Putative GTP cyclohydrolase 1 type 2 Coenzyme transport and metabolism + + + 
A0A023VB93 Uncharacterized protein Coenzyme transport and metabolism + + + 
A0A023VB97 2-oxoglutarate dehydrogenase complex Energy production and conversion + + + 
A0A023VB98 Uncharacterized protein Translation, ribosomal structure and biogenesis + + + 
A0A023VBA3 30S ribosomal protein S1 Translation, ribosomal structure and biogenesis - + + 
A0A023VBA9 Phenylacetaldehyde dehydrogenase Energy production and conversion + + + 
A0A023VBB2 4-aminobutyrate aminotransferase Amino acid transport and metabolism + + + 
A0A023VBC7 High frequency lysogenization protein HflD homolog Mobilome: prophages, transposons + + + 
A0A023VBD4 Aminopeptidase N Amino acid transport and metabolism + + + 
A0A023VBF0 3-hydroxydecanoyl-[acyl-carrier-protein] dehydratase Lipid transport and metabolism + + + 
A0A023VBI5 Glyceraldehyde-3-phosphate dehydrogenase Carbohydrate transport and metabolism + + + 
A0A023VBL3 Serine--tRNA ligase Translation, ribosomal structure and biogenesis + + + 
A0A023VBL4 DeoR faimly transcriptional regulator Transcription + - + 
A0A023VBM2 Glutamate dehydrogenase Amino acid transport and metabolism + + + 
A0A023VBP8 UPF0502 protein CFNIH1_15335 Function unknown + + + 
A0A023VBR5 Dihydroorotate dehydrogenase (quinone) Nucleotide transport and metabolism + - + 
A0A023VBS5 3-oxoacyl-[acyl-carrier-protein] synthase 3 Lipid transport and metabolism + + + 
A0A023VBT0 Threonine--tRNA ligase Translation, ribosomal structure and biogenesis + + + 
A0A023VBT4 Phenylalanine--tRNA ligase beta subunit Translation, ribosomal structure and biogenesis + + + 
A0A023VBV5 Enoyl-[acyl-carrier-protein] reductase [NADH] Lipid transport and metabolism + + + 
A0A023VBX2 Gamma-aminobutyraldehyde dehydrogenase Energy production and conversion - - + 
A0A023VC14 Riboflavin synthase subunit alpha Coenzyme transport and metabolism + + + 
A0A023VC16 Dihydroorotase Nucleotide transport and metabolism + - + 
A0A023VC23 Lactoylglutathione lyase Sec. metabo. biosynthe., transp. and catabo. + + + 
A0A023VC46 Malonyl CoA-acyl carrier protein transacylase Lipid transport and metabolism + + - 
A0A023VC47 Nitrate reductase Energy production and conversion + - + 
A0A023VC57 X-Pro aminopeptidase Amino acid transport and metabolism - + + 
A0A023VC58 Fumarate hydratase Energy production and conversion - + + 
A0A023VC74 Peptidase M32 Amino acid transport and metabolism + + + 
A0A023VC77 NADH dehydrogenase Energy production and conversion + + + 
A0A023VC94 Malonic semialdehyde reductase Energy production and conversion + + + 
A0A023VCA6 Adenylosuccinate lyase Nucleotide transport and metabolism - + + 
A0A023VCB2 Isocitrate dehydrogenase [NADP] Energy production and conversion + + + 
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A0A023VCB3 Serine dehydratase Amino acid transport and metabolism + + + 
A0A023VCG5 50S ribosomal protein L20 Translation, ribosomal structure and biogenesis + + + 
A0A023VCK1 Pyruvate kinase Carbohydrate transport and metabolism - + + 
A0A023VCL3 Pyruvate kinase Carbohydrate transport and metabolism + + + 
A0A023VCL6 DNA-binding protein Transcription + + + 
A0A023VCP3 Ribose-phosphate pyrophosphokinase Nucleotide transport and metabolism + + + 
A0A023VCQ3 Glutaredoxin Posttran. modifi., protein turnover, chaperones + + + 
A0A023VCR2 Transcriptional regulator SlyA Transcription + + - 
A0A023VCR8 Tyrosine--tRNA ligase Translation, ribosomal structure and biogenesis + + + 
A0A023VCS6 Ferritin Inorganic ion transport and metabolism + + + 
A0A023VCT5 Phenylalanine--tRNA ligase alpha subunit Translation, ribosomal structure and biogenesis + + + 
A0A023VCU1 Site-determining protein Cell cycle control, cell division, chr. partitioning + + + 
A0A023VCW5 Uncharacterized protein Not in COG genes - + + 
A0A023VD11 Cobalt-precorrin-3B C(17)-methyltransferase Coenzyme transport and metabolism + + + 
A0A023VD31 Propanediol dehydratase Sec. metabo. biosynthe., transp. and catabo. - - + 
A0A023VD33 Pyridoxamine kinase Coenzyme transport and metabolism + - + 
A0A023VD54 Aspartyl-tRNA synthetase Translation, ribosomal structure and biogenesis + + + 
A0A023VD93 Bifunctional D-altronate/D-mannonate dehydratase Cell wall/membrane/envelope biogenesis + + + 
A0A023VD94 Aldehyde-alcohol dehydrogenase Energy production and conversion + + + 
A0A023VDA0 Nitrate reductase Energy production and conversion + + + 
A0A023VDA7 6-phosphogluconate dehydrogenase, decarboxylating Carbohydrate transport and metabolism + + + 
A0A023VDC3 Diaminobutyrate--2-oxoglutarate aminotransferase Amino acid transport and metabolism - + + 
A0A023VDF2 NAD-dependent malic enzyme Energy production and conversion + + + 
A0A023VDH0 Methionine--tRNA ligase Translation, ribosomal structure and biogenesis + + + 
A0A023VDH8 Beta-D-glucoside glucohydrolase Carbohydrate transport and metabolism + + + 
A0A023VDJ2 Transcriptional regulator Transcription + + + 
A0A023VDJ5 Precorrin-8X methylmutase Coenzyme transport and metabolism + + + 
A0A023VDJ8 GTP cyclohydrolase 1 Coenzyme transport and metabolism + + + 
A0A023VDP0 Histidine biosynthesis bifunctional protein HisB Amino acid transport and metabolism + + + 
A0A023VDQ6 Universal stress protein F Signal transduction mechanisms + + + 
A0A023VDS0 Probable transcriptional regulatory protein Transcription + + + 
A0A023VDT2 Arginine-tRNA ligase Translation, ribosomal structure and biogenesis + - + 
A0A023VDX0 Ribonucleotide-diphosphate reductase subunit beta Nucleotide transport and metabolism + + + 
A0A023VDY2 UTP--glucose-1-phosphate uridylyltransferase Cell wall/membrane/envelope biogenesis + + + 
A0A023VE02 Peptide chain release factor 1 Translation, ribosomal structure and biogenesis + - + 
A0A023VE10 Peptidyl-tRNA hydrolase Translation, ribosomal structure and biogenesis + + + 
A0A023VE23 Aconitate hydratase Energy production and conversion + + + 
A0A023VE26 Bifunctional PTS system fructose-specific transporter Signal transduction mechanisms + + + 
A0A023VE49 Protein MtfA Signal transduction mechanisms + + + 
A0A023VE81 Uncharacterized protein Function unknown + + + 
A0A023VE90 Propanediol dehydratase Sec. metabo. biosynthe., transp. and catabo. + + + 
A0A023VEA3 Aldehyde dehydrogenase Energy production and conversion - + + 
A0A023VEA5 Transcriptional regulator NarL Signal transduction mechanisms + + + 
A0A023VEB3 2-dehydro-3-deoxyphosphooctonate aldolase Cell wall/membrane/envelope biogenesis + + + 
A0A023VEC6 Ribosome-binding ATPase YchF Translation, ribosomal structure and biogenesis + + + 
A0A023VEE0 Glycerol-3-phosphate dehydrogenase Energy production and conversion + + + 
A0A023VEE1 Dihydroxyacetone kinase Carbohydrate transport and metabolism + + + 
A0A023VEH1 PTS mannose transporter subunit IIAB Carbohydrate transport and metabolism + + + 
A0A023VEH4 NADH-quinone oxidoreductase subunit C/D Energy production and conversion + + + 
A0A023VEI5 RNA chaperone ProQ Signal transduction mechanisms + + + 
A0A023VEI7 Acetate kinase Energy production and conversion + + + 
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A0A023VEK7 Fructose-bisphosphate aldolase Carbohydrate transport and metabolism + + + 
A0A023VEL0 Acetyl-coenzyme A carboxylase carboxyl transferase Lipid transport and metabolism + + + 
A0A023VEL2 Uracil phosphoribosyltransferase Nucleotide transport and metabolism + + + 
A0A023VEL7 Antiporter Cell cycle control, cell division, chr. partitioning + - - 
A0A023VEM7 GMP synthase [glutamine-hydrolyzing] Nucleotide transport and metabolism - + + 
A0A023VEN8 Dihydropyrimidine dehydrogenase Nucleotide transport and metabolism + + + 
A0A023VEN9 Cytoskeleton protein RodZ Cell cycle control, cell division, chr. partitioning + + + 
A0A023VEP5 Sulfurtransferase Inorganic ion transport and metabolism - + - 
A0A023VER1 Glucose-6-phosphate 1-dehydrogenase Carbohydrate transport and metabolism + + + 
A0A023VER7 Glutamate--tRNA ligase Translation, ribosomal structure and biogenesis + + + 
A0A023VES9 Cysteine synthase Amino acid transport and metabolism + + + 
A0A023VEU6 Nitrogen regulatory protein P-II 1 Signal transduction mechanisms + + + 
A0A023VEV1 Cobalt-precorrin-2 C(20)-methyltransferase Coenzyme transport and metabolism + + + 
A0A023VEV4 Peroxidase Inorganic ion transport and metabolism + + + 
A0A023VEV8 Cobalt-precorrin-4 C(11)-methyltransferase Coenzyme transport and metabolism + + + 
A0A023VEW5 Methyltransferase Translation, ribosomal structure and biogenesis + + + 
A0A023VEW9 Propanediol utilization protein Amino acid transport and metabolism + - + 
A0A023VEX0 Uncharacterized protein Carbohydrate transport and metabolism + + + 
A0A023VEZ1 UPF0265 protein CFNIH1_21290 Function unknown + + + 
A0A023VF01 Transcriptional regulatory protein RcsB Signal transduction mechanisms + + + 
A0A023VF05 Thiol peroxidase Posttran. modifi., protein turnover, chaperones + - + 
A0A023VF09 Ribonucleoside-diphosphate reductase Nucleotide transport and metabolism + + + 
A0A023VF26 Inosine-5'-monophosphate dehydrogenase Nucleotide transport and metabolism + + + 
A0A023VF41 NADH dehydrogenase Energy production and conversion + + + 
A0A023VF51 UPF0304 protein CFNIH1_23015 Function unknown + + + 
A0A023VF65 Propanediol dehydratase Sec. metabo. biosynthe., transp. and catabo. + + + 
A0A023VF71 Restriction endonuclease Not in COG genes + + + 
A0A023VF72 Cell division protein DedD Cell cycle control, cell division, chr. partitioning + + - 
A0A023VF79 Semialdehyde dehydrogenase Amino acid transport and metabolism + + + 
A0A023VF86 3-oxoacyl-ACP synthase Lipid transport and metabolism + + + 
A0A023VF95 Ribonuclease 3 Transcription + + + 
A0A023VFB4 Uncharacterized protein Function unknown + + + 
A0A023VFC2 Protein GrpE Posttran. modifi., protein turnover, chaperones + + + 
A0A023VFG2 PTS system glucose-specific transporter subunit IIA Carbohydrate transport and metabolism + + + 
A0A023VFH5 Short-chain dehydrogenase Lipid transport and metabolism + + + 
A0A023VFI8 Acetyltransferase CFNIH1_23620 Translation, ribosomal structure and biogenesis - + + 
A0A023VFL3 Malic enzyme Energy production and conversion + + + 
A0A023VFM9 4-hydroxy-tetrahydrodipicolinate synthase Amino acid transport and metabolism + + + 
A0A023VFN2 Dihydropyrimidine dehydrogenase Amino acid transport and metabolism + + + 
A0A023VFR1 DNA gyrase subunit A Replication, recombination and repair + + + 
A0A023VFR4 flavodoxin Lipid transport and metabolism + + + 
A0A023VFR6 Nucleoid-associated protein CFNIH1_22255 Function unknown + + + 
A0A023VFT4 1,4-dihydroxy-2-naphthoyl-CoA synthase Coenzyme transport and metabolism + + + 
A0A023VFU6 Cysteine desulfurase IscS Amino acid transport and metabolism + + + 
A0A023VFV3 NADH-quinone oxidoreductase subunit B Energy production and conversion + + + 
A0A023VFV6 Ribulokinase Carbohydrate transport and metabolism + + + 
A0A023VFW4 Phosphate acetyltransferase Energy production and conversion + + + 
A0A023VFZ7 Ubiquinone biosynthesis O-methyltransferase Coenzyme transport and metabolism + + + 
A0A023VG00 50S ribosomal protein L19 Translation, ribosomal structure and biogenesis + + + 
A0A023VG33 Glucokinase Carbohydrate transport and metabolism + + + 
A0A023VG37 NADH dehydrogenase Energy production and conversion + + + 
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A0A023VG74 Aminoglycoside adenylyltransferase General function prediction only + + + 
A0A023VGB2 Phosphoribosylaminoimidazole-synthase Nucleotide transport and metabolism + + + 
A0A023VGD7 Phosphoenolpyruvate-protein phosphotransferase Carbohydrate transport and metabolism + + + 
A0A023VGE8 Membrane protein Signal transduction mechanisms + + + 
A0A023VGF3 Nucleoside diphosphate kinase Nucleotide transport and metabolism + + + 
A0A023VGG8 Peptidase B Amino acid transport and metabolism + + + 
A0A023VGJ9 Membrane protein Cell motility + + + 
A0A023VGM3 Chaperone protein ClpB Posttran. modifi., protein turnover, chaperones + + + 
A0A023VGN0 Histidine--tRNA ligase Translation, ribosomal structure and biogenesis + + + 
A0A023VGN1 30S ribosomal protein S16 Translation, ribosomal structure and biogenesis + + + 
A0A023VGT7 Serine hydroxymethyltransferase Amino acid transport and metabolism + + + 
A0A023VGU8 Pyridoxine 5'-phosphate synthase Coenzyme transport and metabolism + + + 
A0A023VGV2 Dihydropteroate synthase Coenzyme transport and metabolism + + + 
A0A023VGV9 Autonomous glycyl radical cofactor Coenzyme transport and metabolism + + + 
A0A023VGX8 StdB protein Cell motility + + + 
A0A023VGX9 Signal recognition particle protein Intracellular trafficking, secr., vesicular 
transport 
+ + + 
Secreted 
A0A023V5C2 Penicillin-binding protein 1A Cell wall/membrane/envelope biogenesis    
A0A023V8E2 Beta-lactamase Defense mechanisms    
A0A023V8G6 Type-1 fimbrial protein subunit A Cell motility    
* COG functional class 
Appendix 
   
148 
 
Appendix C - Map of mcr-1-encoding IncX4 plasmids 
Figure A-0.1 Map of mcr-1-encoding IncX4 plasmids used in the study. p002 and p002::Δmcr-1 
have identical sequences apart from the absence of the mcr-1 gene in the latter plasmid (marked with 
the bracket) 
 
